Thioeno[3,2-B]pyridin-7-amine compounds for treating familial dysautonomia

Substituted thieno[3,2-b]pyridine compounds target the pre-mRNA splicing machinery to correct exon skipping in familial dysautonomia, enhancing IKBKAP protein expression and improving neural function.

JP7587511B2Active Publication Date: 2024-11-20PTC THERAPEUTICS INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021547446
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-02-13
Filing Date
2020-02-10
Publication Date
2024-11-20
Estimated Expiration
2040-02-10

AI Technical Summary

Technical Problem

Familial dysautonomia, a congenital sensory autonomic neuropathy, is characterized by widespread sensory and autonomic dysfunction due to mutations in the IKBKAP (ELP1) gene, leading to progressive neuronal degeneration and reduced quality of life with no effective therapeutic options.

Method used

Development of substituted thieno[3,2-b]pyridine compounds that target the pre-mRNA splicing machinery to correct exon skipping patterns and improve neural function.

Benefits of technology

The compounds enhance IKBKAP protein expression and correct pre-mRNA splicing defects, potentially ameliorating the symptoms of familial dysautonomia and improving the quality of life for affected individuals.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587511000001
    Figure 0007587511000001
  • Figure 0007587511000002
    Figure 0007587511000002
  • Figure 0007587511000003
    Figure 0007587511000003
Patent Text Reader

Abstract

The present invention relates to the compound of formula (I) that is useful for improving pre-mRNA splicing in cells.In particular, another aspect of the present invention relates to a substituted thieno[3,2-b]pyridine compound, its formulation and pharmaceutical composition, and its use method for treating or alleviating familial dysautonomia.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 805,283, filed February 13, 2019.

[0002] Statement of Joint Research Agreement The subject matter disclosed was developed, and the claimed invention made, by or on behalf of one or more of the parties to a joint research agreement executed on or prior to the effective filing date of the claimed invention. The claimed invention may be made as a result of activities undertaken within the scope of the joint research agreement. The parties to the joint research agreement are PTC Therapeutics, Inc. and General Hospital Corporation, d / b / a Massachusetts General Hospital. The present invention relates to a compound useful for improving pre-mRNA splicing in cells.In particular, another embodiment of the present invention relates to a substituted thieno[3,2-b]pyridine compound, its form and pharmaceutical composition, and its method of use for treating or ameliorating familial dysautonomia. [Background technology]

[0003] Familial dysautonomia (FD) is a congenital sensory autonomic neuropathy (HSAN) of the central and peripheral nervous system characterized by widespread sensory and variable autonomic dysfunction. FD affects neural development and is associated with progressive neuronal degeneration. Multiple systems are affected, resulting in a marked decrease in quality of life and premature death. FD is caused by mutations in the IKBKAP (also called ELP1) gene, and in all cases described to date, at least one allele carrying a T to C mutation at position 6 of intron 20 is present, resulting in a unique pattern of tissue-specific exon skipping. Kinetin derivatives useful for therapeutic targeting of the pre-mRNA splicing machinery and for the treatment of FD are described in International Patent Application No. 2016 / 115434, the disclosure of which is incorporated by reference in its entirety. All other documents referred to herein are incorporated by reference into this application as if fully set forth herein. Summary of the Invention

[0004] Embodiments herein include compounds comprising a compound of formula (I), or a form thereof. [ka] (I) (wherein R1, R3, R4, R5 and R6 are defined herein).

[0005] Aspects herein include a method for using a compound of formula (I), or a form or composition thereof, to treat or ameliorate FD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula (I), or a form or composition thereof.

[0006] Aspects of the present specification include the use of a compound of formula (I), or a form thereof, for treating or ameliorating FD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula (I), or a form thereof.

[0007] Aspects herein include the use of a compound of formula (I) or a form thereof in the manufacture of a medicament for treating or ameliorating FD in a subject in need thereof, comprising administering to the subject an effective amount of the medicament. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0008] An embodiment of the present specification relates to a compound comprising a compound of formula (I), or a form thereof, wherein the form is selected from the group consisting of a salt, a hydrate, a solvate, and a tautomeric form of the compound. [ka] (I) (In the formula, R1 is 1, 2, 3, or 4 independently selected R 1a optionally substituted phenyl or heteroaryl; Heteroaryl is a radical of a 5-8 membered monocyclic or bicyclic aromatic carbon atom ring system containing 1-3 heteroatoms selected from N, O and S; R 1a Cyano, halo, hydroxy, C 1-6 Alkyl, halo-C 1-6 Alkyl or C 1-6 is an alkoxy; R3 is hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 is alkyl-amino, C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl is one, two, three or four independently selected R 3a may be substituted with a substituent; C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each occurrence of alkynyl may contain a chiral carbon having either the (R) or (S) configuration; R 3a is cyano, halo, hydroxy, oxo, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkoxy, Halo-C 1-6 Alkoxy, carboxyl, amino, C 1-6 Alkoxy-carbonyl, C 1-6 Alkyl-amino, halo-C 1-6Alkyl-amino, (C 1-6 alkyl)2-amino, phenyl-amino, heterocyclyl-amino, heteroaryl-amino, phenyl-(C 1-6 alkyl)-amino, heterocyclyl-(C 1-6 alkyl)-amino, heteroaryl-(C 1-6 Alkyl)-amino, C 1-6 Alkyl-thio, C 1-6 Alkyl-sulfoxyl and C 1-6 alkyl-sulfonyl, Heterocyclyl is a radical of a monocyclic ring of 3-7 members made of carbon atoms containing 1-3 heteroatoms selected from N, O and S; Heteroaryl is a radical of a 5-8 membered monocyclic or bicyclic aromatic carbon atom ring system containing 1-3 heteroatoms selected from N, O and S; Each occurrence of phenyl, heterocyclyl, and heteroaryl is selected from 1, 2, 3, or 4 independently selected R 3a’ may be substituted with a substituent; R3a' is cyano, halo, hydroxy, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 alkoxy or amino, R4 is hydrogen, cyano, halo, hydroxy, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkoxy, Halo-C 1-6 Alkoxy, Amino, C 1-6 Alkyl-amino, (C 1-6 Alkyl)2-amino, C 3-10 cycloalkyl, phenyl, heterocyclyl or heteroaryl; Heterocyclyl is a radical of a monocyclic ring of 3-7 members made of carbon atoms containing 1-3 heteroatoms selected from N, O and S; Heteroaryl is a radical of a 5-8 membered monocyclic or bicyclic aromatic carbon atom ring system containing 1-3 heteroatoms selected from N, O and S; C1-6 Alkyl, C 3-10 Each occurrence of cycloalkyl, phenyl, heterocyclyl, or heteroaryl is selected from 1, 2, 3, or 4 independently selected R 4a may be substituted with a substituent; R 4a Cyano, halo, hydroxy, C 1-6 Alkyl, halo-C 1-6 Alkyl or C 1-6 is an alkoxy; R5 is hydrogen, cyano, halo, hydroxy, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkoxy, carbamoyl, C 3-10 cycloalkyl or heterocyclyl; Heterocyclyl is a radical of a monocyclic ring of 3-7 members made of carbon atoms containing 1-3 heteroatoms selected from N, O and S; R6 is hydrogen, halo or C 1-6 (It is alkyl)

[0009] In one embodiment, R is selected from 1, 2, 3, or 4 independently selected R 1a It includes compounds of formula (I) which are optionally substituted phenyl or heteroaryl, where heteroaryl is a radical of a 5-8 membered monocyclic or bicyclic aromatic carbon atom ring structure containing 1-3 heteroatoms selected from N, O and S. Another embodiment is where R is one, two, three or four independently selected R 1a This includes compounds of formula (I) which are phenyl, optionally substituted.

[0010] Another embodiment is where R is one R 1a This includes compounds of formula (I) which are phenyl, optionally substituted. Another embodiment is where R is one, two, three or four independently selected R 1aIt includes compounds of formula (I) where heteroaryl is an optionally substituted heteroaryl radical of a 5-8 membered monocyclic or bicyclic aromatic carbon atom ring structure containing 1-3 heteroatoms selected from N, O and S.

[0011] Another embodiment is where R is one R 1a It includes compounds of formula (I) where heteroaryl is an optionally substituted heteroaryl radical of a 5-8 membered monocyclic or bicyclic aromatic carbon atom ring structure containing 1-3 heteroatoms selected from N, O and S.

[0012] Another embodiment is heteroaryl selected from furanyl, thiophenyl, 1H-pyrazolyl, 1H-imidazolyl, isoxazolyl, 1,3-thiazolyl, 1,3-oxazolyl, tetrazolyl, 1,2,3-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, and quinolinyl, wherein the heteroaryl is independently selected from 1, 2, 3, or 4 R 1a This includes compounds of formula (I) which may be substituted with substituents. Another embodiment is where R is heteroaryl selected from furanyl, thiophenyl, 1,3-thiazolyl, and pyridinyl, and the heteroaryl is independently selected from 1, 2, 3, or 4 R 1a This includes compounds of formula (I) which may be substituted with substituents.

[0013] Another embodiment is where R1 is furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl, 1H-pyrazol-1-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-imidazol-1-yl, 1H-imidazol-4-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, 1,3-thiazol-2-yl, 1,3-thiazol-4-yl, 1,3-thiazol-5-yl, 1,3-oxazol-2-yl, 1,3-oxazol-4-yl, 1,3-oxazol-5-yl, 1,2 and heteroaryl selected from 1, 2, 3, 4-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl, tetrazol-5-yl, 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl, 1,2,3-thiadiazol-4-yl, 1,2,3-thiadiazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-4-yl, pyrazin-2-yl, pyridazin-3-yl, pyridazin-4-yl, benzofuran-2-yl, benzofuran-5-yl, and quinolin-4-yl, wherein heteroaryl is independently selected from 1, 2, 3, or 4 R 1a This includes compounds of formula (I) which may be substituted with substituents.

[0014] Another embodiment is where R is heteroaryl selected from furan-2-yl, thiophen-2-yl, 1,3-thiazol-2-yl, and pyridin-4-yl, and the heteroaryl is independently selected from 1, 2, 3, or 4 R 1a This includes compounds of formula (I) which may be substituted with substituents.

[0015] In one embodiment, R 1a But cyano, halo, hydroxy, C 1-6 Alkyl, halo-C 1-6 Alkyl or C 1-6 Includes compounds of formula (I) which are alkoxy. Another aspect is R 1a is halo. Another aspect is R 1ais halo selected from fluoro, chloro, bromo and iodo. Another aspect is R 1a is fluoro.

[0016] In one embodiment, R3 is hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl or C 1-6 is alkyl-amino, C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each occurrence of alkynyl is selected from 1, 2, 3, or 4 independently selected R 3a may be substituted with a substituent; C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each occurrence of alkynyl includes compounds of formula (I) which may contain a chiral carbon having either the (R) or the (S) configuration. Another embodiment is where R is hydrogen, 1, 2, 3 or 4 independently selected R 3a C which may be substituted 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Includes compounds of formula (I) where alkynyl may contain a chiral carbon having either the (R) or the (S) configuration. Another embodiment includes compounds of formula (I) where R3 is hydrogen. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C which may be substituted 1-6 Alkyl, C 1-6 Includes compounds of formula (I) where the alkyl may contain a chiral carbon having either the (R) or the (S) configuration. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C which may be substituted 1-6This includes compounds of formula (I) wherein:

[0017] Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C selected from optionally substituted methyl, ethyl, propyl, butyl, pentyl and hexyl 1-6 This includes compounds of formula (I) wherein: Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C selected from optionally substituted methyl, ethyl, propyl, butyl and pentyl 1-6 This includes compounds of formula (I) wherein: Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C which may be substituted 1-6 Alkyl, C 1-6 Includes compounds of formula (I) where alkyl may contain a chiral carbon having the (R) configuration. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C selected from optionally substituted methyl, ethyl, propyl, butyl, pentyl and hexyl 1-6 Alkyl, C 1-6 Includes compounds of formula (I) where alkyl may contain a chiral carbon having the (R) configuration.

[0018] Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C selected from optionally substituted methyl, ethyl, propyl, butyl and pentyl 1-6 Alkyl, C 1-6 Includes compounds of formula (I) where alkyl may contain a chiral carbon having the (R) configuration. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C which may be substituted 1-6 Alkyl, C 1-6 Includes compounds of formula (I) where alkyl may contain a chiral carbon having an (S) configuration. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C selected from optionally substituted methyl, ethyl, propyl, butyl, pentyl and hexyl 1-6 Alkyl, C 1-6 Includes compounds of formula (I) where alkyl may contain a chiral carbon having an (S) configuration.

[0019] Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C selected from optionally substituted methyl, ethyl, propyl, butyl and pentyl 1-6 Alkyl, C 1-6 Includes compounds of formula (I) where alkyl may contain a chiral carbon having an (S) configuration. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C which may be substituted 2-6 alkenyl, C 2-6 Includes compounds of formula (I) where the alkenyl may contain a chiral carbon having either the (R) or the (S) configuration. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C selected from ethenyl, propenyl, butenyl, pentenyl, hexenyl and heptenyl, optionally substituted by substituents. 2-6 Includes compounds of formula (I) which are alkenyl.

[0020] Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a This includes compounds of formula (I) which are butenyl optionally substituted. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C selected from the group consisting of ethenyl, propenyl, butenyl, pentenyl, hexenyl and heptenyl, optionally substituted by substituents. 2-6 alkenyl, C 2-6 Includes compounds of formula (I) where the alkenyl may contain a chiral carbon having the (R) configuration. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a butenyl optionally substituted with a substituent, 2-6 Includes compounds of formula (I) where the alkenyl may contain a chiral carbon having the (R) configuration. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C which may be substituted 2-6 Alkynyl, C 2-6 Includes compounds of formula (I) where alkynyl may contain a chiral carbon having either the (R) or the (S) configuration.

[0021] Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C selected from the group consisting of ethenyl, propenyl, butenyl, pentenyl, hexenyl and heptenyl, optionally substituted by substituents. 2-6 alkenyl, C 2-6 Includes compounds of formula (I) where the alkenyl may contain a chiral carbon having the (S) configuration. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a butenyl optionally substituted with a substituent, 2-6 Includes compounds of formula (I) where the alkenyl may contain a chiral carbon having the (S) configuration. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C selected from ethynyl, propynyl, butynyl, pentynyl, hexynyl and heptynyl, optionally substituted by substituents. 2-6 Includes compounds of formula (I) which are alkynyl. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a This includes compounds of formula (I) which are butynyl, optionally substituted. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C selected from ethynyl, propynyl, butynyl, pentynyl, hexynyl and heptynyl, optionally substituted by substituents. 2-6 Alkynyl, C2-6 Includes compounds of formula (I) where alkynyl may contain a chiral carbon having the (R) configuration. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a butynyl optionally substituted with a substituent, 2-6 Includes compounds of formula (I) where alkynyl may contain a chiral carbon having the (R) configuration.

[0022] Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C selected from ethynyl, propynyl, butynyl, pentynyl, hexynyl and heptynyl, optionally substituted by substituents 2-6 Alkynyl, C 2-6 Includes compounds of formula (I) where alkynyl may contain a chiral carbon having the (S) configuration. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a butynyl optionally substituted with a substituent, 2-6 Includes compounds of formula (I) where alkynyl may contain a chiral carbon having the (S) configuration. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C which may be substituted 1-6 Alkyl-amino, C 1-6 Includes compounds of formula (I) where the alkyl may contain a chiral carbon having either the (R) or the (S) configuration.

[0023] Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C which may be substituted 1-6 Includes compounds of formula (I) which are alkyl-amino. Another embodiment is where R3 is C 1-6 Alkyl-amino, C 1-6 alkyl is one, two, three or four independently selected R 3aThe compounds of formula (I) include those wherein the substituents are selected from optionally substituted methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl and tert-butyl. Another embodiment is where R3 is C 1-6 Alkyl-amino, C 1-6 alkyl is one, two, three or four independently selected R 3a This includes compounds of formula (I) wherein propyl is optionally substituted.

[0024] Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C which may be substituted 1-6 Alkyl-amino, C 1-6 Includes compounds of formula (I) where alkyl may contain a chiral carbon having the (R) configuration. Another embodiment is where R3 is C 1-6 Alkyl-amino, C 1-6 alkyl is one, two, three or four independently selected R 3a is selected from methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl and tert-butyl, which may be substituted by substituents; 1-6 Includes compounds of formula (I) where alkyl may contain a chiral carbon having the (R) configuration.

[0025] Another embodiment is where R3 is C 1-6 Alkyl-amino, C 1-6 alkyl is one, two, three or four independently selected R 3a propyl which may be substituted with a substituent, 1-6 Includes compounds of formula (I) where alkyl may contain a chiral carbon having the (R) configuration. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C which may be substituted 1-6 Alkyl-amino, C 1-6 Includes compounds of formula (I) where alkyl may contain a chiral carbon having an (S) configuration. Another embodiment is where R3 is C1-6 Alkyl-amino, C 1-6 alkyl is one, two, three or four independently selected R 3a is selected from methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl and tert-butyl, which may be substituted by substituents; 1-6 Includes compounds of formula (I) where alkyl may contain a chiral carbon having an (S) configuration.

[0026] Another embodiment is where R3 is C 1-6 Alkyl-amino, C 1-6 alkyl is one, two, three or four independently selected R 3a propyl which may be substituted with a substituent, 1-6 Includes compounds of formula (I) where alkyl may contain a chiral carbon having an (S) configuration. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a C is selected from optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. 3-10 Includes compounds of formula (I) which are cycloalkyl. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a Includes compounds of formula (I) which are cyclopropyl or cyclopentyl, optionally substituted.

[0027] Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a and optionally substituted heterocyclyl, which is a radical of a monocyclic carbon atom ring structure having 3 to 7 members and containing 1 to 3 heteroatoms selected from N, O and S, and which may contain a chiral carbon having the (R) or (S) configuration, including compounds of formula (I). Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3aIncludes compounds of formula (I) which are heterocyclyl selected from optionally substituted azetidinyl, oxetanyl, pyrazolidinyl, tetrahydrofuranyl, oxazolidinyl, thiazolidinyl, isothiazolidinyl, pyrrolidinyl, piperidinyl, piperazinyl, 2H-pyranyl, tetrahydropyranyl, morpholinyl, 1,3-oxazinanyl and azepanyl. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a This includes compounds of formula (I) which are azetidinyl, optionally substituted.

[0028] Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a Azetidin-2-yl, azetidin-3-yl, oxetan-2-yl, oxetan-3-yl, pyrazolidin-1-yl, pyrazolidin-2-yl, pyrazolidin-3-yl, pyrazolidin-4-yl, pyrazolidin-5-yl, tetrahydrofuran-1-yl, tetrahydrofuran-2-yl, oxazolidin-2-yl, oxazolidin-4-yl, oxazolidin-5-yl, thiazolidin-2-yl, thiazolidin-4-yl, thiazolidin-5-yl, isothiazolidin-3-yl, isothiazolidin-4-yl, isothiazolidin-5-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-4-yl, and azepan-1-yl, azepan-2-yl, azepan-3-yl, and azepan-4-yl. Another embodiment is where R3 is 1, 2, 3, or 4 independently selected R 3a This includes compounds of formula (I) that are azetidin-3-yl, optionally substituted.

[0029] In one embodiment, R 3a But cyano, halo, hydroxy, oxo, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkoxy, Halo-C 1-6 Alkoxy, carboxyl, amino, C 1-6 Alkoxy-carbonyl, C 1-6 Alkyl-amino, halo-C 1-6 Alkyl-amino, (C 1-6 alkyl)2-amino, phenyl-amino, heterocyclyl-amino, heteroaryl-amino, phenyl-(C 1-6 alkyl)-amino, heterocyclyl-(C 1-6 alkyl)-amino, heteroaryl-(C 1-6 Alkyl)-amino, C 1-6 Alkyl-thio, C 1-6 Alkyl-sulfoxyl or C 1-6 Alkyl-sulfonyl, C 3-10 Each occurrence of cycloalkyl, phenyl, heterocyclyl, and heteroaryl is selected from 1, 2, 3, or 4 independently selected R 3a’ This includes compounds of formula (I) which may be substituted with substituents.

[0030] Another aspect is R 3a But cyano, halo, hydroxy, oxo, C 1-6 Alkyl, C 1-6 Alkoxy, Halo-C 1-6 Alkoxy, carboxyl, amino, C 1-6 Alkoxy-carbonyl, C 1-6 Alkyl-amino, halo-C 1-6 Alkyl-amino, (C 1-6 alkyl)2-amino, phenyl-amino, heteroaryl-amino, phenyl-(C 1-6 alkyl)-amino, heterocyclyl-(C 1-6alkyl)-amino, heteroaryl-(C 1-6 Alkyl)-amino, C 1-6 Alkyl-thio, C 1-6 Alkyl-sulfoxyl or C 1-6 alkyl-sulfonyl, heterocyclyl is a radical of a 3-7 membered monocyclic carbon atom ring structure containing 1-3 heteroatoms selected from N, O and S, heteroaryl is a radical of a 5-8 membered monocyclic or bicyclic aromatic carbon atom ring structure containing 1-3 heteroatoms selected from N, O and S, C 3-10 Each occurrence of cycloalkyl, phenyl, heterocyclyl, and heteroaryl is selected from 1, 2, 3, or 4 independently selected R 3a’ This includes compounds of formula (I) which may be substituted with substituents.

[0031] Another aspect is R 3a is cyano. Another aspect is R 3a is halo selected from fluoro, chloro, bromo and iodo. Another aspect is R 3a is fluoro. Another aspect is R 3a is hydroxy. Another aspect is R 3a is oxo. Another aspect is R 3a is selected from methyl, ethyl, propyl, butyl, pentyl and hexyl 1-6 This includes compounds of formula (I) wherein: Another aspect is R 3a is selected from methyl and isopropyl 1-6 This includes compounds of formula (I) wherein:

[0032] Another aspect is R 3ais selected from methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, iso-butoxy, tert-butoxy, pentoxy and hexyloxy; 1-6 Includes compounds of formula (I) which are alkoxy. Another aspect is R 3a is methoxy. Another aspect is R 3a Halo-C 1-6 Alkoxy, C 1-6 Includes compounds of formula (I) where alkoxy is selected from methoxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, iso-butoxy, tert-butoxy, pentoxy and hexyloxy, partially or fully substituted with one or more halogen atoms where possible depending on available valences.

[0033] Another aspect is R 3a But, Halo-C 1-6 Alkoxy, C 1-6 Includes compounds of formula (I) where alkoxy is methoxy substituted with 3 fluorine atoms. Another aspect is R 3a is carboxyl. Another aspect is R 3a is amino. Another aspect is R 3a But, C 1-6 Alkoxy-carbonyl, C 1-6 Includes compounds of formula (I) where alkoxy is selected from methoxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, iso-butoxy, tert-butoxy, pentoxy and hexyloxy. Another aspect is R 3a But, C 1-6 Alkoxy-carbonyl, C 1-6 Includes compounds of formula (I) where alkoxy is methoxy.

[0034] Another aspect is R 3a But, C1-6 Alkyl-amino, C 1-6 Includes compounds of formula (I) where alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl and hexyl. Another aspect is R 3a But, C 1-6 Alkyl-amino, C 1-6 Includes compounds of formula (I) where alkyl is methyl. Another aspect is R 3a But, Halo-C 1-6 Alkyl-amino, C 1-6 Includes compounds of formula (I) where alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl and hexyl, partially or fully substituted with one or more halogen atoms where possible depending on available valences. Another aspect is R 3a But, Halo-C 1-6 Alkyl-amino, C 1-6 Includes compounds of formula (I) where alkyl is methyl substituted with 3 fluorine atoms.

[0035] Another aspect is R 3a However, (C 1-6 alkyl)2-amino, C 1-6 Includes compounds of formula (I) where alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl and hexyl. Another aspect is R 3a However, (C 1-6 alkyl)2-amino, C 1-6 Includes compounds of formula (I) where alkyl is methyl. Another aspect is R 3a is phenyl-amino, and phenyl is selected from 1, 2, 3, or 4 independently selected R 3a’ This includes compounds of formula (I) which may be substituted with substituents. Another aspect is R 3ais phenyl-amino, and phenyl is one independently selected R 3a’ This includes compounds of formula (I) which may be substituted with substituents.

[0036] Another aspect is R 3a is heteroaryl-amino, where heteroaryl is a radical of a 5-8 membered monocyclic or bicyclic aromatic carbon atom ring system containing 1-3 heteroatoms selected from N, O and S, and heteroaryl is selected from 1, 2, 3 or 4 independently selected R 3a’ This includes compounds of formula (I) which may be substituted with substituents. Another aspect is R 3a is heteroaryl-amino, heteroaryl is selected from furanyl, thiophenyl, 1H-pyrazolyl, 1H-imidazolyl, isoxazolyl, 1,3-thiazolyl, 1,3-oxazolyl, tetrazolyl, 1,2,3-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, and quinolinyl, and heteroaryl is selected from 1, 2, 3, or 4 independently selected R 3a’ This includes compounds of formula (I) which may be substituted with substituents. Another aspect is R 3a is heteroaryl-amino, heteroaryl is selected from 1H-pyrazolyl, pyridinyl, and pyrazinyl, and each occurrence is selected from 1, 2, 3, or 4 independently selected R 3a’ This includes compounds of formula (I) which may be substituted with substituents.

[0037] Another aspect is R 3a However, phenyl-(C 1-6 alkyl)-amino, C 1-6 alkyl is selected from methyl, ethyl, propyl, butyl, pentyl, and hexyl, and phenyl is selected from 1, 2, 3, or 4 independently selected R 3a’ This includes compounds of formula (I) which may be substituted with substituents. Another aspect is R 3a However, phenyl-(C1-6 alkyl)-amino, C 1-6 alkyl is selected from methyl, ethyl, propyl, butyl, pentyl, and hexyl, and phenyl is selected from one independently selected R 3a’ This includes compounds of formula (I) which may be substituted with substituents. Another aspect is R 3a Phenyl-(C 1-6 alkyl)-amino, C 1-6 Includes compounds of formula (I) where alkyl is methyl. Another aspect is R 3a But, C 1-6 Alkyl-thio, C 1-6 Includes compounds of formula (I) where alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl and hexyl.

[0038] Another aspect is R 3a But, C 1-6 Alkyl-thio, C 1-6 Includes compounds of formula (I) where alkyl is methyl. Another aspect is R 3a But, C 1-6 Alkyl-sulfoxyl, C 1-6 Includes compounds of formula (I) where alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl and hexyl. Another aspect is R 3a But, C 1-6 Alkyl-sulfoxyl, C 1-6 Includes compounds of formula (I) where alkyl is methyl. Another aspect is R 3a But, C 1-6 Alkyl-sulfonyl, C 1-6 Includes compounds of formula (I) where alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl and hexyl. Another aspect is R 3a But, C 1-6Alkyl-sulfonyl, C 1-6 Includes compounds of formula (I) where alkyl is methyl.

[0039] In one embodiment, R 3a’ But cyano, halo, hydroxy, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Includes compounds of formula (I) which are alkoxy or amino. Another aspect is R 3a’ But halo or C 1-6 This includes compounds of formula (I) wherein: Another aspect is R 3a’ is cyano. Another aspect is R 3a’ is halo selected from fluoro, chloro, bromo and iodo. Another aspect is R 3a’ is fluoro or chloro. Another aspect is R 3a’ is selected from methyl, ethyl, propyl, butyl, pentyl and hexyl 1-6 This includes compounds of formula (I) wherein:

[0040] Another aspect is R 3a’ This includes compounds of formula (I) wherein is derived from methyl. Another aspect is R 3a’ is selected from methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, iso-butoxy, tert-butoxy, pentoxy and hexyloxy; 1-6 Includes compounds of formula (I) which are alkoxy. Another aspect is R 3a’ is methoxy. Another aspect is R 3a’ is amino. In one embodiment, R4 is hydrogen, cyano, halo, hydroxy, C 1-6 Alkyl, halo-C 1-6 Alkyl, C1-6 Alkoxy, Halo-C 1-6 Alkoxy, Amino, C 1-6 Alkyl-amino, (C 1-6 Alkyl)2-amino, C 3-10 cycloalkyl, phenyl, heterocyclyl or heteroaryl, where heterocyclyl is a radical of a 3- to 7-membered monocyclic carbon atom ring structure containing 1-3 heteroatoms selected from N, O and S, and heteroaryl is a radical of a 5- to 8-membered monocyclic or bicyclic aromatic carbon atom ring structure containing 1-3 heteroatoms selected from N, O and S, 1-6 Alkyl, C 3-10 Each occurrence of cycloalkyl, phenyl, heterocyclyl, or heteroaryl is selected from 1, 2, 3, or 4 independently selected R 4a This includes compounds of formula (I) which may be substituted with substituents.

[0041] Another embodiment is where R4 is hydrogen, cyano, halo, hydroxy, C 1-6 Alkyl, halo-C 1-6 Alkoxy or C 3-10 Cycloalkyl, C 1-6 Alkyl or C 3-10 Cycloalkyl is one, two, three or four independently selected R 4a This includes compounds of formula (I) which may be substituted with substituents. Another embodiment includes compounds of formula (I) where R4 is hydrogen. Another embodiment includes compounds of formula (I) where R4 is cyano. Another embodiment includes compounds of formula (I) where R4 is halo selected from fluoro, chloro, bromo, and iodo. Another embodiment includes compounds of formula (I) where R4 is halo selected from chloro and bromo. Another embodiment includes compounds of formula (I) where R4 is hydroxy.

[0042] Another embodiment is a C 11111111111111111111111111111 1-6Alkyl, C 1-6 alkyl is one, two, three or four independently selected R 4a This includes compounds of formula (I) which may be substituted with substituents. Another embodiment is where R4 is 1, 2, 3, or 4 independently selected R 4a This includes compounds of formula (I) in which the aryl group is methyl, which may be substituted with a substituent. Another embodiment is where R4 is halo-C 1-6 Alkoxy, C 1-6 Includes compounds of formula (I) where alkoxy is selected from methoxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, iso-butoxy, tert-butoxy, pentoxy and hexyloxy, partially or fully substituted with one or more halogen atoms where possible depending on available valences. Another aspect is R 3a But, Halo-C 1-6 Alkoxy, C 1-6 Includes compounds of formula (I) where alkoxy is methoxy substituted with two fluorine atoms.

[0043] Another embodiment is where R4 is C 3-10 Cycloalkyl, C 3-10 Cycloalkyl is one, two, three or four independently selected R 4a This includes compounds of formula (I) which may be substituted with substituents. Another embodiment is where R4 is 1, 2, 3, or 4 independently selected R 4a C selected from optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl 3-10 Includes compounds of formula (I) which are cycloalkyl. Another embodiment is where R4 is 1, 2, 3, or 4 independently selected R 4a Includes compounds of formula (I) which are cyclopropyl, optionally substituted.

[0044] In one embodiment, R 4aBut cyano, halo, hydroxy, C 1-6 Alkyl, halo-C 1-6 Alkyl or C 1-6 Includes compounds of formula (I) which are alkoxy. In one embodiment, R5 is hydrogen, cyano, halo, hydroxy, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkoxy, carbamoyl, C 3-10 Includes compounds of formula (I) that are cycloalkyl or heterocyclyl, where heterocyclyl is a radical of a 3- to 7-membered monocyclic carbon atom ring structure containing 1 to 3 heteroatoms selected from N, O and S. Another embodiment is where R5 is hydrogen, cyano, halo or C 1-6 This includes compounds of formula (I) wherein:

[0045] Another embodiment includes compounds of Formula (I) where R5 is hydrogen. Another embodiment includes compounds of formula (I) where R5 is cyano. Another embodiment includes compounds of Formula (I) where R5 is halo selected from fluoro, chloro, bromo, and iodo.

[0046] Another embodiment includes compounds of formula (I) where R5 is chloro. Another embodiment is a C 11111111111111111111111111 1-6 This includes compounds of formula (I) wherein:

[0047] Another embodiment includes compounds of Formula (I) where R5 is methyl. In one embodiment, R6 is hydrogen, halo or C 1-6 This includes compounds of formula (I) wherein: Another embodiment includes compounds of formula (I) where R6 is hydrogen.

[0048] In one embodiment, the compound of formula (I) or a form thereof is [ka] TIFF0007587511000004.tif248164 TIFF0007587511000005.tif250158 TIFF0007587511000006.tif249160 TIFF0007587511000007.tif224165 TIFF0007587511000008.tif224164 TIFF0007587511000009.tif227164 TIFF0007587511000010.tif231165 TIFF0007587511000011.tif226162 TIFF0007587511000012.tif243166 TIFF0007587511000013.tif218163 TIFF0007587511000014.tif225163 TIFF0007587511000015.tif248158, wherein the form of the compound is selected from the group consisting of a salt, a hydrate, a solvate, and a tautomeric form thereof.

[0049] Compounds of formula (I) or embodiments thereof (compound no. 1 ) indicates that the salt form is isolated [Table 1] TIFF0007587511000017.tif248158 TIFF0007587511000018.tif248156 TIFF0007587511000019.tif249161 TIFF0007587511000020.tif248157 TIFF0007587511000021.tif248158 TIFF0007587511000022.tif250164 TIFF0007587511000023.tif216166, wherein the form of the compound is selected from the group consisting of a salt, a hydrate, a solvate, and a tautomeric form thereof.

[0050] Another embodiment of the compound of formula (I) or a form thereof is [Table 2] TIFF0007587511000025.tif248157 TIFF0007587511000026.tif249160 TIFF0007587511000027.tif250160 TIFF0007587511000028.tif249160 TIFF0007587511000029.tif248158 TIFF0007587511000030.tif42166, and the compound is in a form selected from the group consisting of a salt, a hydrate, a solvate and a tautomer. The application further provides pharmaceutical compositions comprising a compound provided herein, or a pharma- ceutically acceptable salt thereof, and at least one pharma- ceutically acceptable carrier.

[0051] The application further provides a method of treating familial dysautonomia, a disease of the central and peripheral nervous system associated with one or more pre-mRNA splicing defects, in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharma- ceutical acceptable salt thereof. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials for use in the present invention are described herein; other suitable methods and materials known in the art can also be used.

[0052] The materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflicts, the present specification, including definitions, will control.

[0053] chemistry definition The chemical terms used above and throughout the description herein shall be understood by those of skill in the art to have the following indicated meanings, unless specifically defined otherwise. As used herein, "C 1-6 The term "alkyl" generally refers to a saturated hydrocarbon radical having from 1 to 8 carbon atoms in a straight or branched arrangement, including, but not limited to, methyl, ethyl, n-propyl (also called propyl or propanyl), isopropyl, n-butyl (also called butyl or butanyl), isobutyl, sec-butyl, tert-butyl, n-pentyl (also called pentyl or pentanyl), n-hexyl (also called hexyl or hexanyl), and the like. 1-6 Alkyl is C 1-6 Alkyl, C 1-4 Alkyl, etc., but are not limited to these. 1-6 Alkyl radicals may be substituted, where available valences allow, with the types of substituents described herein.

[0054] As used herein, "hetero-C 1-6 The term "alkyl" generally refers to a saturated hydrocarbon radical having from 1 to 6 carbon atoms in a straight or branched arrangement, in which one or more heteroatoms, such as O, S or N atoms, are members in the chain, and includes, but is not limited to, hetero-methyl, hetero-ethyl, hetero-propyl, hetero-butyl, hetero-pentyl, hetero-hexyl, and the like. In certain embodiments, hetero-C 1-6 Alkyl is hetero-C 2-6Alkyl, Hetero-C 1-4 Alkyl, Hetero-C 2-4 Hetero-C 1-6 Alkyl radicals may be substituted, where available valences allow, with the types of substituents described herein.

[0055] As used herein, "C 2-6 The term "alkenyl" generally refers to a partially unsaturated hydrocarbon radical having from 2 to 8 carbon atoms in a linear or branched arrangement and having one or more carbon-carbon double bonds therein, and includes, but is not limited to, ethenyl (also called vinyl), allyl, propenyl, and the like. In certain embodiments, C 2-6 Alkenyl is C 2-6 Alkenyl, C 2-4 Alkenyl, but not limited to alkenyl. 2-6 Alkenyl radicals may be substituted, where available valences permit, with the types of substituents described herein. As used herein, "C 2-6 The term "alkynyl" generally refers to a partially unsaturated hydrocarbon radical having from 2 to 8 carbon atoms in a linear or branched arrangement and one or more carbon-carbon triple bonds therein, and includes, but is not limited to, ethynyl (also called acetylenyl), propynyl, butynyl, and the like. In certain embodiments, C 2-6 Alkynyl is C 2-6 Alkynyl, C 2-4 Alkynyl and the like. 2-6 Alkynyl radicals may be substituted, where available valences permit, with the types of substituents described herein.

[0056] As used herein, "C 1-6 The term "alkoxy" generally refers to a group of the formula: -OC 1-6Alkyl refers to a saturated hydrocarbon radical having from 1 to 8 carbon atoms in a straight or branched chain arrangement, including, but not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexoxy, and the like. 1-6 Alkoxy is C 1-6 Alkoxy, C 1-4 Alkoxy and the like. 1-6 Alkoxy radicals may be substituted, where available valences allow, with substituent types described herein.

[0057] The term "oxo" as used herein refers to a radical of the formula: =O. The term "carboxyl" as used herein refers to a radical of the formula: -COOH, -C(O)OH or -CO2H. As used herein, "C 1-6 The term "alkoxy-carbonyl" refers to a group of the formula: -COO-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl or -CO2-C 1-6 Refers to an alkyl radical. The term "carbamoyl" as used herein refers to a radical of the formula: -C(O)NH2. As used herein, "C 3-10 The term "cycloalkyl" generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic hydrocarbon radical, including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, 1H-indanyl, indenyl, tetrahydro-naphthalenyl, and the like. 3-10 Cycloalkyl is C 3-8 Cycloalkyl, C 5-8 Cycloalkyl, C 3-10 cycloalkyl, etc. 3-10Cycloalkyl radicals may be optionally substituted, where available valences permit, with the types of substituents described herein. The term "aryl" as used herein generally refers to a radical of a monocyclic, bicyclic or polycyclic aromatic ring structure of carbon atoms, including, but not limited to, phenyl, naphthyl, anthracenyl, fluorenyl, azulenyl, phenanthrenyl, etc. Aryl radicals may be substituted, where available valences permit, with the types of substituents described herein.

[0058] The term "heteroaryl" as used herein generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical in which one or more carbon atom members have been replaced, where structural stability permits, by one or more heteroatoms, such as O, S or N atoms, including, but not limited to, furanyl, thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, 1,3-thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, indolyl, indazolyl, indolizinyl, isoindolyl, benzofuranyl, benzothiophenyl, benzimidazolyl, 1,3-benzothiazolyl, 1,3-benzoxazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, and the like. Heteroaryl radicals may be substituted, where available valences permit on the carbon or nitrogen ring members, with the types of substituents described herein.

[0059] In certain aspects, the nomenclature of heteroaryl radicals may be different, for example and non-limiting example, furanyl may be referred to as furyl, thiophenyl may be referred to as thienyl, pyridinyl may be referred to as pyridyl, benzothiophenyl may be referred to as benzothienyl, and 1,3-benzoxazolyl may be referred to as 1,3-benzooxazolyl.

[0060] In certain other aspects, the terms relating to heteroaryl radicals may also include other positional isomers, for example and in non-limiting examples, the term pyrrolyl may include 2H-pyrrolyl, 3H-pyrrolyl, etc., the term pyrazolyl may include 1H-pyrazolyl, etc., the term imidazolyl may include 1H-imidazolyl, etc., the term triazolyl may include 1H-1,2,3-triazolyl, etc., the term oxadiazolyl may include 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, etc., the term tetrazolyl may include 1H-tetrazolyl, 2H-tetrazolyl, etc., the term indolyl may include 1H-indolyl, etc., the term indazolyl may include 1H-indazolyl, 2H-indazolyl, etc., the term benzimidazolyl may also include 1H-benzimidazolyl, the term purinyl may include 9H-purinyl, etc.

[0061] The term "heterocyclyl" as used herein generally refers to radicals of saturated or partially unsaturated monocyclic, bicyclic or polycyclic carbon atom ring structures in which one or more carbon atom ring members have been replaced, where structural stability permits, by a heteroatom, such as an O, S or N atom, and includes oxiranyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, isoxazolinyl, isoxazolidinyl, isothiazolinyl, isothiazolidinyl, oxazolinyl, oxazoline, oxazolinyl ... Examples include, but are not limited to, lysinyl, thiazolinyl, thiazolidinyl, triazolinyl, triazolidinyl, oxadiazolinyl, oxadiazolidinyl, thiadiazolinyl, thiadiazolidinyl, tetrazolinyl, tetrazolidinyl, pyranyl, dihydro-2H-pyranyl, tetrahydropyranyl, thiopyranyl, 1,3-dioxanyl, 1,3-oxazinanyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,4-diazepanyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl, etc. Heterocyclyl radicals may be substituted on either the carbon or nitrogen atom ring members, where available valences permit, with the types of substituents described herein.

[0062] As used herein, "C 1-6 The term "alkyl-amino" refers to a radical of the formula: -NH-C1-6 alkyl. As used herein, "halo-C" means 1-6 The term "alkyl-amino" refers to a group of the formula: -NH-C 1-6 Alkyl (wherein 1-6 Alkyl refers to a radical which, where available valences permit, is partially or fully substituted with one or more halogen atoms. As used herein, "(C 1-6 The term "amino" refers to a group of the formula: -N(C 1-6 It refers to the radical (alkyl)2. As used herein, "C 1-6 The term "alkyl-carboxyl-amino" refers to a radical of the formula: -NH-C(O)-. The term "aryl-amino" as used herein refers to a radical of the formula: --NH-aryl. The term "heterocyclyl-amino" as used herein refers to a radical of the formula: -NH-heterocyclyl. The term "heteroaryl-amino" as used herein refers to a radical of the formula: -NH-heteroaryl.

[0063] As used herein, “aryl-(C 1-6 The term "amino" refers to a group of the formula: -N(C 1-6 It refers to the radical alkyl-aryl. As used herein, “heterocyclyl-(C 1-6 The term "amino" refers to a group of the formula: -N(C 1-6 (alkyl)-heterocyclyl radical. As used herein, “heteroaryl-(C 1-6 The term "amino" refers to a group of the formula: -N(C 1-6 It refers to the radical (alkyl)-heteroaryl. As used herein, "C 1-6 The term "alkyl-thio" refers to a group of the formula: -SC 1-6 Refers to an alkyl radical.

[0064] As used herein, "C 1-6 The term "alkyl-sulfoxyl" refers to a group of the formula: -S(O)-C 1-6 Refers to an alkyl radical. As used herein, "C 1-6 The term "alkyl-sulfonyl" refers to a group of the formula: -SO2-C 1-6 Refers to an alkyl radical. The term "halo" or "halogen" as used herein generally refers to a halogen atom radical and includes fluoro, chloro, bromo and iodo. As used herein, "halo-C" means 1-6 The term "alkoxy" means a group of the formula: -OC 1-6 Alkyl-halo (wherein 1-6 Alkyl refers to a radical which, where available valences permit, is partially or fully substituted with one or more halogen atoms.

[0065] As used herein, "halo-C" means 1-6 The term "alkyl" refers to a group of the formula: 1-6 Alkyl-halo (wherein 1-6 Alkyl refers to a radical which, where available valences permit, is partially or fully substituted with one or more halogen atoms. As used herein, the term "hydroxy" refers to a radical of the formula: --OH. As used herein, "hydroxy-C 1-6 The term "alkyl" refers to a group of the formula: 1-6 Alkyl-OH (wherein 1-6 Alkyl refers to a radical which, where available valences permit, is partially or fully substituted with one or more hydroxyl radicals.

[0066] The term "substituent" as used herein means a position variable on an atom of a core molecule that is substituted at a designated atomic position and replaces one or more hydrogens on the designated atom, provided that the normal valence of the designated atom is not exceeded and the substitution results in a stable compound. Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds. Those skilled in the art should note that any carbon and heteroatom with a valence that is not expected to be satisfied as described or shown herein is presumed to have a sufficient number of hydrogen atoms to satisfy the valence described or shown. In some instances, one or more substituents with a double bond as a point of attachment (e.g., "oxo" or "=O") may be described, shown, or listed in the substituents herein, and the structure may show only a single bond as a point of attachment to the core structure of formula (I). Those skilled in the art will understand that even if only a single bond is shown, a double bond is intended for such a substituent.

[0067] With respect to the definitions of chemical terms provided herein, the term "such as" as used herein means that variations in chemical structures that one of ordinary skill in the art would expect include, but are not limited to, isomers (including chain, branched or positional structural isomers), hydration of ring systems (including saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring structures), and other variations that, where available valences permit, result in stable compounds. For purposes of this description, when one or more substituted variables of a compound of formula (I) or a form thereof include functional groups that are incorporated in a compound of formula (I), each functional group appearing anywhere within the disclosed compound can be independently selected and, optionally, independently and / or optionally substituted.

[0068] As used herein, the term "independently selected" or "each selected" refers to a functional variable in a list of substituents that may occur more than once on the structure of formula (I), and the substitution pattern at each occurrence is independent of the pattern at any other occurrence. Furthermore, it is understood that the use of a generic substitution variable on any formula or structure to the compounds described herein includes the replacement of the generic substituent with a substituent of a chemical species included within the particular genus, for example, aryl can be replaced with phenyl or naphthalenyl, etc., and the resulting compound would be included within the scope of the compounds described herein. As used herein, the terms "each occurrence" or "if present, at each occurrence" are intended to include, for example, "... 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, aryl, aryl-C 1-4 Alkyl, Heteroaryl, Heteroaryl-C 1-4 Alkyl, heterocyclyl and heterocyclyl-C 1-4 When used following the term "alkyl", each when present alone or as a substituent, is 3-10 It is intended to refer to cycloalkyl, aryl, heteroaryl and heterocyclyl ring systems. The term "optionally substituted," as used herein, means optional substitution with the specified substituted variable, group, radical or moiety.

[0069] Compound Form The term "form" as used herein means a compound of formula (I) having a form selected from the group consisting of its free acid, free base, salt, hydrate, solvate, racemate, enantiomeric, diastereomeric, stereoisomeric and tautomeric forms. In certain embodiments described herein, the compound of formula (I) is in the form of a free acid, a free base, or a salt thereof. In certain embodiments described herein, the compound of formula (I) is in the form of a salt thereof.

[0070] In certain embodiments described herein, the compound of formula (I) may be in the form of a stereoisomer, racemate, enantiomer or diastereoisomer thereof. In certain embodiments described herein, the compounds of formula (I) may be in the form of a tautomer thereof. In certain embodiments described herein, the compound of formula (I) is in a pharma- ceutically acceptable form. In certain embodiments described herein, a compound of formula (I) or a form thereof is isolated for use. As used herein, the term "isolated" refers to the physical state of a compound of formula (I) or a form thereof after it has been isolated and / or purified from a synthetic process (e.g., from a reaction mixture), or from a natural source, or a combination thereof, in sufficient purity to be characterized by standard analytical techniques described herein or known to those of skill in the art, according to an isolation or purification process or processes described herein or known to those of skill in the art (e.g., chromatography, recrystallization, etc.).

[0071] The term "protected" as used herein means that a functional group in a compound of formula (I) or a form thereof is in a form modified to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups are known by those skilled in the art and by reference to TW Greene et al, Protective Groups in organic Synthesis (1991), Wiley, New York. Such functional groups include hydroxy, phenol, amino, and carboxylic acid. Suitable protecting groups for hydroxy or phenol include trialkylsilyl or diarylalkylsilyl (e.g., t-butyldimethylsilyl, t-butyldiphenylsilyl, or trimethylsilyl), tetrahydropyranyl, benzyl, substituted benzyl, methyl, methoxymethanol, and the like. Suitable protecting groups for amino, amidino, and guanidino include t-butoxycarbonyl, benzyloxycarbonyl, and the like. Suitable protecting groups for carboxylic acid include alkyl, aryl, or arylalkyl esters. In one example, the protecting group may be a polymer resin, such as Wang resin or 2-chlorotrityl-chloride resin. Protective groups can be added or removed according to standard techniques well known to those skilled in the art and described herein. It will also be recognized by those skilled in the art that such protected derivatives of the compounds described herein may not possess pharmacological activity themselves, but they may be administered to a subject and then metabolized in the body to form the pharmacologically active compounds described herein. Such derivatives may therefore be described as "prodrugs". All prodrugs of the compounds described herein are within the scope of the uses described herein.

[0072] The term "prodrug" as used herein refers to a form of the compound (e.g., a drug precursor) that is converted in vivo to obtain the active compound of formula (I) or a form thereof. The conversion can occur by various mechanisms (e.g., by metabolic and / or non-metabolic chemical processes), for example, by hydrolysis and / or metabolism in blood, liver and / or other organs and tissues. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the ACS Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.

[0073] In one example, when the compound of formula (I) or a form thereof contains a carboxylic acid functional group, the prodrug may include an ester formed by replacing the hydrogen atom of the acidic group with a functional group, such as an alkyl. In another example, when the compound of formula (I) or a form thereof contains a hydroxyl functional group, the prodrug form may be prepared by replacing the hydrogen atom of the hydroxyl with another functional group, such as an alkyl, alkylcarbonyl, or phosphonate ester. In another example, when the compound of formula (I) or a form thereof contains an amine functional group, the prodrug form may be prepared by replacing one or more of the amine hydrogen atoms with a functional group, such as an alkyl or substituted carbonyl. Pharmaceutically acceptable prodrugs of the compound of formula (I) or a form thereof include compounds substituted with one or more of the following groups: carboxylate ester, sulfonate ester, amino acid ester, phosphonate ester, and mono-, di-, or triphosphate ester, or alkyl substituents, as appropriate. It will be appreciated by those skilled in the art that one or more of such substituents, as described herein, may be used to obtain a compound of formula (I) or a form thereof as a prodrug.

[0074] One or more compounds described herein may exist in unsolvated as well as solvated forms with pharma- ceutically acceptable solvents, such as water, ethanol, and the description herein is intended to encompass both solvated and unsolvated forms. The term "solvate" as used herein refers to the physical association of a compound described herein with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonds, including hydrogen bonds. In some instances, a solvate can be isolated, for example when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. As used herein, "solvate" encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like.

[0075] As used herein, the term "hydrate" refers to a solvate where the solvent molecule is water.

[0076] The compound of formula (I) may form salts, which are intended to be included within the scope of this description. Reference herein to the compound of formula (I) or a form thereof is understood to include reference to its salt forms, unless otherwise indicated. The term "salt(s)" as used herein refers to acid salts formed with inorganic and / or organic acids, and basic salts formed with inorganic and / or organic bases. Furthermore, when the compound of formula (I) or a form thereof contains both a basic moiety, such as, but not limited to, an amine moiety, and an acidic moiety, such as, but not limited to, a carboxylic acid, zwitterions ("internal salts") may be formed and may be included within the term "salt(s)" as used herein. As used herein, the term "pharmaceutical acceptable salt(s)" refers to salts of the compounds described herein that are safe and effective for use in mammals (i.e., non-toxic, physiologically acceptable) and that possess biological activity, although other salts are also useful. Salts of the compounds of formula (I) can be formed, for example, by reacting the compound of formula (I) or a form thereof with an amount, e.g., an equivalent amount, of an acid or base in a medium, e.g., one in which the salt is precipitated or in an aqueous medium, followed by lyophilization.

[0077] Pharmaceutically acceptable salts include salts of one or more of the acidic or basic groups present in the compounds described herein.Specific embodiments of acid addition salts include, but are not limited to, acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, bitartrate, borate, bromide, butyrate, chloride, citrate, camphorate, camphorsulfonate, ethanesulfonate, formate, fumarate, gentisate, gluconate, glucaronate, glutamate, iodide, isonicotinate, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, pamoate, pantothenate, phosphate, propionate, saccharate, salicylate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate (also known as tosylate), trifluoroacetate, etc. Certain embodiments of acid addition salts include chlorides or dichlorides.

[0078] Additionally, acids generally considered suitable for forming pharma- ceutically useful salts from basic pharmaceutical compounds are discussed, for example, in P. Stahl et al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33, 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and The Orange Book (Food & Drug Administration, Washington, DC on their website), the disclosures of which are incorporated herein by reference. Suitable base salts include, but are not limited to, aluminum, ammonium, calcium, lithium, magnesium, potassium, sodium and zinc salts. All such acid and base salts are intended to be included within the scope of pharma- ceutically acceptable salts described herein, and furthermore, all such acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of this description.

[0079] Compounds of formula (I) and forms thereof may further exist in tautomeric forms, and all such tautomeric forms are assumed and intended to be included within the scope of the compounds of formula (I) or forms thereof described herein. The compounds of formula (I) or a form thereof may contain asymmetric or chiral centers and therefore may exist as different stereoisomers. This specification is intended to include all stereoisomers of the compounds of formula (I) as well as mixtures thereof, including racemic mixtures.

[0080] The compounds described herein may contain one or more chiral centers and may exist as racemic mixtures (R / S) or as substantially pure enantiomers and diastereoisomers. The compounds may also exist as substantially pure (R) or (S) enantiomers (if one chiral center is present). In one particular embodiment, the compounds described herein are (S) isomers and may exist as enantiomerically pure compositions that substantially contain only the (S) isomer. In another particular embodiment, the compounds described herein are (R) isomers and may exist as enantiomerically pure compositions that substantially contain only the (R) isomer. Those skilled in the art will appreciate that if more than one chiral center is present, the compounds described herein may also exist as (R,R), (R,S), (S,R) or (S,S) isomers as defined by IUPAC nomenclature recommendations. As used herein, the term "chiral" refers to a carbon atom that is bonded to four nonidentical substituents. The stereochemical definitions and conventions used herein generally According to SP Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994. In describing optically active compounds, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule around its chiral center(s). The substituents attached to said chiral centers are ranked according to the Cahn, Ingold and Prelog precedence rules (Cahn et al. Angew. Chem. Inter. Edit. 1966, 5, 385; errata 511).

[0081] As used herein, the term "substantially pure" refers to a compound that consists essentially of 90% or more, 92% or more, 95% or more, 98% or more, 99% or more, or equal to 100% of a single isomer. In one illustrative aspect, the compound of formula (I) or a form thereof is a substantially pure (S) enantiomeric form present in an amount of 90% or more, 92% or more, 95% or more, 98% or more, 99% or more, or an amount equal to 100%. In one illustrative aspect, the compound of formula (I) or a form thereof is a substantially pure (R) enantiomeric form present in an amount of 90% or more, in an amount of 92% or more, in an amount of 95% or more, in an amount of 98% or more, in an amount of 99% or more, or in an amount equal to 100%.

[0082] As used herein, a "racemate" is any mixture of isometric forms that is not "enantiomerically pure," including, for example, but not limited to, mixtures in ratios of about 50 / 50, about 60 / 40, about 70 / 30, or about 80 / 20. Furthermore, the present specification encompasses all geometric and positional isomers. For example, when a compound of formula (I) or a form thereof incorporates a double bond or fused ring, both cis- and trans-forms, as well as mixtures, are encompassed within the scope of the description. Diastereoisomeric mixtures can be separated into their individual diastereoisomers based on their physicochemical differences by methods well known to those skilled in the art, for example, by chromatography and / or fractional crystallization. Enantiomers can be separated by using chiral HPLC columns or other chromatographic methods known to those skilled in the art. Enantiomers can also be separated by conversion of the enantiomeric mixture to a diastereoisomeric mixture by reaction with a suitable optically active compound (e.g., a chiral auxiliary, e.g., a chiral alcohol or Mosher's acid chloride), separation of the diastereoisomers, and conversion of the individual diastereoisomers to the corresponding pure enantiomers (e.g., hydrolysis). Some of the compounds of formula (I) may also be atropisomers (e.g., substituted biaryls) and are considered as part of this description.

[0083] All stereoisomers (e.g., geometric isomers, optical isomers) of the compounds (including salts, solvates, esters and prodrugs of the compounds, and salts, solvates and esters of the prodrugs), including enantiomeric forms (which may exist even without asymmetric carbons), rotamer forms, atropisomers and diastereoisomeric forms, which may exist due to asymmetric carbons on various substituents, are contemplated within the scope of this description, as are positional isomers (e.g., 4-pyridyl and 3-pyridyl). Individual stereoisomers of the compounds described herein may, for example, be substantially free of other isomers or may be present in the racemic mixtures described above.

[0084] Use of the terms "salts," "solvates," "esters," "prodrugs," and the like are intended to apply equally to the salts, solvates, esters and prodrugs of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or isotopologues of the present compounds.

[0085] The term "isotopologue" refers to an isotope-enriched compound described herein that is identical to that recited herein except that one or more atoms have been replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number normally found in nature. Examples of isotopes that may be incorporated into the compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, e.g., 2 H, 3 H, 13 C. 14 C. 15 N, 18 O. 17 O. 31 P, 32 P, 35 S, 18 F, 35 Cl and 36 Cl, each of which is also within the scope of this description. Certain isotopically enriched compounds described herein (e.g., 3 H and 14 C) are useful for compound and / or substrate tissue distribution assays. 3 H) and carbon-14 (i.e. 14 C) isotopes are particularly preferred because they are easily prepared and detectable. Additionally, heavier isotopes, such as deuterium (i.e., 2 H) may be preferred in some circumstances since it may provide certain therapeutic advantages resulting from increased metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements).

[0086] Use of the compound Provided herein is a method for treating a disease in a subject in need of the method. The term "subject" as used herein refers to any animal, including mammals, for example, mice, rats, other rodents, rabbits, dogs, cats, pigs, cows, sheep, horses, primates and humans. In some embodiments, the subject is a human. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of a compound provided herein (e.g., a compound of formula (I)) or a pharmacologic acceptable salt thereof. In certain embodiments, the disease is familial dysautonomia, a disease of the central and peripheral nervous system associated with one or more pre-mRNA splicing defects.

[0087] The application further provides a method of treating familial dysautonomia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula (I)). In some embodiments of the methods provided herein, the compound is selected from the group of compounds of formula (I): or a pharma- ceutically acceptable salt thereof. In some aspects, a method for improving pre-mRNA splicing of the IKBKAP gene includes contacting the gene (e.g., in a cell or subject expressing the gene) with a compound provided herein (e.g., a compound of Formula (I)).

[0088] As used herein, the phrase "therapeutically effective amount" refers to an amount of an active compound or pharmaceutical agent that elicits a desired biological or medical response in a tissue, system, animal, individual, or human by a researcher, veterinarian, physician, or other clinician. In some embodiments, the dosage of the compound or a pharmacopoeiacally acceptable salt thereof administered to a subject or individual is about 1 mg to about 2 g, about 1 mg to about 1000 mg, about 1 mg to about 500 mg, about 1 mg to about 100 mg, about 1 mg to about 50 mg, or about 50 mg to about 500 mg. The term "treating" or "treatment" as used herein refers to one or more of: (1) preventing a disease; e.g., preventing a disease, condition, or disorder in an individual who may be predisposed to the disease, condition, or disorder but who does not further develop or exhibit the pathology or symptomology of the disease; (2) inhibiting a disease; e.g., inhibiting a disease, condition, or disorder (i.e., halting further development of the pathology and / or symptomology) in an individual who does or exhibits the pathology or symptomology of the disease, condition, or disorder; and (3) ameliorating a disease; e.g., ameliorating a disease, condition, or disorder (i.e., abrogating the pathology and / or symptomology) in an individual who does or exhibits the pathology or symptomology of the disease, condition, or disorder, e.g., reducing the severity of the disease or suppressing or alleviating one or more symptoms of the disease.

[0089] Also provided herein is a method for increasing IKBKAP (also referred to as ELP1) protein expression in a patient in need thereof, the method comprising administering to the patient an effective amount of a compound provided herein (i.e., a compound of formula (I) or a pharma- ceutically acceptable salt thereof). For example, such a method comprises increasing IKBKAP protein expression in a serum sample from the patient. Further provided herein is a method for increasing the average percentage of IKBKAP protein expression in a patient in need thereof, the method comprising administering to the patient an effective amount of a compound provided herein (i.e., a compound of formula (I) or a pharma-ceutically acceptable salt thereof). Also provided herein is a method for increasing IKBKAP protein expression in a cell (e.g., ex vivo or in vivo), comprising contacting the cell with a therapeutically effective amount of a compound provided herein (i.e., a compound of formula (I) or a pharma- ceutically acceptable salt thereof). In some embodiments, the method is an in vitro method. In some embodiments, the method is an in vivo method. In some embodiments, the amount of IKBKAP protein expression is increased in a cell selected from the group consisting of a lung cell, a muscle cell, a liver cell, a heart cell, a brain cell, a kidney cell, and a neuronal cell (e.g., a sciatic neuron or a trigeminal neuron), or any combination thereof. In some embodiments thereof, the amount of IKBKAP protein expression is increased in plasma.

[0090] Also provided herein is a method for increasing IKBKAP protein levels in a patient in need thereof, the method comprising administering to the patient an effective amount of a compound provided herein (i.e., a compound of formula (I) or a pharma- ceutically acceptable salt thereof). For example, such a method comprises increasing IKBKAP protein levels in a serum sample from the patient. Further provided herein is a method for increasing the mean percentage of IKBKAP protein levels in a patient in need thereof, the method comprising administering to the patient an effective amount of a compound provided herein (i.e., a compound of formula (I) or a pharma-ceutically acceptable salt thereof).

[0091] Also provided herein is a method for increasing IKBKAP protein levels in a cell (e.g., ex vivo or in vivo), comprising contacting the cell with a therapeutically effective amount of a compound provided herein (i.e., a compound of Formula (I) or a pharma- ceutically acceptable salt thereof). In some embodiments, the method is an in vitro method. In some embodiments, the method is an in vivo method. In some embodiments, the level of the amount of IKBKAP protein is increased in cells selected from the group consisting of lung cells, muscle cells, liver cells, heart cells, brain cells, kidney cells and neuronal cells (e.g., sciatic nerve cells or trigeminal nerve cells) or any combination thereof. In some embodiments, the level of the amount of IKBKAP protein is increased in plasma.

[0092] Also provided herein is a method for increasing full-length IKBKAP mRNA in a patient in need thereof, comprising administering to the patient an effective amount of a compound provided herein (i.e., a compound of formula (I) or a pharma- ceutically acceptable salt thereof). For example, such a method comprises increasing the concentration of full-length IKBKAP mRNA in a serum sample from the patient. Further provided herein is a method for increasing the average percentage of exon inclusion (i.e., the percentage of correctly spliced ​​or full-length IKBKAP mRNA) in a patient in need thereof, comprising administering to the patient an effective amount of a compound provided herein (i.e., a compound of formula (I) or a pharma-ceutically acceptable salt thereof). In some embodiments, full-length IKBKAP mRNA can be measured in serum, for example, in blood samples obtained from patients before administration of a compound provided herein, and in blood samples obtained from patients after administration of a compound provided herein.In some embodiments, blood samples obtained from patients after administration are obtained 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 14 days, 21 days, 28 days, and / or 30 days after administration of a compound provided herein.See, for example, FB Axelrod et al., Pediatr Res (2011) 70(5): 480-483; and RS Shetty et al., Human Molecular Genetics (2011) 20(21): 4093-4101, both of which are incorporated by reference in their entirety.

[0093] Further provided herein is a method for increasing full-length IKBKAP mRNA in a cell, comprising contacting the cell with a therapeutically effective amount of a compound provided herein (i.e., a compound of formula (I)). The amount of full-length IKBKAP mRNA in the treated cell is increased compared to the cell in a subject without the compound provided herein. The method for increasing the amount of full-length IKBKAP mRNA in a cell can be carried out by contacting the cell with a compound provided herein (i.e., a compound of formula (I) or a medicamentously acceptable salt form thereof) in vitro, thereby increasing the amount of full-length IKBKAP mRNA in the cell in vitro. The use of such in vitro methods for increasing the amount of full-length IKBKAP mRNA includes, but is not limited to, in screening assays (e.g., the compound provided herein is used as a positive control or standard for a compound(s) with unknown activity or efficacy in increasing the amount of full-length IKBKAP mRNA). In some embodiments, the amount of full-length IKBKAP mRNA is increased in cells selected from the group consisting of lung cells, muscle cells, liver cells, heart cells, brain cells, kidney cells and neuronal cells (e.g., sciatic or trigeminal neuronal cells), or any combination thereof, hi some embodiments thereof, the amount of full-length IKBKAP mRNA is increased in plasma.

[0094] The method of increasing full-length IKBKAP mRNA in a cell can be carried out, for example, by contacting a cell (e.g., a lung cell, a muscle cell, a liver cell, a heart cell, a brain cell, a kidney cell or a nerve cell) with a compound provided herein (i.e., a compound of formula (I) or a pharma- ceutically acceptable salt thereof) in vivo, thereby increasing the amount of full-length IKBKAP mRNA in a subject in vivo. The contact is achieved by having a compound provided herein or a pharma-ceutically acceptable salt form thereof present in the subject in an amount effective to achieve an increase in the amount of full-length IKBKAP mRNA. This can be achieved, for example, by administering an effective amount of a compound provided herein or a pharma-ceutically acceptable salt form thereof to the subject. The use of such in vivo methods of increasing the amount of full-length IKBKAP mRNA includes, but is not limited to, use in a method of treating a disease or condition in which an increase in the amount of full-length IKBKAP mRNA is beneficial. In some embodiments thereof, the amount of full-length IKBKAP mRNA is increased in a cell selected from the group consisting of lung cells, muscle cells, liver cells, heart cells, brain cells, kidney cells, and nerve cells (e.g., sciatic nerve cells or trigeminal nerve cells), or any combination thereof, in a patient suffering from, for example, a disease or disorder provided herein (e.g., familial dysautonomia).The method is preferably effected by administering an effective amount of a compound provided herein, or a medicamentously acceptable salt form thereof, to a subject suffering from familial dysautonomia. In some aspects, one or more of the compounds provided herein may be administered to a subject in need thereof in combination with at least one additional pharmaceutical agent. In some embodiments, the additional pharmaceutical agent is a compound provided herein (e.g., a compound of formula (I)).

[0095] Additional examples of additional pharmaceutical agents suitable for use in combination with the compounds of the present application for treating the diseases presented herein include, but are not limited to, antioxidants, anti-inflammatory agents, steroids, immunosuppressants or other agents, such as therapeutic antibodies.In some aspects, the compounds provided herein can be administered to a subject in need thereof in combination with at least one additional pharmaceutical agent to treat familial dysautonomia.In some embodiments, the additional pharmaceutical agent is phosphatidylserine.

[0096] When used as therapeutic agents, the compounds provided herein may be administered in the form of pharmaceutical compositions, and thus the methods described herein may include administering the pharmaceutical compositions. These compositions may be prepared as described herein or elsewhere, and may be administered by a variety of routes, depending on whether local or systemic treatment is desired and the area to be treated. Administration may be intrapulmonary (e.g., by inhalation or insufflation of powders or aerosols, such as by a nebulizer; intratracheal or intranasal), oral, or parenteral. Parenteral administration may include, but is not limited to, intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular infusion or injection; or intracranial (e.g., intrathecal, intraocular, or intraventricular) administration. Parenteral administration may be in the form of a single bolus dose, or may be, for example, by a continuous infusion pump. Conventional pharmaceutical carriers, aqueous, powder or oil bases, thickeners, and the like, may be necessary or desirable. In some aspects, the compounds provided herein are suitable for oral and parenteral administration. In some aspects, the compounds provided herein are suitable for oral administration. In some embodiments, the compounds provided herein are suitable for parenteral administration. In some embodiments, the compounds provided herein are suitable for intravenous administration. In some embodiments, the compounds provided herein are suitable for transdermal administration (e.g., administration using a patch or microneedle). Pharmaceutical compositions for topical administration may include transdermal patches (e.g., regular or electrostimulation type), ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners, and the like may be necessary or desirable.

[0097] Also provided are pharmaceutical compositions that contain as active ingredients a compound provided herein (e.g., a compound of formula (I)) or a pharma- ceutical acceptable salt thereof in combination with one or more pharma- ceutical acceptable carriers (excipients). In making the compositions provided herein, the active ingredient is typically mixed with an excipient, diluted by an excipient, or enclosed within such a carrier, for example, in the form of a capsule, sachet, paper, or other container. When an excipient serves as a diluent, it can be a solid, semi-solid, or liquid material that acts as a vehicle, carrier, or medium for the active ingredient. Thus, the composition can be in the form of a tablet, pill, powder, lozenge, sachet, cachet, elixir, suspension, emulsion, solution, syrup, aerosol (as a solid or in a liquid medium), ointment, soft and hard gelatin capsules, suppositories, sterile injection solutions, and sterile packaged powders.

[0098] Some examples of suitable excipients include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methylcellulose.The formulation may further include, but is not limited to, lubricants such as talc, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preservatives such as methyl benzoate and propyl hydroxybenzoate; sweeteners; flavoring agents or combinations thereof.

[0099] The active compound can be effective over a wide dosage range and is generally administered in a medicamentously effective amount.It is understood that the amount of compound administered and the administration schedule are usually determined by the physician according to the relevant circumstances, including the condition to be treated, the route of administration selected, the actual compound to be administered, the age, weight and response of the individual subject, the severity of the subject's symptoms, etc.

[0100] Also provided herein is a kit that includes a compound provided herein, more particularly a compound of formula (I) or a pharma- ceutically acceptable salt thereof.In some embodiments, the kit can include, for example, one or more delivery systems for the compound provided herein or a pharma- ceutically acceptable salt thereof, and instructions for using the kit (e.g., instructions for treating a subject).In some embodiments, the kit can include a compound provided herein or a pharma- ceutically acceptable salt thereof, and one or more additional agents as described herein. In some embodiments, the kit can include one or more compounds provided herein or additional pharmaceuticals, or pharmacologic acceptable salts thereof, and a label indicating that the contents should be administered to a subject who is resistant to standard of care agents or adjuvants used in the treatment of familial dysautonomia.In some embodiments, the additional pharmaceutical is phosphatidylserine.In another embodiment, the kit can include one or more compounds provided herein or additional pharmaceuticals, or pharmacologic acceptable salts thereof, and a label indicating that the contents should be administered to a subject who has cells that express abnormal IKBKAP pre-mRNA splicing.In another embodiment, the kit can include one or more compounds provided herein or additional pharmaceuticals, or pharmacologic acceptable salts thereof, and a label indicating that the contents should be administered to a subject who has a disease of the central nervous system or peripheral nervous system that results from abnormal pre-mRNA splicing.

[0101] In another embodiment, the kit can include one or more compounds provided herein or additional pharmaceuticals, or pharmacologic acceptable salts thereof, and a label indicating that the contents should be administered to a subject with familial dysautonomia.In some embodiments, the kit can include one or more compounds provided herein or pharmacologic acceptable salts thereof, and a label indicating that the contents should be administered with one or more additional pharmaceuticals provided herein.

[0102] In another embodiment, the concentration-biological effect relationship observed for the compound of formula (I) or a form thereof indicates a target plasma concentration in the range of about 0.001 μg·hr / mL to about 50 μg·hr / mL, about 0.01 μg·hr / mL to about 20 μg·hr / mL, about 0.05 μg·hr / mL to about 10 μg·hr / mL, or about 0.1 μg·hr / mL to about 5 μg·hr / mL. To achieve such plasma concentrations, the compounds described herein may be administered at varying doses, including but not limited to, from 1.0 ng to 10,000 mg.

[0103] In one embodiment, the dose administered to achieve an effective target plasma concentration may be administered based on subject or patient specific factors, and may be administered on a weight basis in the range of about 0.001 mg / kg / day to about 3500 mg / kg / day, or about 0.001 mg / kg / day to about 3000 mg / kg / day, or about 0.001 mg / kg / day to about 2500 mg / kg / day, or about 0.001 mg / kg / day to about 2000 mg / kg / day, or about 0.001 mg / kg / day to about 1500 mg / kg / day, or about 0.001 mg / kg / day to about 1000 mg / kg / day. or about 0.001 mg / kg / day to about 500 mg / kg / day, or about 0.001 mg / kg / day to about 250 mg / kg / day, or about 0.001 mg / kg / day to about 200 mg / kg / day, or about 0.001 mg / kg / day to about 150 mg / kg / day, or about 0.001 mg / kg / day to about 100 mg / kg / day, or about 0.001 mg / kg / day to about 75 mg / kg / day, or about 0.001 mg / kg / day to about 50 mg / kg / day, or about 0.001 mg / kg / day to about 25 mg / kg / day, or about 0.001 mg / kg / day to about 10 mg / kg / day, or about 0.001 mg / kg / day to about 5 mg / kg / day, or about 0.001 mg / kg / day to about 1 mg / kg / day, or about 0.001 mg / kg / day to about 0.5 mg / kg / day, or about 0.001 mg / kg / day to about 0.1 mg / kg / day, or about 0.01 mg / kg / day to about 3500 mg / kg / day, or about 0.01 mg / kg / day to about 3000 mg / kg / day, or about 0.01 mg / kg / day to about 2500 mg / kg / day, or about 0.01 mg / kg / day to about 2000 mg / kg / day, or about 0.01 mg / kg / day to about 1500mg / kg / day, or about 0.01mg / kg / day to about 1000mg / kg / day, or about 0.01mg / kg / day to about 500mg / kg / day, or about 0.01mg / kg / day to about 250mg / kg / day, or about 0.01mg / kg / day to about 200mg / kg / day, or about 0.01mg / kg / day to about 150mg / kg / day, or about 0.01mg / kg / day to about 100mg / kg / day, or about 0.01mg / kg / day to about 75mg / kg / day, or about 0.01mg / kg / day to about 50mg / kg / day, or about 0.0.01 mg / kg / day to about 25 mg / kg / day, or about 0.01 mg / kg / day to about 10 mg / kg / day, or about 0.01 mg / kg / day to about 5 mg / kg / day, or about 0.01 mg / kg / day to about 1 mg / kg / day, or about 0.01 mg / kg / day to about 0.5 mg / kg / day, or about 0.01 mg / kg / day to about 0.1 mg / kg / day, or about 0. 1 mg / kg / day to about 3500 mg / kg / day, or about 0.1 mg / kg / day to about 3000 mg / kg / day, or about 0.1 mg / kg / day to about 2500 mg / kg / day, or about 0.1 mg / kg / day to about 2000 mg / kg / day, or about 0.1 mg / kg / day to about 1500 mg / kg / day, or about 0.1 mg / kg / day to about 1000 mg / kg / day, or about 0.1 mg / kg / day to about 500 mg / kg / day, or about 0.1 mg / kg / day to about 250 mg / kg / day, or about 0.1 mg / kg / day to about 200 mg / kg / day, or about 0.1 mg / kg / day to about 150 mg / kg / day, or about 0.1 mg / kg / day to about 100 mg / kg / day, or about 0.1 mg / kg / day to about 75 mg / kg / day, or or from about 0.1 mg / kg / day to about 50 mg / kg / day, or from about 0.1 mg / kg / day to about 25 mg / kg / day, or from about 0.1 mg / kg / day to about 10 mg / kg / day, or from about 0.1 mg / kg / day to about 5 mg / kg / day, or from about 0.1 mg / kg / day to about 1 mg / kg / day, or from about 0.1 mg / kg / day to about 0.5 mg / kg / day. The effective amount for a given subject can be determined by routine experimentation within the skill and judgment of the clinician or person skilled in the art, taking into account factors related to the subject.Dosage regimen may be adjusted to provide sufficient levels of active agent(s) or to maintain desired effects.Factors to be considered include genetic screening, severity of disease state, status of disease progression, subject's general health, ethnicity, age, weight, sex, diet, time and frequency of administration, drug combination(s), reaction sensitivity, experience with other therapies and tolerance / response to treatment.

[0104] The dose administered to achieve an effective target plasma concentration may be administered orally once (once in an approximately 24 hour period, i.e., "qd"), twice (once in an approximately 12 hour period, i.e., "bid" or "q.12h"), three times (once in an approximately 8 hour period, i.e., "tid" or "q.8h") or four times (once in an approximately 6 hour period, i.e., "qds", "qid" or "q.6h") daily.

[0105] In certain embodiments, the dose administered to achieve an effective target plasma concentration may be administered in single, divided or continuous doses to patients or subjects having a body weight ranging from about 40 to about 200 kg (doses may be adjusted above or below this range for patients or subjects, particularly children under 40 kg). A typical adult subject is expected to have a median body weight in the range of about 70 kg. Long-acting pharmaceutical compositions may be administered every 2, 3 or 4 days, once per week or once every two weeks, depending on the half-life and clearance rate of the particular formulation.

[0106] The compounds and compositions described herein can be administered to a subject via any drug delivery route known in the art, non-limiting examples include oral, ocular, rectal, buccal, topical, nasal, sublingual, transdermal, subcutaneous, intramuscular, intravenous (bolus and injection), intracerebral and intrapulmonary routes of administration. In another embodiment, the administered dose may be adjusted based on the dosage forms described herein formulated to deliver about 0.02, 0.025, 0.03, 0.05, 0.06, 0.075, 0.08, 0.09, 0.10, 0.20, 0.25, 0.30, 0.50, 0.60, 0.75, 0.80, 0.90, 1.0, 1.10, 1.20, 1.25, 1.50, 1.75, 2.0, 3.0, 5.0, 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 400, 500, 1000, 1500, 2000, 2500, 3000 or 4000 mg / day.

[0107] For any compound, the effective amount can be first evaluated in cell culture assays or relevant animal models, such as mouse, guinea pig, chimpanzee, marmoset or tamarin animal models. Relevant animal models can also be used to determine appropriate concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes of administration in humans. Therapeutic efficacy and toxicity, such as ED 50 (the dose that is therapeutically effective in 50% of the population) and LD 50 The LD (the dose lethal to 50% of the population) can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio between therapeutic and toxic effects is the therapeutic index, and the LD 50 / ED 50 In certain embodiments, the effective amount is such that a large therapeutic index is achieved. In further specific embodiments, the dosage is within the ED 50 The dosage may vary within this range depending on the dosage form used, the sensitivity of the patient, and the route of administration.

[0108] Another aspect included within the scope of the present specification is the use of in vivo metabolic products of the compounds described herein. Such products may result, for example, from the oxidation, reduction, hydrolysis, amidation, esterification of the administered compound, primarily by enzymatic processes. Thus, the description includes the use of compounds produced by a process that includes contacting the compounds described herein with mammalian tissue or a mammal for a period of time sufficient to obtain metabolic products thereof.

[0109] Such products typically include radiolabeled isotopologues of the compounds described herein (e.g., 14 C or 3H), administering a detectable dose (e.g., greater than about 0.5 mg / kg) of the radiolabeled compound to a mammal, such as a rat, mouse, guinea pig, dog, monkey, or human, allowing sufficient time for metabolism to occur (typically about 30 seconds to about 30 hours), and identifying the metabolic conversion products in urine, bile, blood, or other biological samples. The conversion products are "radiolabeled" by being isotopically enriched and therefore easily isolated (some are isolated by using antibodies capable of binding to antigenic determinants surviving in the metabolites). The structures of the metabolites are determined by conventional techniques, such as by MS or NMR analysis. In general, analysis of the metabolites can be performed in the same manner as conventional drug metabolism studies well known to those of skill in the art. The conversion products are useful in diagnostic assays for therapeutic amounts of the compounds described herein, even if they do not themselves possess biological activity unless otherwise found in vivo.

[0110] Preparation of compounds General synthesis method As disclosed herein, the general method for preparing the compounds of formula (I) described herein or a form thereof is available via standard well-known synthetic methodology. Many of the starting materials are commercially available or, if not available, can be prepared using the routes described below using techniques known to those skilled in the art. The synthetic schemes shown herein include multiple reaction steps, each of which is intended to be independent and can be carried out with or without any of the preceding or subsequent step(s). In other words, isolation is contemplated for each of the individual reaction steps of the synthetic schemes shown herein.

[0111] Scheme A: Compounds of formula (I) may be prepared as described in Scheme A below. [ka]

[0112] Compound A1 having an optional R4 substituent is treated with an optionally substituted 3-chloro-3-oxopropanoate in the presence of a base (e.g. triethylamine) in a suitable solvent (e.g. DCM) at a suitable temperature (e.g. room temperature) to give compound A2. Compound A2 is cyclized to compound A3 in the presence of a base (e.g. sodium ethoxide) in a suitable solvent (e.g. ethanol) at a suitable temperature (e.g. reflux temperature). Hydrolysis of A3 in an aqueous solution of a base (e.g. NaOH) gives compound A4, which is treated with a chlorinating agent (e.g. POCl3) at a suitable temperature to give compound A5.

[0113] Compound A5 is treated with an optionally substituted aryl / heteroarylmethylamine in the presence of a base (e.g., TEA) using a suitable solvent (e.g., DMSO) at a suitable temperature to give compound A6. Protection of A6 with Boc2O in the presence of DMAP as a catalyst gives A7. Compound A7 can be reacted with an optionally substituted cyclic sulfamidate prepared from the corresponding amino alcohol in the presence of a strong base (e.g., LDA) in a suitable solvent (e.g., THF) at a suitable temperature, e.g., −78° C., to give A8. Deprotection can be achieved by treatment with an acid (e.g., HCl in dioxane or TFA) to give compound A8.

[0114] Scheme B: Compounds of formula (I) may be prepared as described in Scheme B below. [ka]

[0115] Compound B1 is reacted with iodine in the presence of a strong base (e.g. LDA) in a suitable solvent (e.g. THF) at a suitable temperature, e.g. -78°C, to give compound B2. Compound B2 can be converted to compound B3 by a Negeshi reaction using an optionally substituted, suitably protected amino-containing alkyl / cycloalkylzinc reagent in the presence of a catalyst (e.g. Pd(dppf)Cl2) in a suitable solvent (e.g. THF) at a suitable temperature. Treatment of B3 with an acid (e.g. HCl in dioxane or TFA) gives compound B4.

[0116] Scheme C: Compounds of formula (I) may be prepared as described in Scheme C below. [ka]

[0117] Compound C1 can be converted to the corresponding aldehyde C2 by treatment with a strong base (e.g. LDA) at a suitable temperature, e.g. -78°C, followed by DMF in a suitable solvent (e.g. THF). Compound C2 can be condensed with Ellman's sulfinamide in the presence of a Lewis acid (e.g. CuSO4) in a suitable solvent (e.g. DCE) at a suitable temperature to give compound C3. Reaction of C3 with a Grignard reagent in a suitable solvent (e.g. THF) gives compound C4, which can be further deprotected with an acid (e.g. HCl in dioxane or TFA) to give compound C5.

[0118] Specific Synthesis Examples For more detailed explanation and to aid in understanding, the following non-limiting examples are presented to more particularly illustrate the scope of the compounds described herein, and should not be construed as specifically limiting the scope thereof. Such variations of the compounds described herein that may be within the scope of identification by those skilled in the art and may be currently known or may be developed later are considered to be within the scope of the compounds described herein and are claimed below. These examples illustrate the preparation of certain compounds. Those skilled in the art will understand that the techniques described in these examples represent techniques that are fully functional in the practice of synthesis as described by those skilled in the art and therefore constitute preferred modes in the practice. However, it should be appreciated that those skilled in the art should recognize in light of this disclosure that many variations can be made in the specific methods disclosed and still obtain similar or similar results without departing from the spirit and scope of the present specification.

[0119] Other than the following examples of embodied compounds, unless otherwise indicated, all numbers expressing amounts of raw materials, reaction conditions, experimental data, and the like used in the specification and claims should be understood to be modified by the term "about". Thus, all such numbers represent approximations that may vary depending on the desired properties sought to be obtained by the reaction or as a result of variable experimental conditions. Thus, within the expected range of experimental reproducibility, the term "about" in relation to the resulting data refers to the range of the data, provided that it may vary according to the standard deviation from the mean. Similarly, in relation to the results of the experiments obtained, the resulting data may be rounded up or down consistently without loss of significant figures. At the very least, and without any attempt to limit the application of the doctrine of equivalents to the claims, each numerical parameter should be interpreted in light of the number of significant digits and rounding techniques used by those skilled in the art.

[0120] Notwithstanding that the numerical ranges and parameters setting forth the broad ranges herein are approximations, the numerical values ​​set forth in the examples set forth below are reported as precisely as possible, however, any numerical values ​​inherently contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.

[0121] Compound example As used above, and throughout the specification, the following abbreviations, unless otherwise indicated, shall be understood to have the following meanings: [Table 3] TIFF0007587511000035.tif214170

[0122] Intermediate 1 tert-Butyl (S)-4-(((tert-butyldimethylsilyl)oxy)methyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide [ka]

[0123] Step 1: N-(tert-butoxycarbonyl)-O-(tert-butyldimethylsilyl)-L-serinate To a solution of methyl (tert-butoxycarbonyl)-L-serinate (25 g, 114.0 mmol) in DCM (250 mL) was added imidazole (62.1 g, 912 mmol) and TBSCl (32 g, 205.9 mmol) at 0° C. The mixture was stirred for 2 h and then poured into a mixture of DCM (300 mL) and water (200 mL). The organic phase was separated, washed with water (2×100 mL) and brine (1×100 mL), dried over Na2SO4, and filtered. The filtrate was concentrated in vacuo to give methyl N-(tert-butoxycarbonyl)-O-(tert-butyldimethylsilyl)-L-serinate (35.5 g, 93.3% yield) as an oil. LC-MS: m / z: 356.2 [M+Na] + .

[0124] Step 2: tert-Butyl (R)-(1-((tert-butyldimethylsilyl)oxy)-3-hydroxypropan-2-yl)carbamate To a solution of methyl N-(tert-butoxycarbonyl)-O-(tert-butyldimethylsilyl)-L-serinate (35.5 g, 106 mmol) in THF (200 mL) and EtOH (100 mL) was added CaCl2 (23.6 g, 213 mmol) followed by NaBH4 (16.1 g, 426 mmol) at 0° C. The mixture was stirred at 0° C. for 0.5 h and at room temperature for 16 h, then poured into a mixture of EtOAc (200 mL) and water (150 mL). The organic phase was separated, washed with water (2×200 mL) and brine (1×150 mL), dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated in vacuo to give tert-butyl (R)-(1-((tert-butyldimethylsilyl)oxy)-3-hydroxypropan-2-yl)carbamate (30 g, 92.3% yield) as a white solid. LC-MS: m / z: 328.2 [M+Na] + ;RT=1.93 minutes.

[0125] Step 3: tert-Butyl (4S)-4-(((tert-butyldimethylsilyl)oxy)methyl)-1,2,3-oxathiazolidine-3-carboxylate 2-oxide To a solution of imidazole (54 g, 785.3 mmol) in DCM (300 mL) at 0° C. was added SOCl2 (12.9 mL, 176.0 mmol). The mixture was stirred at 0° C. for 1 h and tert-butyl (R)-(1-((tert-butyldimethylsilyl)oxy)-3-hydroxypropan-2-yl)carbamate (30 g, 98.2 mmol) was added. The mixture was stirred at 0° C. for an additional 1 h and then poured into a mixture of EtOAc (500 mL) and water (400 mL). The organic layer was separated and washed with water (2×800 mL) and brine (800 mL), then dried over Na2SO4 and filtered. The filtrate was concentrated in vacuo to give tert-butyl (4S)-4-(((tert-butyldimethylsilyl)oxy)methyl)-1,2,3-oxathiazolidine-3-carboxylate 2-oxide (32.6 g, 94.4% yield) as a white solid. LC-MS: m / z: 374.1 [M+Na] + ;RT=2.08 minutes.

[0126] Step 4: tert-Butyl (4S)-4-[[tert-butyl(dimethyl)silyl]oxymethyl]-2,2-dioxo-oxathiazolidine-3-carboxylate To a solution of tert-butyl (4S)-4-(((tert-butyldimethylsilyl)oxy)methyl)-1,2,3-oxathiazolidine-3-carboxylate 2-oxide (32.6 g, 92.7 mmol) in water (300 mL) and DCM (300 mL) was added NaIO4 (31.8 g, 148.0 mmol) and RuCl3 (1.94 g, 9.3 mmol) at room temperature. The mixture was stirred overnight and then extracted with DCM (3 x 500 mL). The combined organic phase was washed with saturated NaHSO3 (aq., 500 mL), dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated in vacuo. The residue was purified by flash chromatography (silica) eluting with DCM / hexanes (50-100%) to give tert-butyl (4S)-4-[[tert-butyl(dimethyl)silyl]oxymethyl]-2,2-dioxo-oxathiazolidine-3-carboxylate (18 g, 52.8% yield) as a white solid. LC-MS: m / z: 390.2 [M+Na] + ; RT=2.05 minutes; 1 H NMR (400 MHz, CDCl3) δ ppm 4.53-4.51 (m, 2 H), 4.2 (s, 1 H), 3.76-3.69 (m, 2 H), 1.46 (s, 9 H), 0.81 (s, 9 H), 0.00 (s, 6 H).

[0127] Intermediate 2 tert-Butyl (S)-4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide [ka] Step 1: N-(tert-butoxycarbonyl)-O-(tert-butyldimethylsilyl)-L-homoserine To a solution of (tert-butoxycarbonyl)-L-homoserine (21 g, 96.0 mmol) and imidazole (52 g, 770 mmol) in DCM (210 mL) was added TBSCl (23 g, 153 mmol). The mixture was stirred at room temperature for 5 h. Water (100 mL) was then added and the organic phase was separated, washed with brine (80 mL), dried over anhydrous Na2SO4 and concentrated in vacuo to give N-(tert-butoxycarbonyl)-O-(tert-butyldimethylsilyl)-L-homoserine (31.9 g, 99% yield) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ ppm 5.85 (d, 1H), 4.22 (m, 1 H), 3.69-3.75 (m, 2 H), 1.93-2.01 (m, 2 H), 1.36 (s, 9H), 0.83 (s, 9 H), 0.00 (s, 6 H).

[0128] Step 2: tert-Butyl (S)-(4-((tert-butyldimethylsilyl)oxy)-1-hydroxybutan-2-yl)carbamate To a solution of N-(tert-butoxycarbonyl)-O-(tert-butyldimethylsilyl)-L-homoserine (31.9 g, 96 mmol) and N-methylmorpholine (10.7 g, 105 mmol) in THF (300 mL) at 0° C., isopropyl chloroformate (12.8 g, 105 mmol) was added. The mixture was stirred at 0° C. for 1 h and then filtered. The filtrate was cooled to 0° C. and a solution of NaBH4 (4 g, 105.0 mmol) in water was slowly added thereto. The mixture was stirred at 0° C. for 2 h and then diluted with water (100 mL). The organic phase was separated, washed with brine (2×100 mL), dried over Na2SO4, and filtered. The filtrate was concentrated in vacuo to give tert-butyl (S)-(4-((tert-butyldimethylsilyl)oxy)-1-hydroxybutan-2-yl)carbamate (20 g, 57% yield) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ ppm 5.41 (s, 1 H), 3.75-3.79 (m, 1 H), 3.66 (t, 1H), 3.55-3.58 (m, 2 H), 1.69-1.99 (m, 2 H), 1.85-1.66 (m, 2 H), 1.36 (s, 9 H), 0.83 (s, 9 H), 0.00 (s, 6 H).

[0129] Step 3: tert-Butyl (4S)-4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1,2,3-oxathiazolidine-3-carboxylate 2-oxide To a solution of imidazole (22 g, 313 mmol) in DCM (200 mL) at 0° C. was added SOCl2 (13.5 g, 113 mmol). The mixture was stirred at room temperature for 1 h, cooled to 0° C., and a solution of tert-butyl (S)-(4-((tert-butyldimethylsilyl)oxy)-1-hydroxybutan-2-yl)carbamate (20 g, 62.7 mmol) in DCM (100 mL) was added. The mixture was stirred at room temperature for 2 h and diluted with water (100 mL). The organic phase was separated, washed with brine (100 mL), dried over Na2SO4, and filtered. The filtrate was concentrated in vacuo to give tert-butyl (4S)-4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1,2,3-oxathiazolidine-3-carboxylate 2-oxide as a colorless oil (23 g, 99% yield). 1 H NMR (400 MHz, CDCl3) δ ppm 3.83-4.05 (m, 1 H), 3.62-3.69 (m, 2 H), 3.53-3.59 (m, 2 H), 1.60-1.78 (m, 2 H), 1.36 (d, 9 H), 0.81 (d, 9 H), 0.02 (d, 6 H).

[0130] Step 4: tert-Butyl (S)-4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide To a mixture of tert-butyl (4S)-4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1,2,3-oxathiazolidine-3-carboxylate 2-oxide (23 g, 62.7 mmol) and NaIO4 (31 g, 144 mmol) in DCM (300 mL) and water (310 mL) was added RuCl3 (0.83 g, 4 mmol). The reaction was stirred at room temperature for 5 h. The organic phase was separated, washed with 10% NaHSO3 (4 x 150 mL) and brine (150 mL), dried over Na2SO4, and filtered. The filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with petroleum ether and ethyl acetate (20:1) to give tert-butyl (S)-4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide as a white solid (5 g, 21% yield). 1 H NMR (400 MHz, CDCl3) δ ppm 4.95 (q, 2 H), 4.30-3.35 (m, 1 H), 3.64-3.77 (m, 2 H), 1.96-2.11 (m, 2 H), 1.52 (s, 9 H), 0.83 (s, 9 H), 0.00 (s, 6 H).

[0131] Intermediate 3 tert-Butyl (R)-4-(fluoromethyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide [ka] Step 1: tert-Butyl (4R)-4-(benzyloxymethyl)-2-oxo-oxathiazolidine-3-carboxylate To a solution of imidazole (4.5 g, 4.37 mL, 66.1 mmol, 3.80 eq.) in DCM (160 mL) at -78°C was added thionyl chloride (2.290 g, 1.40 mL, 19.2 mmol, 1.10 eq.) followed by N,N-diisopropylethylamine (4.450 g, 6.00 mL, 34.1 mmol, 1.96 eq.). After 30 min, a solution of tert-butyl N-[(1S)-1-(benzyloxymethyl)-2-hydroxy-ethyl]carbamate (4.894 g, 17.39 mmol, 1.00 eq.) in DCM (20 mL) was added at -78°C over 30 min. The mixture was allowed to warm to room temperature and stirred overnight. The reaction was quenched with water (50 mL). The organic layer was separated and the aqueous layer was extracted with DCM (2 x 50 mL). The combined organic layers were washed with water (50 mL) and brine (100 mL), dried over sodium sulfate, and then concentrated to give tert-butyl (4R)-4-(benzyloxymethyl)-2-oxo-oxathiazolidine-3-carboxylate (5.9 g, 18.0 mmol, 1.04 eq.) as an oil, which was used without purification.

[0132] Step 2: tert-Butyl (4R)-4-(benzyloxymethyl)-2,2-dioxo-oxathiazolidine-3-carboxylate To a solution of tert-butyl (4R)-4-(benzyloxymethyl)-2-oxo-oxathiazolidine-3-carboxylate (5.9 g, 18.0 mmol, 1.00 eq.) in CH3CN (160 mL) and water (100 mL) was added NaIO4 (6.0 g, 28.0 mmol, 1.55 eq.) followed by RuCl3 (16 mg, 0.077 mmol, 0.0043 eq.) at 0°C. The mixture was stirred at 0°C for 45 min and then diluted with water (50 mL). The mixture was extracted with diethyl ether (2 x 80 mL). The combined organic extracts were washed with water (50 mL), followed by brine (100 mL) and dried over sodium sulfate. The volatiles were removed under reduced pressure and the residue was purified by flash column chromatography (120 g, 0-100% DCM / hexanes) to give tert-butyl (4R)-4-(benzyloxymethyl)-2,2-dioxo-oxathiazolidine-3-carboxylate (5.228 g, 85% yield) as a colorless oil which solidified on standing at room temperature after trituration with hexanes.

[0133] Step 3: tert-Butyl N-[(1R)-1-(benzyloxymethyl)-2-fluoro-ethyl]carbamate To a solution of tert-butyl (4R)-4-(benzyloxymethyl)-2,2-dioxo-oxathiazolidine-3-carboxylate (5.228 g, 15.22 mmol, 1.00 eq.) in THF (70 mL) was added TBAF (1 M) in THF (18.0 mL, 18.0 mmol, 1.18 eq.) at 0° C. The mixture was stirred at 0° C. for 1 h and then at room temperature overnight. The reaction was quenched with aqueous citric acid (1N, ca. 20 mL). The mixture was extracted with EtOAc (2×80 mL). The combined organic phase was washed with water followed by brine (ca. 50 mL). The volatiles were removed under reduced pressure and the residue was purified by flash column chromatography (0-30% EtOAc in hexanes with 10% DCM) to give tert-butyl N-[(1R)-1-(benzyloxymethyl)-2-fluoro-ethyl]carbamate (3.250 g, 75% yield) as a colorless oil.

[0134] Step 4: tert-Butyl N-[(1R)-1-(fluoromethyl)-2-hydroxy-ethyl]carbamate To a solution of tert-butyl N-[(1R)-1-(benzyloxymethyl)-2-fluoro-ethyl]carbamate (2.505 g, 8.84 mmol, 1.00 eq.) in EtOAc (30 mL) was added 128 mg (approximately 5% mass) of 10% palladium on carbon (Degussa type) at room temperature. The flask was evacuated and backfilled with a hydrogen balloon (1 atm) for three cycles. The mixture was stirred at room temperature for 3 h, then filtered and evaporated. The filtrate was concentrated to give tert-butyl N-[(1R)-1-(fluoromethyl)-2-hydroxy-ethyl]carbamate (1.725 g, quantitative).

[0135] Step 5: tert-Butyl (4R)-4-(fluoromethyl)-2-oxo-oxathiazolidine-3-carboxylate To a solution of imidazole (3.0 g, 2.91 mL, 44.07 mmol, 3.73 eq.) in DCM (110 mL) at -78°C was added thionyl chloride (1.00 mL, 13.73 mmol, 1.16 eq.) followed by N,N-diisopropylethylamine (3.90 mL, 22.2 mmol, 1.87 eq.). The reaction was stirred at -78°C for 30 min and a solution of tert-butyl N-[(1R)-1-(fluoromethyl)-2-hydroxy-ethyl]carbamate (2.285 g, 11.83 mmol, 1.00 eq.) in DCM (15 mL) was added over 30 min at -78°C. The mixture was allowed to warm to room temperature and stirred at room temperature overnight. The reaction was quenched with water (50 mL). The organic layer was separated, washed with water (50 mL) and brine (100 mL), dried over sodium sulfate and concentrated to give tert-butyl (4R)-4-(fluoromethyl)-2-oxo-oxathiazolidine-3-carboxylate (2.830 g) as an oil, which was carried on to the next step without further purification.

[0136] Step 6: tert-Butyl (4R)-4-(fluoromethyl)-2,2-dioxo-oxathiazolidine-3-carboxylate To a solution of tert-butyl (4R)-4-(fluoromethyl)-2-oxo-oxathiazolidine-3-carboxylate (2.830 g, 11.8 mmol, 1.00 eq.) in a mixture of CH3CN (100 mL) and water (60 mL), NaIO4 (3.940 g, 18.4 mmol, 1.55 eq.) was added followed by RuCl3 (20 mg, 0.096 mmol, 0.0081 eq.) at 0° C. The mixture was stirred at 0° C. for 45 min, then diluted with water (50 mL) and extracted with diethyl ether (2×80 mL). The combined organic phase was washed with water (50 mL) and brine (100 mL), dried over sodium sulfate and evaporated. The residue was purified by flash column chromatography (120 g, 0-100% DCM / hexanes) to give tert-butyl (4R)-4-(fluoromethyl)-2,2-dioxo-oxathiazolidine-3-carboxylate (2384 mg, 78.9% yield). 1 H NMR (400 MHz, CDCl3) δ ppm 4.47-4.74 (m, 5 H), 1.56 (s, 9 H).

[0137] Intermediate 4 3-Bromo-5,7-dichlorothieno[3,2-b]pyridine [ka]

[0138] Step 1: Methyl 3-amino-4-bromothiophene-2-carboxylate To a solution of methyl 3-aminothiophene-2-carboxylate (40.0 g, 255.0 mmol) in AcOH (1000 mL) was added Br2 (80.2 g, 510.0 mmol) at 25° C. The mixture was stirred at 65° C. for 12 h and then cooled to room temperature. The mixture was then poured into water (2000 mL) and the suspension was filtered. The filter cake was collected, dried in vacuum, and then purified by silica gel column chromatography eluting with 10% EtOAc in petroleum ether to give methyl 3-amino-4-bromothiophene-2-carboxylate as a yellow solid (30.0 g, 50.0% yield). 1 H NMR (400 MHz, CDCl3) δ 7.29 (s, 1 H), 5.64 (m, 2 H), 3.84 (s, 3 H).

[0139] Step 2: Methyl 4-bromo-3-(3-ethoxy-3-oxopropanamido)thiophene-2-carboxylate To a solution of methyl 3-amino-4-bromothiophene-2-carboxylate (30.0 g, 128 mmol) in DCM (500 mL) was added triethylamine (16.8 g, 166 mmol) and ethyl 3-chloro-3-oxopropanoate (25.0 g, 166 mmol) at 0° C. The mixture was stirred at 25° C. for 3 h. The mixture was quenched with ice water (1.5 L) and extracted with DCM (3×500 mL). The combined organic layers were dried over Na2SO4 and filtered. The filtrate was concentrated to give methyl 4-bromo-3-(3-ethoxy-3-oxopropanamido)thiophene-2-carboxylate as a brown solid (40.0 g, 90.0% yield), which was used in the next step without further purification. LC-MS: m / z: 350.0 [M+H] + ;RT=1.59 minutes.

[0140] Step 3: Ethyl 3-bromo-5,7-dioxo-4,5,6,7-tetrahydrothieno[3,2-b]pyridine-6-carboxylate To a solution of methyl 4-bromo-3-(3-ethoxy-3-oxopropanamido)thiophene-2-carboxylate (35.0 g, 100 mmol) in ethanol (500 mL) was added sodium ethanolate (10.0 g, 166 mmol) at 0° C. The mixture was stirred at 100° C. for 12 h and then cooled to room temperature. The mixture was filtered. The filter cake was washed with ethyl acetate (100 mL) and dried in vacuum to give ethyl 3-bromo-5,7-dioxo-4,5,6,7-tetrahydrothieno[3,2-b]pyridine-6-carboxylate as a brown solid (33.0 g, 95.0% yield), which was used in the next step without further purification. LC-MS: m / z: 317.6 [M+H] + ;RT=1.53 minutes.

[0141] Step 4: 3-Bromothieno[3,2-b]pyridine-5,7(4H,6H)-dione To a solution of ethyl 3-bromo-5,7-dioxo-4,5,6,7-tetrahydrothieno[3,2-b]pyridine-6-carboxylate (30.0 g, 94.6 mmol) in water (1000 mL) was added sodium hydroxide (7.60 g, 189 mmol) at 0° C. The mixture was stirred at 110° C. for 12 h and then cooled to room temperature. The pH was adjusted to pH=6 with HCl (10 N) and the mixture was filtered. The filter cake was collected and dried in vacuum to give 3-bromothieno[3,2-b]pyridine-5,7(4H,6H)-dione as a brown solid (20.0 g, 86.0% yield), which was used in the next step without further purification. LC-MS: m / z: 245.9 [M+H] + ;RT=1.35 minutes.

[0142] Step 5: 3-Bromo-5,7-dichlorothieno[3,2-b]pyridine To POCl3 (60 mL) was added 3-bromothieno[3,2-b]pyridine-5,7(4H,6H)-dione (20.0 g, 81.6 mmol). The mixture was stirred and refluxed for 12 h, then cooled to room temperature, quenched with ice water (1.5 L), and extracted with ethyl acetate (3 x 500 mL). The combined organic layers were dried over Na2SO4 and filtered. The filtrate was concentrated to give a residue. The residue was purified by silica column chromatography using petroleum ether and ethyl acetate (5:1) to give 3-bromo-5,7-dichlorothieno[3,2-b]pyridine as a white solid (20.0 g, 87.0% yield). 1 H NMR 400 MHz (DMSO-d6) δ ppm 8.58 (s, 1H), 7.99 (s, 1H).

[0143] Intermediate 5 3,5,7-Trichloro-thieno[3,2-b]pyridine [ka] Step 1: Methyl 3-acetamidothiophene-2-carboxylate Methyl 3-aminothiophene-2-carboxylate (80 g, 508.9 mmol) was added to Ac2O (300 mL) at room temperature and the mixture was stirred at room temperature overnight. The reaction was quenched with MeOH (800 mL) and the mixture was stirred at room temperature for 30 min. The solvent was removed in vacuum and the residue was neutralized to pH=9-10 with saturated aqueous NaHCO3. The mixture was extracted with ethyl acetate (3×400 mL). The combined organic layers were dried over Na2SO4 and filtered. The filtrate was concentrated in vacuum to give methyl 3-acetamidothiophene-2-carboxylate (96 g, 94.7% yield) as an off-white solid. LC-MS: m / z: 200.1 [M+H] + ;RT=1.63 minutes.

[0144] Step 2: Methyl 3-acetamido-4,5-dichlorothiophene-2-carboxylate To a solution of methyl 3-acetamidothiophene-2-carboxylate (96 g, 482.6 mmol) in CHCl3 (500 mL) was added SO2Cl2 (96 mL, 1206.1 mmol) dropwise. The mixture was stirred at 75 °C overnight, cooled to room temperature, and concentrated in vacuo to give a solid which was triturated with diethyl ether to give methyl 3-acetamido-4,5-dichlorothiophene-2-carboxylate (103.6 g, 80.2% yield) as an off-white solid. 1 H NMR 400 MHz (CDCl3) δ ppm 8.24 (s, 1H), 3.87-3.90 (m, 3H), 2.23 (s, 3H).

[0145] Step 3: Methyl 3-acetamido-4-chlorothiophene-2-carboxylate To a solution of methyl 3-acetamido-4,5-dichlorothiophene-2-carboxylate (103.5 g, 386.0 mmol) in HO and HOAc (3:1 (v / v), 800 mL) was added Zn powder (100.9 g, 1544.2 mmol). The mixture was stirred at 100° C. overnight. After cooling to room temperature, the mixture was filtered. The filtrate was extracted with ethyl acetate (3×1000 mL). The combined organic layers were washed with water and brine, dried over anhydrous NaSO, and evaporated in vacuo to give methyl 3-acetamido-4-chlorothiophene-2-carboxylate (72.2 g, 80.1% yield) as an off-white solid. 1 H NMR 400 MHz (CDCl3) δ ppm 7.36 (s, 1H), 7.26 (s, 1H), 3.87-3.88 (m, 3H), 2.23 (s, 3H).

[0146] Step 4: Methyl 3-amino-4-chlorothiophene-2-carboxylate A mixture of methyl 3-acetamido-4-chlorothiophene-2-carboxylate (70.0 g, 299.5 mmol) in MeOH and conc. HCl (1:1 (v / v), 300 mL) was stirred at 110° C. overnight, then cooled to room temperature and concentrated in vacuo. The resulting solid was dissolved in water (200 mL) and neutralized with aqueous NaHCO3. The mixture was extracted with ethyl acetate (3×300 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography using petroleum ether / ethyl acetate (8:1) as eluent to give methyl 3-amino-4-chlorothiophene-2-carboxylate (47.1 g, 82.2% yield) as an off-white solid. LC-MS: m / z: 192.0 [M+H] + ;RT=1.70 minutes.

[0147] Step 5: Methyl 4-chloro-3-(3-ethoxy-3-oxopropanamido)thiophene-2-carboxylate To a solution of methyl 3-amino-4-chlorothiophene-2-carboxylate (45.0 g, 234.8 mmol) in DCM (300 mL) at 0° C., Et3N (47.5 g, 469.7 mmol) was added dropwise followed by ethyl 3-chloro-3-oxopropanoate (53.1 g, 352.3 mmol). The mixture was stirred at room temperature overnight and then washed with water (2×300 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified by silica gel column chromatography using petroleum ether / ethyl acetate (1:1) as eluent to give methyl 4-chloro-3-(3-ethoxy-3-oxopropanamido)thiophene-2-carboxylate (41.8 g, 58.3% yield) as an off-white solid. LC-MS: m / z: 306.0 [M+H] + ; RT=1.55 minutes; 1 H NMR 400 MHz (CDCl3) δ ppm 10.12 (s, 1H), 8.01 (s, 1H), 4.11-4.13 (m, 2H), 3.79 (s, 3H), 3.48 (s, 2H), 1.19-1.22 (m, 3H).

[0148] Step 6: Ethyl 3-chloro-5,7-dioxo-4,5,6,7-tetrahydrothieno[3,2-b]pyridine-6-carboxylate To a solution of methyl 4-chloro-3-(3-ethoxy-3-oxopropanamido)thiophene-2-carboxylate (40.0 g, 130.8 mmol) in EtOH (300 mL) was added NaOEt (9.0 g, 130.8 mmol). The mixture was stirred at 85° C. overnight and then cooled to room temperature. The product was obtained by filtration to give ethyl 3-chloro-5,7-dioxo-4,5,6,7-tetrahydrothieno[3,2-b]pyridine-6-carboxylate (34.3 g, 95.8% yield) as an off-white solid. LC-MS: m / z: 274.0 [M+H] + ; RT=1.56 minutes; 1 H NMR 400 MHz (CDCl3) δ ppm 7.55 (s, 1H), 4.07-4.09 (m, 2H), 3.44-3.46 (m, 1H), 1.18-1.21 (m, 3H), 1.06-1.08 (m, 1H).

[0149] Step 7: 3-Ethylchlorothieno[3,2-b]pyridine-5,7(4H,6H)-dione Ethyl 3-chloro-5,7-dioxo-4,5,6,7-tetrahydrothieno[3,2-b]pyridine-6-carboxylate (34.3 g, 125.2 mmol) was added to a solution of NaOH (10.0 g, 250.4 mmol) in HO (200 mL). The mixture was stirred at 105 °C overnight and then cooled to room temperature. The pH was adjusted to about 6-7 with conc. HCl. The filter cake was collected and dried in vacuum to give 3-chlorothieno[3,2-b]pyridine-5,7(4H,6H)-dione (22.3 g, 88.3% yield) as an off-white solid. LC-MS: m / z: 202.0 [M+H] + ;RT=1.34 minutes.

[0150] Step 8: 3,5,7-Trichlorothieno[3,2-b]pyridine 3-Chlorothieno[3,2-b]pyridine-5,7(4H,6H)-dione (22.0 g, 109.1 mmol) and N,N-dimethylaniline (6.6 g, 0.5 eq, 54.5 mmol) were added to POCl3 (150 mL). The mixture was stirred at 110° C. overnight and then cooled to room temperature. Excess POCl3 was removed in vacuum and the solid was poured into ice water (100 mL). The white solid was obtained by filtration, dried in vacuum and further purified by silica column chromatography using petroleum ether and ethyl acetate (5:1) to give 3,5,7-trichlorothieno[3,2-b]pyridine (18.7 g, 72.1% yield) as an off-white solid. LC-MS: m / z: 237.9, 239.9, 241.9 [M+H] + ; RT=2.01 minutes; 1 H NMR (400 MHz, CDCl3) δ ppm 8.49 (s, 1H), 7.99 (s, 1H).

[0151] Intermediate 6 tert-Butyl (5-chloro-2-iodo-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate [ka] To a solution of tert-butyl (5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (410 mg, 1.08 mmol, 1.0 eq.) prepared according to the procedure in Example 2 in THF (3 mL) was added LDA (2.0 M in THF, 0.60 mL, 1.1 eq.) at -78°C. After stirring for 15 min, a solution of iodine (288 mg, 1.14 mmol, 1.05 eq.) in THF (2 mL) was added dropwise and stirring was continued for 1 h. The reaction was quenched by the addition of EtOAc and NH4Cl (sat. aq.) and allowed to warm to room temperature. The organic layer was washed with sodium thiosulfate solution, water and brine, dried over sodium sulfate and evaporated. The residue was purified by flash column chromatography on silica gel eluting with 0-15% EtOAc in hexanes to give tert-butyl (5-chloro-2-iodo-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (436 mg, 80% yield). MS m / z 505.5, 507.5 [M+H] + .

[0152] Example 1 (Compound 2) 5-Chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine [ka] A mixture of 5,7-dichloro-3-methyl-thieno[3,2-b]pyridine (201 mg, 0.922 mmol, 1.00 eq.) and 2-furylmethanamine (895 mg, 0.81 mL, 9.22 mmol, 10.0 eq.) in DMSO (0.8 mL) was stirred at 100° C. for 24 h. The mixture was cooled, diluted with ethyl acetate, washed with water and brine, dried and evaporated. The residue was purified on silica gel with ethyl acetate and hexane to give 5-chloro-N-(2-furylmethyl)-3-methyl-thieno[3,2-b]pyridin-7-amine (230 mg, 90% yield). MS m / z 279.1, 281.1 [M+H] + , 1H NMR (400 MHz, CDCl3) δ ppm 7.44 (d, J= 1.2 Hz, 1 H), 7.26 (d, J= 1.1 Hz, 1 H), 6.58 (s, 1 H), 6.39 (dd, J= 3.2, 1.8 Hz, 1 H), 6.35 (d, J= 3.2 Hz, 1 H), 4.70 (br s, 1 H), 4.54 (d, J= 5.3 Hz, 2 H), 2.49 (d, J= 1.1 Hz, 3 H).

[0153] The following compounds were prepared according to the procedure of Example 1 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 4]

[0154] Example 2 (Compound 28) 2-[(2S)-2-Aminopropyl]-5-chloro-3-methyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride [ka] Step 1: tert-Butyl N-(5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl)-N-(2-thienylmethyl)carbamate To a solution of 5-chloro-3-methyl-N-(2-thienylmethyl)thieno[3,2-b]pyridin-7-amine (3.90 g, 13.0 mmol, 1.0 eq.) prepared according to the procedure in Example 1 in CHCl (53 mL) was added di-tert-butyl dicarbonate (5.8 g, 26.0 mmol, 2.0 eq.) followed by 4-(dimethylamino)pyridine (1.6 g, 13.0 mmol, 1.0 eq.). The mixture was stirred at room temperature for 2 h. The mixture was diluted with ethyl acetate and water and washed with brine. The organic layer was dried over NaSO, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography using ethyl acetate in hexanes (5-35% gradient) to give tert-butyl N-(5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl)-N-(2-thienylmethyl)carbamate (4.77 g, 91% yield). MS m / z 395.1 [M+H] + ; 1 H NMR (400 MHz, CDCl3) δ ppm 7.41 (s, 1 H), 7.24 (dd, J=1.00 Hz, 1 H), 7.06 (s, 1 H), 6.89 (dd, J=1.00 Hz, 1 H), 6.81 (d, J=1.00 Hz, 1 H), 5.07 (s, 2 H), 2.51 (d, J=1.07 Hz, 3 H), 1.47 (s, 9 H).

[0155] Step 2: tert-Butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-(2-thienylmethyl)carbamate To a solution of tert-butyl N-(5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl)-N-(2-thienylmethyl)carbamate (4.77 g, 12.1 mmol, 1.0 eq.) in THF (24 mL) at -78°C was added lithium diisopropylamide (2.0 M) in THF / heptane / ethylbenzene (7.2 mL, 14.5 mmol, 1.2 eq.). After 15 min, a solution of tert-butyl (4S)-4-methyl-2,2-dioxo-oxathiazolidine-3-carboxylate (3.44 g, 14.5 mmol, 1.2 eq.) in THF (24 mL) was added to the reaction solution and the mixture was stirred at -78°C for 20 min. The reaction was quenched with 1.0 M citric acid and then stirred for 30 min. The mixture was diluted with ethyl acetate and washed with water and brine. The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography using ethyl acetate in CHCl2 (0-25% gradient) to give tert-butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-(2-thienylmethyl)carbamate (4.10 g, 61% yield). MS m / z 553.0, 555.0 [M+H] + , 1 H NMR (400 MHz, CDCl3) δ ppm 7.22 (d, J=5.33 Hz, 1 H), 6.99 (s, 1 H), 6.86 (dd, J=5.04, 3.51 Hz, 1 H), 6.78 (d, J=2.90 Hz, 1 H), 5.02 (dd, J=1.00 Hz, 2 H), 4.46 (br s, 1 H), 4.01 (br s, 1 H), 3.07 - 3.16 (m, 1 H), 2.93 - 3.07 (m, 1 H), 2.41 (s, 3 H), 1.45 (s, 18 H), 1.14 (d, J=6.71 Hz, 3H).

[0156] Step 3: 2-[(2S)-2-aminopropyl]-5-chloro-3-methyl-N-(2-thienylmethyl)thieno[3,2-b]pyridin-7-amine General Boc-deprotection procedure: A mixture of tert-butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-(2-thienylmethyl)carbamate (4.10 g, 7.4 mmol, 1.0 eq.) and HCl (4 M) in dioxane (35 mL) was stirred at room temperature for 1 h. The mixture was diluted with diethyl ether (2×) and filtered. The filter cake was washed with ether, collected and dried to give 2-[(2S)-2-aminopropyl]-5-chloro-3-methyl-N-(2-thienylmethyl)thieno[3,2-b]pyridin-7-amine dihydrochloride (2.5 g, 96% yield). MS m / z 352.1, 354.1 [M+H] + , 1 H NMR (methanol-d4) δ ppm 7.38 (dd, J= 5.19, 1.07 Hz, 1 H), 7.18 (d, J= 2.75 Hz, 1 H), 7.10 (s, 1 H), 7.01 (dd, J= 5.04, 3.51 Hz, 1 H), 4.97 (s, 2 H), 3.60 - 3.72 (m, 1 H), 3.37 - 3.44 (m, 1 H), 3.24 - 3.30 (m, 1 H), 2.47 (s, 3 H), 1.39 (d, J= 6.56 Hz, 3 H).

[0157] The following compounds were prepared according to the procedure of Example 2 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 5] TIFF0007587511000046.tif248155 TIFF0007587511000047.tif248158 TIFF0007587511000048.tif250156 TIFF0007587511000049.tif52158

[0158] Example 3 (Compound 17) (2R)-2-Amino-3-(5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol dihydrochloride [ka] Step 1: tert-Butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-hydroxy-propyl]-5-chloro-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate To a solution of tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-[tert-butyl(dimethyl)silyl]oxy-propyl]-5-chloro-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (41 mg, 0.063 mmol, 1.0 eq.) prepared according to the procedure in Example 2 in THF (0.5 mL) at 0° C., TBAF (1.0 M in THF) (0.25 mL, 0.25 mmol, 4.0 eq.) was added. After 1 h at room temperature, the mixture was diluted with ether, water, washed with brine, dried and evaporated. The residue was purified on silica gel with ethyl acetate and hexanes (5-65% gradient) to give tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-hydroxy-propyl]-5-chloro-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (33 mg, 98% yield). MS m / z 538.3, 540.1 [M+H] + .

[0159] Step 2: (2R)-2-amino-3-[5-chloro-7-(2-furylmethylamino)thieno[3,2-b]pyridin-2-yl]propan-1-ol A mixture of tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-hydroxy-propyl]-5-chloro-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (33 mg, 0.061 mmol, 1.0 eq.), anisole (0.1 mL) and HCl (4M in dioxane) (1.0 mL) was stirred at room temperature for 30 min, then 3 drops of MeOH were added and the mixture was stirred for another 30 min. The mixture was diluted with ether and filtered. The solid was collected and dried to give (2R)-2-amino-3-[5-chloro-7-(2-furylmethylamino)thieno[3,2-b]pyridin-2-yl]propan-1-ol dihydrochloride (21 mg, 83% yield). MS m / z 338.3, 340.2 [M+H] + . 1 H NMR (methanol-d4) δ ppm 7.52 (d, J= 1.2 Hz, 1 H), 7.42 (s, 1 H), 7.16 (s, 1 H), 6.49 (s, 1 H), 6.41 - 6.45 (m, 1 H), 4.77 (s, 2 H), 3.79 - 3.86 (m, 1 H), 3.64 - 3.71 (m, 2 H), 3.44 - 3.50 (m, 1 H), 3.36 - 3.42 (m, 1 H).

[0160] The following compounds were prepared according to the procedure of Example 3 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 6]

[0161] Example 4 (Compound 42) 5-Chloro-N-[(furan-2-yl)methyl]-3-methyl-2-[(2S)-2-(methylamino)propyl]thieno[3,2-b]pyridin-7-amine hydrochloride [ka] Step 1: tert-Butyl (S)-(2-(2-((tert-butoxycarbonyl)(methyl)amino)propyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate To a solution of tert-butyl (S)-(2-(2-((tert-butoxycarbonyl)amino)propyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (120 mg, 0.22 mmol, 1.0 eq.) in THF (1 mL) was added LHMDS (1.0 M in THF, 0.27 mL, 1.1 eq.) at -50°C. After 30 min, MeI (42 mg, 1.2 eq.) in THF (1 mL) was added. The mixture was gradually warmed to room temperature over 1 h, stirred at room temperature for 1 h, cooled to -50°C, and then quenched with a few drops of citric acid. After warming to room temperature, the reaction was diluted with water and EtOAc. The organic layer was washed with water, brine, dried over sodium sulfate, and evaporated. The residue was purified by flash column chromatography on silica gel eluting with 0-10% EtOAc in DCM followed by preparative HPLC eluting with 20-100% ACN in water (with 0.1% formic acid) to give tert-butyl (S)-(2-(2-((tert-butoxycarbonyl)(methyl)amino)propyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (35 mg, 28% yield) as a white solid. MS m / z 550.2, 552.2 [M+H] + .

[0162] Step 2: (S)-5-Chloro-N-(furan-2-ylmethyl)-3-methyl-2-(2-(methylamino)propyl)thieno[3,2-b]pyridin-7-amine tert-Butyl (S)-(2-(2-((tert-butoxycarbonyl)(methyl)amino)propyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (35 mg, 0.064 mmol) was stirred in a solution of HCl (4M in dioxane, 1 mL) at room temperature for 1 h. The mixture was concentrated in vacuo. The solid was triturated with diethyl ether and filtered to give (S)-5-chloro-N-(furan-2-ylmethyl)-3-methyl-2-(2-(methylamino)propyl)thieno[3,2-b]pyridin-7-amine dihydrochloride (12 mg, 49% yield). MS m / z 350.1, 352.1 [M+H] + ; 1 H NMR (methanol-d4) δ ppm 7.49 (t, J= 1.2 Hz, 1 H), 6.90 (s, 1 H), 6.41 (d, J= 1.3 Hz, 2 H), 4.66 (s, 2 H), 3.57 - 3.60 (m, 1 H), 3.44 - 3.47 (m, 1 H), 3.18 - 3.23 (m, 1 H), 2.80 (s, 3 H), 2.43 (s, 3 H), 1.35 (d, J= 6.6 Hz, 3 H).

[0163] Example 5 (Compound 104) 2-[(2R)-2-Amino-3-(methylsulfanyl)propyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine dihydrochloride [ka] Step 1: [(2R)-2-(tert-butoxycarbonylamino)-3-[7-[tert-butoxycarbonyl(2-furylmethyl)amino]-5-chloro-3-methyl-thieno[3,2-b]pyridin-2-yl]propyl]methanesulfonate To a solution of tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-hydroxy-propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (217.0 mg, 0.393 mmol, 1.0 eq.) prepared according to the procedure in Example 3 in DCM (2.5 mL) was added a solution of methanesulfonyl chloride (592 mg, 0.40 mL, 5.17 mmol, 13.1 eq.) in DCM (9.60 mL) followed by N,N-diisopropylethylamine (75.5 mg, 0.10 mL, 0.57 mmol, 1.46 eq.) at 0°C. The reaction was stirred at 0° C. for 1 h, then quenched with sodium bicarbonate (approximately 5 mL) and extracted with DCM (5×10 mL) using a phase separator. The volatiles were removed under reduced pressure to give [(2R)-2-(tert-butoxycarbonylamino)-3-[7-[tert-butoxycarbonyl(2-furylmethyl)amino]-5-chloro-3-methyl-thieno[3,2-b]pyridin-2-yl]propyl]methanesulfonate (262.2 mg, 0.42 mmol, 1.06 eq.) as a pale yellow foam, which was carried on to the next step without further purification. MS m / z 630.4, 632.3 [M+H] + .

[0164] Step 2: tert-Butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-methylsulfanyl-propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate To a solution of [(2R)-2-(tert-butoxycarbonylamino)-3-[7-[tert-butoxycarbonyl(2-furylmethyl)amino]-5-chloro-3-methyl-thieno[3,2-b]pyridin-2-yl]propyl]methanesulfonate (262.2 mg, 0.42 mmol, 1.0 eq.) in DMF (2.5 mL) was added sodium methanethiolate (45.0 mg, 0.58 mmol, 1.39 eq.) at room temperature. The mixture was stirred at room temperature overnight and then quenched with water (2 mL). The mixture was extracted with EtOAc (2×30 mL). The combined organic layers were washed with water followed by brine (30 mL) and dried over sodium sulfate. The volatiles were removed under reduced pressure and the residue was purified by silica gel flash column chromatography (12 g, 0-20% EtOAc in hexanes with 10% DCM) to give tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-methylsulfanyl-propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (202.3 mg, 84% yield) as a pale yellow foam. MS m / z 582.3, 584.3 [M+H] + .

[0165] Step 3: (R)-2-(2-amino-3-(methylthio)propyl)-5-chloro-N-(furan-2-ylmethyl)-3-methylthieno[3,2-b]pyridin-7-amine Removal of the Boc group following the general procedure described in step 3 of Example 2 gave (R)-2-(2-amino-3-(methylthio)propyl)-5-chloro-N-(furan-2-ylmethyl)-3-methylthieno[3,2-b]pyridin-7-amine dihydrochloride. MS m / z 382.3, 384.3 [M+H] + ; 1H NMR (500 MHz, DMSO-d6) δ ppm 8.31 - 8.48 (m, 3 H), 7.68 (br s, 1 H), 7.59 (d, J=0.92 Hz, 1 H), 6.60 (s, 1 H), 6.40 (dd, J=3.05, 1.83 Hz, 1 H), 6.35 (d, J=3.05 Hz, 1 H), 4.51 (s, 2 H), 3.46 - 3.54 (m, 1 H), 3.36 (dd, J=14.84, 6.15 Hz, 1 H), 3.29 (dd, J=14.92, 7.57 Hz, 1 H), 2.83 (dd, J=14.21, 6.37 Hz, 1 H), 2.76 (dd, J=14.14, 5.93 Hz, 1 H), 2.28 (s, 3 H), 2.11 (s, 3 H).

[0166] The following compounds were prepared according to the procedure of Example 5 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 7]

[0167] Example 6 (Compound 111) (3S)-3-Amino-4-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)butanenitrile dihydrochloride [ka] Step 1: tert-Butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)-3-cyano-propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate To a solution of [(2R)-2-(tert-butoxycarbonylamino)-3-[7-[tert-butoxycarbonyl(2-furylmethyl)amino]-5-chloro-3-methyl-thieno[3,2-b]pyridin-2-yl]propyl]methanesulfonate (216 mg, 0.34 mmol, 1.0 eq.) prepared according to the procedure in Example 5 in DMF (2.5 mL) was added sodium cyanide (30 mg, 0.58 mmol, 1.7 eq.) at room temperature. The reaction was stirred at 60° C. for 3 h. The reaction was quenched with water (2.0 mL) and then extracted with EtOAc (2×40 mL). The combined organic phase was washed with water, followed by brine (30 mL), and then dried over sodium sulfate. The volatiles were removed under reduced pressure and the residue was purified by flash column chromatography (12 g, 0-20% EtOAc in hexanes with 10% DCM) to give tert-butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)-3-cyano-propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (134.2 mg, 70% yield) as an off-white foam. MS m / z 561.3, 563.3 [M+H] + .

[0168] Step 2: (S)-3-amino-4-(5-chloro-7-((furan-2-ylmethyl)amino)-3-methylthieno[3,2-b]pyridin-2-yl)butanenitrile Removal of the Boc group following the general procedure described in step 3 of Example 2 gave (S)-3-amino-4-(5-chloro-7-((furan-2-ylmethyl)amino)-3-methylthieno[3,2-b]pyridin-2-yl)butanenitrile hydrochloride. MS m / z 361.3, 363.3 [M+H] + , 359.2, 361.2 [MH] - ; 1H NMR 500 MHz (DMSO-d6) δ ppm 8.61 (br s, 3 H), 7.66 (br s, 1 H), 7.59 (s, 1 H), 6.60 (s, 1 H), 6.40 (br s, 1 H), 6.35 (br s, 1 H), 4.51 (br s, 2 H), 3.33 - 3.45 (m, 2 H), 3.24 (br dd, J=14.95, 8.24 Hz, 1 H), 2.91 - 3.06 (m, 2 H), 2.28 (s, 3 H).

[0169] The following compounds were prepared according to the procedure of Example 6 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 8]

[0170] Example 7 (Compound 64 and Compound 65) 2-[(2R)-2-Amino-3-(trifluoromethoxy)propyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine formate and (2R)-3-(3-bromo-5-chloro-7-{[(1,3-thiazol-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)-2-[(trifluoromethyl)amino]propan-1-ol formate [ka] Step 1: tert-butyl N-[3-bromo-2-[(2R)-2-(tert-butoxycarbonylamino)-3-(trifluoromethoxy)propyl]-5-chloro-thieno[3,2-b]pyridin-7-yl]-N-(thiazol-2-ylmethyl)carbamate and tert-butyl N-[(1R)-1-[[3-bromo-7-[tert-butoxycarbonyl(thiazol-2-ylmethyl)amino]-5-chloro-thieno[3,2-b]pyridin-2-yl]methyl]-2-hydroxy-ethyl]-N-(trifluoromethyl)carbamate tert-Butyl N-[3-bromo-2-[(2R)-2-(tert-butoxycarbonylamino)-3-hydroxy-propyl]-5-chloro-thieno[3,2-b]pyridin-7-yl]-N-(thiazol-2-ylmethyl)carbamate (64 mg, 0.10 mmol, 1.0 eq.), prepared according to the procedure in Example 3, silver trifluoromethanesulfonate (78 mg, 0.30 mmol, 3.0 eq.), Selectfluor® (56 mg, To a mixture of 2,6-di-tert-butylphenol (11 mg, 0.050 mmol, 0.50 eq.), potassium fluoride (23 mg, 0.40 mmol, 4.0 eq.) and 2,6-di-tert-butylphenol (11 mg, 0.050 mmol, 0.50 eq.) was added a solution of 2-fluoropyridine (30 mg, 0.027 mL, 0.30 mmol, 3.0 eq.) and (trifluoromethyl)trimethylsilane (43 mg, 0.046 mL, 0.30 mmol, 3.0 eq.) in EtOAc (0.5 mL). The mixture was stirred at room temperature overnight. The mixture was diluted with DCM and purified on silica gel using ethyl acetate in dichloromethane (0-25-75% gradient) to give tert-butyl N-[3-bromo-2-[(2R)-2-(tert-butoxycarbonylamino)-3-(trifluoromethoxy)propyl]-5-chloro-thieno[3,2-b]pyridin-7-yl]-N-(thiazol-2-ylmethyl)carbamate (3.5 mg, 4.9% yield) as the less polar fraction. 1H NMR (CDCl3) δ ppm 7.52 - 7.77 (m, 1 H), 7.40 - 7.25 (m, 2 H), 5.08 (br s, 2 H), 4.68 - 4.82 (m, 1 H), 4.11 - 4.23 (m, 1 H), 3.98 (dd, J= 17.3, 3.6 Hz, 2 H), 3.23 (d, J= 6.3 Hz, 2 H), 1.29 - 1.42 (m, 18 H), and tert-butyl N-[(1R)-1-[[3-bromo-7-[tert-butoxycarbonyl(thiazol-2-ylmethyl)amino]-5-chloro-thieno[3,2-b]pyridin-2-yl]methyl]-2-hydroxy-ethyl]-N-(trifluoromethyl)carbamate (35 mg, 49% yield). 1 H NMR (chloroform-d) δ ppm 7.77 (br s, 1 H), 7.44 (br s, 1 H), 7.35 (s, 1 H), 5.22 (d, J= 6.6 Hz, 2 H), 4.86 (br s, 1 H), 4.26 (br s., 1 H), 4.02 - 4.12 (m, 2 H), 3.32 (d, J= 6.0 Hz, 2 H), 1.36 - 1.49 (m, 18 H).

[0171] Step 2: 2-[(2R)-2-amino-3-(trifluoromethoxy)propyl]-3-bromo-5-chloro-N-(thiazol-2-ylmethyl)thieno[3,2-b]pyridin-7-amine Removal of the Boc group according to the general procedure described in step 3 of Example 2, tert-butyl N-[3-bromo-2-[(2R)-2-(tert-butoxycarbonylamino)-3-(trifluoromethoxy)propyl]-5-chloro-thieno[3,2-b]pyridin-7-yl]-N-(thiazol-2-ylmethyl)carbamate (3.5 mg) was treated with HCl in dioxane and then purified by HPLC to give 2-[(2R)-2-amino-3-(trifluoromethoxy)propyl]-3-bromo-5-chloro-N-(thiazol-2-ylmethyl)thieno[3,2-b]pyridin-7-amine, formate, MS m / z 501.2, 503.1, 505.1 [M+H] + ; 1 H NMR (methanol-d4) δ ppm 8.39 (s, 1 H), 7.74 - 7.82 (m, 1 H), 7.51 - 7.58 (m, 1 H), 6.57 (s, 1 H), 4.90 (s, 2 H), 4.04 - 4.22 (m, 2 H), 3.62 - 3.79 (m, 1 H), 3.33 - 3.41 (m, 1 H), 3.19 - 3.27 (m, 1 H).

[0172] (2R)-3-[3-bromo-5-chloro-7-(thiazol-2-ylmethylamino)thieno[3,2-b]pyridin-2-yl]-2-(trifluoromethylamino)propan-1-ol formate Deprotection of tert-butyl N-[(1R)-1-[[3-bromo-7-[tert-butoxycarbonyl(thiazol-2-ylmethyl)amino]-5-chloro-thieno[3,2-b]pyridin-2-yl]methyl]-2-hydroxy-ethyl]-N-(trifluoromethyl)carbamate gave (2R)-3-[3-bromo-5-chloro-7-(thiazol-2-ylmethylamino)thieno[3,2-b]pyridin-2-yl]-2-(trifluoromethylamino)propan-1-ol, formate. MS m / z 501.2, 503.1, 505.1 [M+H] + ; 1H NMR (methanol-d4) δ ppm 8.37 (s, 1 H), 7.80 (d, J= 3.1 Hz, 1 H), 7.56 (d, J= 3.2 Hz, 1 H), 6.59 (s, 1 H), 4.92 (s, 2 H), 4.26 (br s, 1 H), 4.14 - 4.22 (m, 1 H), 3.80 - 3.94 (m, 1 H), 3.35 - 3.47 (m, 2 H).

[0173] Example 8 (Compound 113) 2-[(2R)-2-Amino-3-(methanesulfonyl)propyl]-3,5-dichloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride [ka] Step 1: tert-Butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-methylsulfonyl-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate To a solution of tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-methylsulfanyl-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (256.0 mg, 0.42 mmol, 1.0 eq.) prepared according to the procedure in Example 5 in DCM (3.0 mL) was added 3-chloroperoxybenzoic acid (189.4 mg, 0.82 mmol, 1.9 eq.) at 0° C. The reaction was stirred at 0° C. for 1 h and then quenched with sodium bicarbonate (3.0 mL). The mixture was extracted with DCM (5×10 mL) using a phase separator. The combined organic phase was dried over sodium sulfate and then concentrated. The residue was purified by flash column chromatography (24 g, 0-40% EtOAc in hexanes with 10% DCM) to give tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-methylsulfonyl-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (232.8 mg, 86% yield) as an off-white foam. MS m / z 634.3[M+H] + , 656.4[M+Na] + .

[0174] Step 2: (R)-2-(2-amino-3-(methylsulfonyl)propyl)-3,5-dichloro-N-(furan-2-ylmethyl)thieno[3,2-b]pyridin-7-amine Removal of the Boc group following the general procedure described in step 3 of Example 2 gave (R)-2-(2-amino-3-(methylsulfonyl)propyl)-3,5-dichloro-N-(furan-2-ylmethyl)thieno[3,2-b]pyridin-7-amine dihydrochloride, MS m / z 434.3, 436.3 [M+H] + , 432.2 [MH] - ; 1H NMR (500 MHz, DMSO-d6) δ ppm 8.47 (br s, 3 H), 7.98 (br t, J=5.49 Hz, 1 H), 7.60 (s, 1 H), 6.71 (s, 1 H), 6.37 - 6.43 (m, 2 H), 4.54 (br d, J=5.19 Hz, 2 H), 3.95 - 4.06 (m, 1 H), 3.45 - 3.66 (m, 4 H), 3.17 (s, 3 H).

[0175] The following compounds were prepared according to the procedure of Example 8 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 9]

[0176] Example 9 (Compound 47) 2-[(2S)-2-Amino-4-fluorobutyl]-3,5-dichloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride [ka] Step 1: tert-Butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)-4-fluoro-butyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(thiazol-2-ylmethyl)carbamate To a mixture of tert-butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)-4-hydroxy-butyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(thiazol-2-ylmethyl)carbamate (35 mg, 0.058 mmol, 1.0 eq.) prepared according to the procedure in Example 3 and pyridine-2-sulfonyl fluoride (11 mg, 0.064 mmol, 1.1 eq.) in toluene (0.2 mL) was added 7-methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene (18 mg, 0.017 mL, 0.12 mmol, 2.0 eq.). The mixture was stirred at room temperature for 3 days, then diluted with DCM and purified on silica gel with ethyl acetate in hexanes (5-50% gradient) to give tert-butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)-4-fluoro-butyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(thiazol-2-ylmethyl)carbamate (30 mg, 85% yield). MS m / z 627.2, 629.1 [M+Na] + .

[0177] Step 2: (3S)-3-amino-4-[3,5-dichloro-7-(thiazol-2-ylmethylamino)thieno[3,2-b]pyridin-2-yl]butan-1-ol The general Boc-deprotection procedure described in Example 2, step 3 using HCl in dioxane was then followed to give (3S)-3-amino-4-[3,5-dichloro-7-(thiazol-2-ylmethylamino)thieno[3,2-b]pyridin-2-yl]butan-1-ol dihydrochloride (14 mg, 99% yield). MS m / z 405.1, 407.2, 409.1 [M+H] + ; 1H NMR (methanol-d4) δ: 8.08 (d, J= 3.5 Hz, 1 H), 7.91 (d, J= 3.5 Hz, 1 H), 6.99 (s, 1 H), 5.23 (s, 2 H), 4.61 - 4.81 (m, 2 H), 3.85 - 3.95 (m, 1 H), 3.51 (qd, J= 14.9, 7.2 Hz, 2 H), 2.12 - 2.26 (m, 2 H).

[0178] The following compounds were prepared according to the procedure of Example 9 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 10]

[0179] Example 10 (Compound 107) 2-[(2S)-2-Amino-4,4-difluorobutyl]-3-bromo-5-chloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride [ka] Step 1: (3S)-3-amino-4-[3-bromo-5-chloro-7-(2-thienylmethylamino)thieno[3,2-b]pyridin-2-yl]butan-1-ol To a solution of tert-butyl N-[3-bromo-2-[(2S)-2-(tert-butoxycarbonylamino)-4-[tert-butyl(dimethyl)silyl]oxy-butyl]-5-chloro-thieno[3,2-b]pyridin-7-yl]-N-(2-thienylmethyl)carbamate (300 mg, 0.4 mmol) prepared according to the procedure in Example 2 in CHCl (3 mL) was added trifluoroacetic acid (0.5 mL, 7 mmol). After stirring at room temperature for 4 hours, the reaction was concentrated under reduced pressure. The product was used in the subsequent step without further purification. MS m / z 446.8, 448.2, 450.2 [M+H] + .

[0180] Step 2: N-[(1S)-1-[[3-bromo-5-chloro-7-(2-thienylmethylamino)thieno[3,2-b]pyridin-2-yl]methyl]-3-hydroxy-propyl]-2-nitro-benzenesulfonamide To a solution of (3S)-3-amino-4-[3-bromo-5-chloro-7-(2-thienylmethylamino)thieno[3,2-b]pyridin-2-yl]butan-1-ol (100 mg, 0.2 mmol) in CHCl (1 mL) was added 2-nitrobenzenesulfonyl chloride (50 mg, 0.2 mmol, 1.0 eq) followed by N,N-diisopropylethylamine (0.12 mL, 0.69 mmol, 3.5 eq) at room temperature. After stirring for 1 h at room temperature, the mixture was diluted with water (5 mL) and extracted with CHCl (3×10 mL). The combined organic layers were washed with 1M HCl (10 mL), followed by drying with saturated NaHCO (10 mL) and then NaSO, filtered, and concentrated. The precipitate was triturated with diethyl ether and filtered to give N-[(1S)-1-[[3-bromo-5-chloro-7-(2-thienylmethylamino)thieno[3,2-b]pyridin-2-yl]methyl]-3-hydroxy-propyl]-2-nitro-benzenesulfonamide (119 mg, 84% yield) as a pale yellow solid. MS m / z 631.2, 633.2, 635.2 [M+H] + ; 1 H NMR (DMSO-d6) δ ppm 8.08 (br d, J= 8.5 Hz, 1 H), 7.84 (br t, J= 5.8 Hz, 1 H), 7.65 (t, J= 7.9 Hz, 2 H), 7.30-7.47 (m, 3 H), 7.10-7.20 (m, 1 H), 7.03 (t, J= 4.1 Hz, 1H), 6.59 (s, 1H), 4.71 (br d, J= 5.8 Hz, 2H), 4.41 (t, J= 4.9 Hz, 1H), 3.78-3.97 (m, 1H), 3.44-3.54 (m, 1H), 3.15 (br dd, J= 14.3, 5.2 Hz, 1H), 2.99 (dd, J= 14.5, 8.7 Hz, 1H), 1.63-1.81 (m, 2H).

[0181] Step 3: N-[(1S)-1-[[3-bromo-5-chloro-7-(2-thienylmethylamino)thieno[3,2-b]pyridin-2-yl]methyl]-3-oxo-propyl]-2-nitro-benzenesulfonamide To a suspension of N-[(1S)-1-[[3-bromo-5-chloro-7-(2-thienylmethylamino)thieno[3,2-b]pyridin-2-yl]methyl]-3-hydroxy-propyl]-2-nitro-benzenesulfonamide (50 mg, 0.08 mmol) in CHCl (2 mL) was added Dess-Martin periodinane, 1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one (40 mg, 0.09 mmol, 1.1 eq.). After stirring at room temperature for 4 hours, the mixture was concentrated to give N-[(1S)-1-[[3-bromo-5-chloro-7-(2-thienylmethylamino)thieno[3,2-b]pyridin-2-yl]methyl]-3-oxo-propyl]-2-nitro-benzenesulfonamide, which was used without further purification. MS m / z 629.2, 631.2, 633.2 [M+H] + .

[0182] Step 4: (S)-N-(1-(3-bromo-5-chloro-7-((thiophen-2-ylmethyl)amino)thieno[3,2-b]pyridin-2-yl)-4,4-difluorobutan-2-yl)-2-nitrobenzenesulfonamide To a solution of N-[(1S)-1-[[3-bromo-5-chloro-7-(2-thienylmethylamino)thieno[3,2-b]pyridin-2-yl]methyl]-3-oxo-propyl]-2-nitro-benzenesulfonamide from step 3 in CHCl (1 mL) was added diethylaminosulfur trifluoride (0.25 g, 1M) at room temperature. After stirring for 30 min, the reaction was quenched with saturated NaHCO (5 mL) and extracted with CHCl (10 mL). The organic layer was dried over NaSO, filtered, and concentrated to give (S)-N-(1-(3-bromo-5-chloro-7-((thiophen-2-ylmethyl)amino)thieno[3,2-b]pyridin-2-yl)-4,4-difluorobutan-2-yl)-2-nitrobenzenesulfonamide, which was used without further purification. MS m / z 651.1, 653.3 [M+H] + .

[0183] Step 5: 2-[(2S)-2-amino-4,4-difluoro-butyl]-3-bromo-5-chloro-N-(2-thienylmethyl)thieno[3,2-b]pyridin-7-amine To a solution of N-[(1S)-1-[[3-bromo-5-chloro-7-(2-thienylmethylamino)thieno[3,2-b]pyridin-2-yl]methyl]-3,3-difluoro-propyl]-2-nitro-benzenesulfonamide in DMF (1 mL, 12.9 mmol) was added thiophenol (0.02 mL, 0.2 mmol) and K2CO3 (40 mg, 0.29 mmol). After stirring at room temperature for 18 h, the mixture was diluted with MeOH (1 mL), filtered, and purified by preparative HPLC. The collected fractions were concentrated and then treated with 1M HCl / Et2O (1 mL) to give 2-[(2S)-2-amino-4,4-difluoro-butyl]-3-bromo-5-chloro-N-(2-thienylmethyl)thieno[3,2-b]pyridin-7-amine dihydrochloride (4.0 mg, 9.4% yield) as a white solid. MS m / z 466.1, 468.0, 470.1 [M+H] + ; 1H NMR (methanol-d4) δ ppm 7.33 (d, J= 5.2 Hz, 1 H), 7.11 (d, J= 3.1 Hz, 1H), 7.00 (t, J= 4.3 Hz, 1H), 6.66 (s, 1H), 6.04-6.37 (m, 1 H), 4.71-4.83 (m, 2 H), 3.98 (quintet, J= 6.8 Hz, 1 H), 3.36-3.51 (m, 2 H), 2.25-2.45 (m, 2 H).

[0184] Example 11 (Compound 45) 2-[(2R)-2-Amino-3-methoxypropyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine dihydrochloride [ka] Step 1: tert-Butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-methoxy-propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate To a solution of tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-hydroxy-propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (126.6 mg, 0.23 mmol, 1.0 eq.) prepared according to the procedure in Example 3 in DMF (0.5 mL) and THF (2.0 mL) was added sodium hydride (60% by weight) in mineral oil (15 mg, 0.38 mmol, 1.6 eq.) at 0° C. The mixture was stirred at 0° C. for 5 min, then iodomethane (2.0 M) in tert-butyl methyl ether (112 mg, 0.120 mL, 0.24 mmol, 1.0 eq.) was added. The reaction was allowed to warm to room temperature and then stirred at room temperature overnight. The reaction was quenched with water (ca. 5 mL) and then extracted with EtOAc (2 x 40 mL). The combined organic phase was washed with water followed by brine (ca. 30 mL). The volatiles were removed under reduced pressure and the residue was purified by flash column chromatography (12 g, 0-30% EtOAc in hexanes with 10% DCM) to give tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-methoxy-propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (88.0 mg, 0.155 mmol, 0.68 eq.) as an off-white solid. MS m / z 566.3 [M+H] + , 588.2, 590.3 [M+Na] + .

[0185] Step 2: (R)-2-(2-amino-3-methoxypropyl)-5-chloro-N-(furan-2-ylmethyl)-3-methylthieno[3,2-b]pyridin-7-amine Removal of the Boc group using HCl in dioxane according to the general procedure described in step 3 of Example 2 gave (R)-2-(2-amino-3-methoxypropyl)-5-chloro-N-(furan-2-ylmethyl)-3-methylthieno[3,2-b]pyridin-7-amine hydrochloride. MS m / z 366.3, 368.2 [M+H] + ;1 H NMR 500 MHz (DMSO-d6) δ ppm 8.33 (br s, 3 H), 7.65 (br s, 1 H), 7.56 - 7.62 (m, 1 H), 6.60 (s, 1 H), 6.39 - 6.42 (m, 1 H), 6.36 (d, J=3.05 Hz, 1 H), 4.51 (br s, 2 H), 3.44 - 3.53 (m, 2 H), 3.34 - 3.43 (m, 1 H), 3.31 (s, 3 H), 3.24 (dd, J=14.55, 5.29 Hz, 1 H), 3.18 (dd, J=14.49, 9.25 Hz, 1 H), 2.25 (s, 3 H).

[0186] The following compounds were prepared according to the procedure of Example 11 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 11]

[0187] Example 12 (Compound 115) 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-D-alanine dihydrochloride [ka] Step 1: tert-Butyl (R)-(2-(2-((tert-butoxycarbonyl)amino)-3-oxopropyl)-3,5-dichlorothieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate To tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-hydroxy-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (614 mg, 1.0 mmol) prepared according to the procedure in Example 3 in CHCl (3 mL) was added Dess-Martin periodinane, 1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one (546 mg, 1.3 mmol, 1.3 eq). After stirring at room temperature for 2 h, the mixture was concentrated under reduced pressure, diluted with diethyl ether (3 mL) and stirred with saturated NaSO (1 mL) and saturated NaHCO (1 mL) for 30 min. The organic layer was separated, dried over MgSO4, filtered, and concentrated to give tert-butyl (R)-(2-(2-((tert-butoxycarbonyl)amino)-3-oxopropyl)-3,5-dichlorothieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (510 mg, 83% yield) as a clear oil. MS m / z 569.9 [M+H] + ; 1 H NMR (DMSO-d6) δ ppm 9.51 (s, 1H), 7.55 (m, 2H), 6.33 (br s, 1H), 6.24 (br s, 1H), 4.90-4.98 (m, 2H), 4.10-4.23 (m, 1H), 3.35-3.41 (m, 1H), 3.13-3.26 (m, 1H), 1.39 (s, 9H), 1.36 (s, 9H).

[0188] Step 2: (2R)-2-(tert-butoxycarbonylamino)-3-[7-[tert-butoxycarbonyl(2-furylmethyl)amino]-3,5-dichloro-thieno[3,2-b]pyridin-2-yl]propanoic acid To a solution of tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-oxo-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (510 mg, 0.9 mmol) in tert-butanol (4.0 mL) and water (1.0 mL) was added NaH2PO4 (322 mg, 2.7 mmol, 3 eq.), followed by 2-methyl-2-butene (0.8 mL, 9 mmol, 10 eq.) and finally NaClO2 (162 mg, 1.8 mmol, 2.0 eq.). After stirring at room temperature for 0.5 h, the mixture was diluted with CHCl2 (10 mL) and washed with water (10 mL). The organic layer was separated, dried over Na2SO4, filtered, and concentrated to give (2R)-2-(tert-butoxycarbonylamino)-3-[7-[tert-butoxycarbonyl(2-furylmethyl)amino]-3,5-dichloro-thieno[3,2-b]pyridin-2-yl]propanoic acid (498 mg, 95% yield) as a white solid. MS m / z 586.1 [M+H] + ; 1 H NMR (DMSO-d6) δ ppm 12.79-13.13 (m, 1 H), 7.55-7.59 (m, 1 H), 7.51-7.54 (m, 1 H), 7.25-7.33 (m, 1 H), 6.29-6.36 (m, 1 H), 6.20-6.26 (m, 1 H), 4.90-5.01 (m, 2 H), 4.19-4.25 (m, 1 H), 3.50-3.59 (m, 1 H), 3.21-3.29 (m, 1 H), 1.37-1.40 (s, 9 H), 1.33-1.37 (s, 9 H).

[0189] Step 3: (2R)-2-Amino-3-[3,5-dichloro-7-(2-furylmethylamino)thieno[3,2-b]pyridin-2-yl]propanoic acid A mixture of (2R)-2-(tert-butoxycarbonylamino)-3-[7-[tert-butoxycarbonyl(2-furylmethyl)amino]-3,5-dichloro-thieno[3,2-b]pyridin-2-yl]propanoic acid (80 mg, 0.14 mmol) in a solution of HCl (4M in dioxane) (1 mL, 4 mmol) was stirred at room temperature for 1 h. The mixture was concentrated under reduced pressure. The solid was triturated with diethyl ether and filtered to give (2R)-2-amino-3-[3,5-dichloro-7-(2-furylmethylamino)thieno[3,2-b]pyridin-2-yl]propanoic acid dihydrochloride (55 mg, 88% yield). MS m / z 366.1, 368.2 [M+H] + ; 1 H NMR (DMSO-d6) δ ppm 8.64 (br s, 3 H), 7.93-8.06 (m, 1 H), 7.57-7.65 (m, 1 H), 6.68-6.75 (m, 1 H), 6.35-6.46 (m, 2 H), 4.48-4.60 (m, 2 H), 4.11-4.23 (m, 1 H), 3.48-3.57 (m, 2H), no COOH peak observed.

[0190] The following compounds were prepared according to the procedure of Example 12 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 12]

[0191] Example 13 (Compound 72) 2-[(2R)-2-Aminobut-3-en-1-yl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride [ka] Step 1: tert-Butyl (R)-(3-bromo-2-(2-((tert-butoxycarbonyl)amino)but-3-en-1-yl)-5-chlorothieno[3,2-b]pyridin-7-yl)(thiazol-2-ylmethyl)carbamate To a suspension of methyltriphenylphosphonium bromide (260 mg, 0.71 mmol, 2.1 eq.) in THF (3.5 mL) was added KHMDS (1 M) in THF (0.68 mL, 0.68 mmol, 2.0 eq.). The mixture was stirred at room temperature for 2 h and then cooled to -78°C. tert-Butyl (R)-(3-bromo-2-(2-((tert-butoxycarbonyl)amino)-3-oxopropyl)-5-chlorothieno[3,2-b]pyridin-7-yl)(thiazol-2-ylmethyl)carbamate (215 mg, 0.34 mmol, 1.0 eq.) prepared according to the procedure in Example 12 in THF (2.5 mL) was added, the temperature was allowed to warm to room temperature and stirred overnight. The reaction was quenched with saturated NH4Cl, extracted with ethyl acetate, dried over sodium sulfate and evaporated. The residue was purified on silica gel with ethyl acetate and hexanes (5-35% gradient) to give tert-butyl (R)-(3-bromo-2-(2-((tert-butoxycarbonyl)amino)but-3-en-1-yl)-5-chlorothieno[3,2-b]pyridin-7-yl)(thiazol-2-ylmethyl)carbamate (86 mg, 40% yield). 1 H NMR (CDCl3) δ: 7.71 (d, J= 3.1 Hz, 1 H), 7.30 - 7.39 (m, 2 H), 5.87 (s, 1 H), 5.23 (d, J= 17.1 Hz, 1 H), 5.16 - 5.20 (m, 3 H), 4.50 - 4.75 (m, 2 H), 3.20 - 3.40 (m, 2 H), 1.38 - 1.51 (m, 18 H).

[0192] Step 2: 2-[(2R)-2-aminobut-3-enyl]-3-bromo-5-chloro-N-(thiazol-2-ylmethyl)thieno[3,2-b]pyridin-7-amine Removal of the Boc group using HCl in dioxane according to the general procedure described in step 3 of Example 2 gave 2-[(2R)-2-aminobut-3-enyl]-3-bromo-5-chloro-N-(thiazol-2-ylmethyl)thieno[3,2-b]pyridin-7-amine dihydrochloride. MS m / z 429.0, 431.1, 433.0 [M+H] + ; 1 H NMR (methanol-d4) δ: 7.82-7.89 (m, 1 H), 7.63-7.69 (m, 1 H), 6.66-6.73 (m, 1 H), 5.81-5.91 (m, 1 H), 5.28-5.37 (m, 2 H), 4.98 (s, 2 H), 4.06-4.17 (m, 1 H), 3.38-3.46 (m, 2 H).

[0193] The following compounds were prepared according to the procedure of Example 13 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 13]

[0194] Example 14 (Compound 123) 2-[(2R)-2-aminobut-3-yn-1-yl]-3-methyl-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine [ka] Step 1: tert-Butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)but-3-ynyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate To a stirred suspension of tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-oxo-propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (202 mg, 0.37 mmol, 1.0 eq.), potassium carbonate (100 mg, 0.043 mL, 0.72 mmol, 1.97 eq.), prepared according to the procedure in Example 12, in MeOH (5.0 mL) was added dimethyl(1-diazo-2-oxopropyl)phosphonate (10% by weight) in acetonitrile (800 mg, 1.0 mL, 0.42 mmol, 1.1 eq.) at 0° C. The reaction was stirred at room temperature overnight. The volatiles were removed under reduced pressure and the residue was subjected to aqueous workup and purification by flash column chromatography (24 g, 0-20% EtOAc / Hexanes) to give tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)but-3-ynyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (136.5 mg, 68% yield) as an off-white foam. MS m / z 546.2, 548.4 [M+H] + .

[0195] Step 2: (R)-2-(2-aminobut-3-yn-1-yl)-5-chloro-N-(furan-2-ylmethyl)-3-methylthieno[3,2-b]pyridin-7-amine A general deprotection procedure using HCl in dioxane was then performed to give (R)-2-(2-aminobut-3-yn-1-yl)-5-chloro-N-(furan-2-ylmethyl)-3-methylthieno[3,2-b]pyridin-7-amine hydrochloride. MS m / z 346.2, 348.3 [M+H] + ; 1H NMR (500 MHz, DMSO-d6) δ ppm 8.84 (br d, J= 4.27 Hz, 3 H), 7.67 (br s, 1 H), 7.55 - 7.63 (m, 1 H), 6.60 (s, 1 H), 6.40 (dd, J= 3.05, 1.83 Hz, 1 H), 6.36 (d, J= 2.75 Hz, 1 H), 4.51 (br s, 2 H), 4.23 - 4.36 (m, 1 H), 3.72 (d, J= 2.25 Hz, 1 H), 3.49 (dd, J= 14.19, 4.73 Hz, 1 H), 3.32 (dd, J= 14.19, 10.25 Hz, 1 H), 2.29 (s, 3 H).

[0196] The following compounds were prepared according to the procedure of Example 14 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 14]

[0197] Example 15 (Compound 124) 3-(3,5-Dichloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)-N-(2-fluorophenyl)-D-alaninamide dihydrochloride [ka] Step 1: tert-Butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-(4-chloroanilino)-3-oxo-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate To a solution of (2R)-2-(tert-butoxycarbonylamino)-3-[7-[tert-butoxycarbonyl(2-furylmethyl)amino]-3,5-dichloro-thieno[3,2-b]pyridin-2-yl]propanoic acid (100 mg, 0.17 mmol), chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate (55 mg, 0.2 mmol, 1.1 eq.) and 4-chloroaniline (30 mg, 0.2 mmol, 1.1 eq.) in acetonitrile (1 mL), 1-methylimidazole (0.03 mL, 0.4 mmol, 2 eq.) was added. After stirring at room temperature for 1 h, the mixture was diluted with water (5 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic phase was dried over MgSO4, filtered, and concentrated. The residue was purified on silica gel eluting with 0-30% ethyl acetate in hexanes to give tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-(4-chloroanilino)-3-oxo-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (52 mg, 44% yield) as a clear foam. MS m / z 695.3, 697.3 [M+H] + ; 1 H NMR (CDCl3) δ ppm 8.51 (br s, 1 H), 7.46 (d, J= 8.5 Hz, 2 H), 7.26-7.32 (m, 4 H), 7.18 (s, 1 H), 6.27 (br s, 1 H), 6.19 (d, J= 3.1 Hz, 1 H), 4.79-4.86 (m, 2H), 4.65-4.72 (m, 1H), 3.52-3.64 (m, 2H), 1.44 (s, 9H), 1.41 (s, 9H).

[0198] Step 2: (2R)-2-amino-N-(4-chlorophenyl)-3-[3,5-dichloro-7-(2-furylmethylamino)thieno[3,2-b]pyridin-2-yl]propanamide A mixture of tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-(4-chloroanilino)-3-oxo-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (52 mg, 0.07 mmol) in HCl (4M in dioxane) (1 mL, 4 mmol) was stirred at room temperature for 4 h. The mixture was concentrated and the solid was triturated with diethyl ether and filtered to give (2R)-2-amino-N-(4-chlorophenyl)-3-[3,5-dichloro-7-(2-furylmethylamino)thieno[3,2-b]pyridin-2-yl]propanamide hydrochloride (33 mg, 78% yield) as a beige solid. MS m / z 495.0, 497.0 [M+H] + ; 1 H NMR (DMSO-d6) δ ppm 10.94-11.08 (s, 1 H), 8.70-8.82 (br s, 3 H), 7.90-8.02 (m, 1 H), 7.54-7.66 (m, 3 H), 7.40 (d, J=8.9 Hz, 2 H), 6.68 (s, 1 H), 6.32-6.44 (m, 2 H), 4.47-4.59 (m, 2 H), 4.22-4.32 (m, 1 H), 3.51-3.67 (m, 2 H).

[0199] The following compounds were prepared according to the procedure of Example 15 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 15] TIFF0007587511000073.tif129161

[0200] Example 16 (Compound 51) 2-[(2S)-2-Aminopropyl]-5-chloro-3-cyclopropyl-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride [ka] Step 1: tert-Butyl (S)-(2-(2-((tert-butoxycarbonyl)amino)propyl)-5-chloro-3-cyclopropylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate To a solution of tert-butyl (S)-(3-bromo-2-(2-((tert-butoxycarbonyl)amino)propyl)-5-chlorothieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (88 mg, 0.15 mmol, 1.0 eq.) and potassium cyclopropyl trifluoroborate (29 mg, 0.19 mmol, 1.3 eq.) prepared according to the procedure in Example 2 in dioxane (0.8 mL) was added Pd(dppf)Cl2 (12 mg, 0.1000 eq.) and K2CO3 (2M in H2O, 0.22 mL, 3.0 eq.). The sealed tube was heated to 90 °C for 5 h. After cooling, the mixture was diluted with EtOAc and NH4Cl (aq.) and extracted with EtOAc. The combined organic phase was dried and concentrated. The residue was purified by flash column chromatography on silica gel eluting with 0-10% EtOAc in DCM to give a mixture of the desired product and unreacted starting material, which was then further purified on preparative HPLC using 25-100% CH3CN in water with 0.1% TFA to give tert-butyl (S)-(2-(2-((tert-butoxycarbonyl)amino)propyl)-5-chloro-3-cyclopropylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (53 mg, 64% yield) as a white solid. MS m / z 562.2, 564.2 [M+H] + .

[0201] Step 2: (S)-2-(2-aminopropyl)-5-chloro-3-cyclopropyl-N-(furan-2-ylmethyl)thieno[3,2-b]pyridin-7-amine tert-Butyl (S)-(2-(2-((tert-butoxycarbonyl)amino)propyl)-5-chloro-3-cyclopropylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (53 mg, 0.094 mmol) was stirred in a solution of HCl (4 M in dioxane, 1 mL) at room temperature for 1 h. Organic volatiles were removed. The residue was triturated with diethyl ether and filtered to give (S)-2-(2-aminopropyl)-5-chloro-3-cyclopropyl-N-(furan-2-ylmethyl)thieno[3,2-b]pyridin-7-amine (33 mg, 89% yield) as the hydrochloride salt. MS m / z 362.1, 364.2 [M+H] + ; 1 H NMR (methanol-d4) δ ppm 7.49 (t, J= 0.9 Hz, 1 H), 7.04 (s, 1H), 6.42 (dd, J= 3.2, 12.5 Hz, 2 H), 4.71 (s, 2 H), 3.75 - 3.78 (m, 1 H), 3.42 - 3.44 (m, 1 H), 3.38 - 3.40 (m, 1 H), 1.84-1.87 (m, 1 H), 1.39 (d, J= 6.6 Hz, 3 H), 1.19-1.21 (m, 2 H), 0.85-0.86 (m, 2 H).

[0202] The following compounds were prepared according to the procedure of Example 16 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 16]

[0203] Example 17 (Compound 109) 2-[(2S)-2-Aminopropyl]-5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridine-3-carbonitrile formate [ka] Step 1: tert-Butyl (S)-(1-(5-chloro-3-cyano-7-((furan-2-ylmethyl)amino)thieno[3,2-b]pyridin-2-yl)propan-2-yl)carbamate A mixture of tert-butyl (S)-(3-bromo-2-(2-((tert-butoxycarbonyl)amino)propyl)-5-chlorothieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (67 mg, 0.11 mmol, 1.0 eq.) prepared according to the procedure in Example 2 and CuCN (22 mg, 2.2 eq.) in DMF (0.6 mL) was degassed with argon. The sealed tube was heated at 150° C. for 8 h. After cooling, 0.1 mL of NH4Cl (sat. aq.) and 0.1 mL of NaHCO3 (sat. aq.) were added. The mixture was stirred for 15 min, filtered and washed with MeOH (0.5 mL×3). The combined filtrate was purified by preparative HPLC eluting with 10-100% ACN in water with 0.1% formic acid to give tert-butyl (S)-(1-(5-chloro-3-cyano-7-((furan-2-ylmethyl)amino)thieno[3,2-b]pyridin-2-yl)propan-2-yl)carbamate (15 mg, 30% yield). MS m / z 447.2, 449.2 [M+H] + .

[0204] Step 2: (S)-2-(2-aminopropyl)-5-chloro-7-((furan-2-ylmethyl)amino)thieno[3,2-b]pyridine-3-carbonitrile tert-Butyl (S)-(1-(5-chloro-3-cyano-7-((furan-2-ylmethyl)amino)thieno[3,2-b]pyridin-2-yl)propan-2-yl)carbamate (15 mg, 0.034 mmol) was stirred in a solution of HCl (4 M in dioxane, 1 mL) at room temperature for 1 h. Organic volatiles were removed. The solid was purified by preparative HPLC eluting with 5-50% ACN in water with 0.1% formic acid to give (S)-2-(2-aminopropyl)-5-chloro-7-((furan-2-ylmethyl)amino)thieno[3,2-b]pyridine-3-carbonitrile (5 mg, 36% yield) as the formate salt. MS m / z 347.1, 349.1 [M+H] + ; 1 H NMR (methanol-d4) δ ppm 8.44 (s, 1 H), 7.36 (s, 1 H), 6.61 (s, 1 H), 6.27 (d, J= 1.3 Hz, 2 H), 4.45 (s, 2 H), 3.48 - 3.51 (m, 1 H), 3.27 - 3.31 (m, 2 H), 1.21 (d, J= 6.6 Hz, 3 H).

[0205] Example 18 (Compound 50 and Compound 49) 2-[(2S)-2-Aminopropyl]-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridine-3,5-dicarbonitrile hydrochloride and 2-[(2S)-2-Aminopropyl]-3-bromo-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridine-5-carbonitrile hydrochloride [ka] Step 1: tert-butyl (S)-(2-(2-((tert-butoxycarbonyl)amino)propyl)-3,5-dicyanothieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate and tert-butyl (S)-(3-bromo-2-(2-((tert-butoxycarbonyl)amino)propyl)-5-cyanothieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate To a solution of tert-butyl (S)-(3-bromo-2-(2-((tert-butoxycarbonyl)amino)propyl)-5-chlorothieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (90 mg, 0.15 mmol, 1.0 eq), prepared according to the procedure in Example 2, in DMF (1 mL) was added zinc cyanide (11 mg, 0.60 eq.), Pd2(dba)3 (7.1 mg, 0.05 eq.) and Xantphos (8.9 mg, 0.10 eq.). The sealed tube was stirred at 120° C. for 1 h. After cooling, the mixture was diluted with EtOAc and NH4Cl (aq.) and extracted with EtOAc. The combined organic phases were dried and concentrated. The residue was purified by flash column chromatography on silica gel eluting with 0-10% EtOAc in DCM to give a mixture which was further purified by preparative HPLC using 25-100% ACN in water with 0.1% TFA to give tert-butyl (S)-(2-(2-((tert-butoxycarbonyl)amino)propyl)-3,5-dicyanothieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (23 mg, 29% yield), MS m / z 536.3 [MH] - To obtain tert-butyl (S)-(3-bromo-2-(2-((tert-butoxycarbonyl)amino)propyl)-5-cyanothieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (35 mg, 40% yield). MS m / z 591.2, 593.2 [M+H] + .

[0206] Step 2: (S)-2-(2-aminopropyl)-7-((furan-2-ylmethyl)amino)thieno[3,2-b]pyridine-3,5-dicarbonitrile Deprotection of tert-butyl (S)-(2-(2-((tert-butoxycarbonyl)amino)propyl)-3,5-dicyanothieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate using the general Boc-deprotection described in Example 2, step 3, afforded (S)-2-(2-aminopropyl)-7-((furan-2-ylmethyl)amino)thieno[3,2-b]pyridine-3,5-dicarbonitrile (17 mg, 95% yield) as the hydrochloride salt. MS m / z 338.0 [M+H] + ; 1 H NMR (methanol-d4) δ ppm 7.48 (d, J= 0.9 Hz, 1 H), 7.20 (s, 1 H), 6.40-6.42 (m, 2 H), 4.64 (s, 2 H), 3.79 - 3.81 (m, 1 H), 3.55 - 3.59 (m, 1 H), 3.45 - 3.49 (m, 1 H), 1.42 (d, J= 6.6 Hz, 3 H).

[0207] (S)-2-(2-aminopropyl)-3-bromo-7-((furan-2-ylmethyl)amino)thieno[3,2-b]pyridine-5-carbonitrile Deprotection of tert-butyl (S)-(3-bromo-2-(2-((tert-butoxycarbonyl)amino)propyl)-5-cyanothieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate using the general Boc-deprotection procedure described in Example 2, step 3, afforded (S)-2-(2-aminopropyl)-3-bromo-7-((furan-2-ylmethyl)amino)thieno[3,2-b]pyridine-5-carbonitrile (19 mg, 83% yield) as the hydrochloride salt. MS m / z 391.0, 393.0 [M+H] + ; 1H NMR (methanol-d4) δ ppm 7.49 (d, J= 0.9 Hz, 1 H), 7.22 (s, 1 H), 6.40-6.42 (m, 2 H), 4.66 (s, 2 H), 3.76 - 3.80 (m, 1 H), 3.41 - 3.45 (m, 1 H), 3.37 - 3.39 (m, 1 H), 1.42 (d, J= 6.6 Hz, 3 H).

[0208] The following compounds were prepared according to the procedure of Example 18 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 17] TIFF0007587511000079.tif55158

[0209] Example 19 (Compound 60) 2-[(2S)-2-Aminopropyl]-3-chloro-5-methyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride [ka] Step 1: tert-Butyl N-(3-chloro-5-methyl-thieno[3,2-b]pyridin-7-yl)-N-(thiazol-2-ylmethyl)carbamate A mixture of tert-butyl N-(3,5-dichlorothieno[3,2-b]pyridin-7-yl)-N-(thiazol-2-ylmethyl)carbamate (100 mg, 0.240 mmol, 1.0 eq.), 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (44 mg, 0.049 mL, 0.35 mmol, 1.5 eq.), CsCO (171 mg, 0.524 mmol, 2.2 eq.) and PdCldppf DCM (14.4 mg, 0.0175 mmol, 0.0727 eq.) in dioxane (1.0 mL) and water (0.1 mL) was stirred at 120° C. for 2 h, then cooled, diluted with ethyl acetate, washed with brine, dried and evaporated. The residue was purified on silica gel using ethyl acetate and dichloromethane (0-50% gradient) to give tert-butyl N-(3-chloro-5-methyl-thieno[3,2-b]pyridin-7-yl)-N-(thiazol-2-ylmethyl)carbamate (71 mg, 75% yield). 1 H NMR (CDCl3) δ: 7.69 (d, J= 2.6 Hz, 1 H), 7.34 (d, J= 2.9 Hz, 1 H), 7.07 - 7.20 (m, 1 H), 5.19 (br s, 2 H), 4.40 - 4.63 (m, 1 H), 4.00 - 4.11 (m, 1 H), 3.22 (br s, 2 H), 2.74 (br s, 3 H), 1.46 (s, 18 H), 1.19 (d, J= 5.8 Hz, 3 H).

[0210] Step 2: 2-[(2S)-2-aminopropyl]-3-chloro-5-methyl-N-(thiazol-2-ylmethyl)thieno[3,2-b]pyridin-7-amine Deprotection of tert-butyl N-(3-chloro-5-methyl-thieno[3,2-b]pyridin-7-yl)-N-(thiazol-2-ylmethyl)carbamate using the general Boc-deprotection procedure with HCl in dioxane gave 2-[(2S)-2-aminopropyl]-3-chloro-5-methyl-N-(thiazol-2-ylmethyl)thieno[3,2-b]pyridin-7-amine dihydrochloride (52 mg, 96% yield). MS m / z 353.1, 355.1 [M+H] + . 1 H NMR (methanol-d4) δ: 7.88 - 7.95 (m, 1 H), 7.71 - 7.78 (m, 1 H), 6.97 - 7.05 (m, 1 H), 5.21 (s, 2 H), 3.73 - 3.85 (m, 1 H), 3.46 - 3.54 (m, 1 H), 3.37 - 3.44 (m, 1 H), 2.73 (s, 3 H), 1.43 (d, J= 6.6 Hz, 3 H).

[0211] Example 20 (Compound 21) 2-[(1S)-1-Aminoethyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine hydrochloride [ka] Step 1: tert-Butyl (5-chloro-2-formyl-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate To a solution of tert-butyl N-(5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl)-N-(2-furylmethyl)carbamate (90 mg, 0.24 mmol, 1.0 eq.) prepared according to the procedure in Example 2 in THF (1 mL) at -78°C, LDA (2.0 M in THF, 0.14 mL, 1.2 eq.) was added. After 30 min, DMF (0.11 mL, 1.4 mmol, 5.8 eq.) was added dropwise. The temperature was warmed to -50°C and the reaction was quenched with saturated aqueous NH4Cl solution and then diluted with EtOAc. The mixture was washed with water followed by brine and the organic layer was dried over sodium sulfate and evaporated. The residue was purified by flash column chromatography on silica gel eluting with 0-25% EtOAc in hexanes to give tert-butyl (5-chloro-2-formyl-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (83 mg, 86% yield) as a white solid. 1 H NMR (acetone-d6) δ ppm 10.5 (s, 1 H), 7.55 (s, 1 H), 7.45 (s, 1 H), 6.29-6.33 (m, 2 H), 5.03 (s, 2H), 2.84 (s, 3 H), 1.43 (s, 9 H).

[0212] Step 2: tert-Butyl (R,E)-(2-(((tert-butylsulfinyl)imino)methyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate A mixture of tert-butyl (5-chloro-2-formyl-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (151 mg, 0.37 mmol, 1.0 eq.), R-(+)-2-methylpropane-2-sulfinamide (54 mg, 0.45 mmol, 1.2 eq.) and CuSO4 (91 mg, 0.56 mmol, 1.5 eq.) in DCE (0.4 mL) was stirred at 55 °C for 18 h. After cooling, the mixture was purified by flash column chromatography on silica gel eluting with 0-50% EtOAc in hexanes to give tert-butyl (R,E)-(2-(((tert-butylsulfinyl)imino)methyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (140 mg, 74% yield). MS m / z 510.4, 512.4 [M+H] + .

[0213] Step 3: tert-Butyl (2-((S)-1-(((R)-tert-butylsulfinyl)amino)ethyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate and tert-Butyl (2-((R)-1-(((R)-tert-butylsulfinyl)amino)ethyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate To a solution of tert-butyl (R,E)-(2-(((tert-butylsulfinyl)imino)methyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (140 mg, 0.27 mmol, 0.74 eq.) in THF (2.3 mL) was added MeMgBr (3.0 M in EtO, 0.31 mL, 2.5 eq.) at -78°C. The mixture was allowed to warm to 0°C over 1 h and then quenched with a saturated solution of NH4Cl and EtOAc. The mixture was washed with water followed by brine and the organic layer was dried over sodium sulfate and evaporated. The residue was purified by flash column chromatography on silica gel eluting with 0-100% EtOAc in hexanes to give tert-butyl (2-((S)-1-(((R)-tert-butylsulfinyl)amino)ethyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (88 mg, 45% yield, major diastereoisomer); MS m / z 526.5, 528.5 [M+H]. + ; 1 H NMR (acetone-d6) δ ppm 7.44 (d, J= 0.9 Hz, 1 H), 7.25 (s, 1 H), 6.30-6.32 (m, 1 H), 6.25-6.27 (m, 1 H), 5.07-5.10 (m, 1 H), 4.95-4.97 (m, 3 H), 2.41 (t, 3 H), 1.60 (d, J= 6.6 Hz, 3 H), 1.41 (s, 9 H), 1.20 (s, 9 H), and tert-butyl (2-((R)-1-(((R)-tert-butylsulfinyl)amino)ethyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (26 mg, 13% yield, minor diastereoisomer), MS m / z 526.5, 528.5 [M+H] + ; 1H NMR (acetone-d6) δ ppm 7.43 (s, 1 H), 7.26 (s, 1 H), 6.29-6.31 (m, 1 H), 6.23-6.25 (m, 1 H), 5.10-5.11 (m, 1 H), 4.97 (d, J= 4.9 Hz, 2H), 4.69 (br s, 1 H), 2.43 (t, 3 H), 1.60 (d, J= 6.6 Hz, 3 H), 1.41 (s, 9 H), 1.20 (s, 9 H).

[0214] Step 4: (S)-2-(1-aminoethyl)-5-chloro-N-(furan-2-ylmethyl)-3-methylthieno[3,2-b]pyridin-7-amine A solution of (2-((S)-1-(((R)-tert-butylsulfinyl)amino)ethyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (20 mg, 0.038 mmol) in HCl (4 M in dioxane, 1 mL) was stirred at room temperature for 1 h. The organic volatiles were removed and the residue was triturated with diethyl ether and filtered to give (S)-2-(1-aminoethyl)-5-chloro-N-(furan-2-ylmethyl)-3-methylthieno[3,2-b]pyridin-7-amine (12 mg, 74% yield) as the dihydrochloride salt. MS m / z 322.1, 324.1 [M+H] + ; 1 H NMR (DMSO-d6) δ ppm 8.67 (br s, 3 H), 7.80 (br s, 1 H), 7.60 (d, J= 0.9 Hz, 1 H), 6.63 (s, 1 H), 6.40-6.41 (m, 1 H), 6.35-6.37 (m, 1 H), 4.96-4.99 (m, 1 H), 4.53 (br s, 2 H), 2.36 (s, 3 H), 1.64 (d, J= 6.8 Hz, 3 H).

[0215] Example 21 (Compound 26) 5-Chloro-N-[(furan-2-yl)methyl]-3-methyl-2-[(1S)-1-(methylamino)ethyl]thieno[3,2-b]pyridin-7-amine hydrochloride [ka] Step 1: tert-Butyl (2-((S)-1-(((R)-tert-butylsulfinyl)(methyl)amino)ethyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate To a solution of tert-butyl (2-((S)-1-(((R)-tert-butylsulfinyl)amino)ethyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (88 mg, 0.17 mmol, 1.0 eq.) in DMF (0.3 mL) was added NaH (60% in oil, 8.7 mg, 1.3 eq.) at 0° C. After 10 min, a solution of iodomethane (31.0 mg, 1.3 eq.) in DMF (0.3 mL) was added. After 30 min, the reaction was quenched with citric acid (1.0 M) and diluted with EtOAc. The organic phase was washed with water and brine, dried over sodium sulfate and evaporated. The residue was purified by flash column chromatography on silica gel eluting with 0-70% EtOAc in hexanes to give tert-butyl (2-((S)-1-(((R)-tert-butylsulfinyl)(methyl)amino)ethyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (79 mg, 87% yield). MS m / z 540.6, 542.6, [M+H] + .

[0216] Step 2: (S)-2-(1-aminoethyl)-5-chloro-N-(furan-2-ylmethyl)-3-methylthieno[3,2-b]pyridin-7-amine A solution of tert-butyl (2-((S)-1-(((R)-tert-butylsulfinyl)(methyl)amino)ethyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (79 mg, 0.15 mmol) in HCl (4 M in dioxane, 1 mL) was stirred at room temperature for 1 h. Organic volatiles were removed. The residue was triturated with diethyl ether and filtered to give (S)-2-(1-aminoethyl)-5-chloro-N-(furan-2-ylmethyl)-3-methylthieno[3,2-b]pyridin-7-amine (41 mg, 72% yield) as the hydrochloride salt. MS m / z 336.3, 338.1 [M+H] + ; 1 H NMR (DMSO-d6) δ ppm 9.38 (br s, 1 H), 9.07 (br s, 1 H), 7.79 (t, J= 6.0 Hz, 1 H), 7.60 (s, 1 H), 6.66 (s, 1 H), 6.37-6.42 (m, 2 H), 4.93-4.98 (m, 1 H), 4.53 (d, J= 5.8 Hz, 2 H), 2.60 (br s, 3 H), 2.38 (s, 3 H), 1.64 (d, J= 6.8 Hz, 3 H).

[0217] The following compounds were prepared according to the procedure of Example 21 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 18]

[0218] Example 22 (Compound 22 and Compound 3) 2-[(1R)-1-Aminoethyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine hydrochloride and 1-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)ethan-1-ol [ka] Step 1: tert-Butyl (5-chloro-2-(1-hydroxyethyl)-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate and tert-Butyl (2-((R)-1-(((R)-tert-butylsulfinyl)amino)ethyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate A mixture of tert-butyl N-(5-chloro-2-formyl-3-methyl-thieno[3,2-b]pyridin-7-yl)-N-(2-furylmethyl)carbamate (160 mg, 0.39 mmol, 1.0 eq.), S-(+)-2-methylpropane-2-sulfinamide (54 mg, 0.45 mmol, 1.2 eq.) and CuSO4 (96 mg, 0.59 mmol, 1.5 eq.) in DCE (0.4 mL) was stirred at 55° C. for 18 h. The mixture was filtered through a Celite pad and the solid was washed with DCE. The filtrate was concentrated. To a solution of the residue in THF (2 mL) was added MeMgBr (3.0 M in Et2O, 0.52 mL, 4.0 eq.) at −78° C. The mixture was allowed to warm gradually to 0°C over 1 h and then quenched with a saturated solution of NH4Cl and EtOAc. The mixture was washed with water followed by brine and the organic layer was dried over sodium sulfate and evaporated. The residue was purified by flash column chromatography on silica gel eluting with 0-60% EtOAc in hexanes to give tert-butyl (5-chloro-2-(1-hydroxyethyl)-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (44 mg, 27%), MS m / z 423.2, 425.2 [M+H] + and then 100% EtOAc to give tert-butyl (2-((R)-1-(((R)-tert-butylsulfinyl)amino)ethyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (40 mg, 27%, major diastereoisomer), MS m / z 526.5, 528.5 [M+H] + .

[0219] Step 2: 1-(5-chloro-7-((furan-2-ylmethyl)amino)-3-methylthieno[3,2-b]pyridin-2-yl)ethan-1-ol (2-((R)-1-(((R)-tert-butylsulfinyl)amino)ethyl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (20 mg, 0.038 mmol) in a solution of HCl (4 M in dioxane, 1 mL) was stirred at room temperature for 1 h, then the organic volatiles were removed. The residue was triturated with diethyl ether and filtered to give (R)-2-(1-aminoethyl)-5-chloro-N-(furan-2-ylmethyl)-3-methylthieno[3,2-b]pyridin-7-amine (12 mg, 74% yield) as the hydrochloride salt. MS m / z 322.1, 324.1 [M+H] + ; 1 H NMR (DMSO-d6) δ ppm 8.67 (br s, 3 H), 7.80 (br s, 1 H), 7.60 (d, J= 0.9 Hz, 1 H), 6.63 (s, 1 H), 6.40-6.41 (m, 1 H), 6.35-6.37 (m, 1 H), 4.96-4.99 (m, 1 H), 4.53 (br s, 2 H), 2.36 (s, 3 H), 1.64 (d, J= 6.8 Hz, 3 H). t-Butyl (5-chloro-2-(1-hydroxyethyl)-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (35 mg, 0.083 mmol) in a solution of HCl (4 M in dioxane, 1 mL) was stirred at room temperature for 1 h, then the organic volatiles were removed. The residue was triturated with diethyl ether and filtered to give 1-(5-chloro-7-((furan-2-ylmethyl)amino)-3-methylthieno[3,2-b]pyridin-2-yl)ethan-1-ol (13 mg, 49% yield) as a white solid. MS m / z 323.1, 325.1 [M+H] + ; 1H NMR (acetone-d6) δ ppm 7.45 (s, 1 H), 6.58 (s, 1 H), 6.32-6.33 (m, 2 H), 5.31 (q, J= 6.4 Hz, 1 H), 4.59 (d, J= 5.3 Hz, 2 H), 3.50 (br s, 1H), 2.25 (s, 3 H), 1.45 (d, J= 6.4 Hz, 3 H).

[0220] The following compounds were prepared according to the procedure of Example 22 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 19]

[0221] Example 23 (Compound 5 and Compound 25) (5-Chloro-7-((furan-2-ylmethyl)amino)thieno[3,2-b]pyridin-2-yl)methanol and 5-Chloro-N-(furan-2-ylmethyl)-2-((methylamino)methyl)thieno[3,2-b]pyridin-7-amine hydrochloride [ka] Step 1: tert-butyl ((7-((tert-butoxycarbonyl)(furan-2-ylmethyl)amino)-5-chlorothieno[3,2-b]pyridin-2-yl)methyl)(methyl)carbamate and tert-butyl (2-(((tert-butoxycarbonyl)oxy)methyl)-5-chlorothieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate To a solution of tert-butyl N-(5-chloro-2-formyl-3-methyl-thieno[3,2-b]pyridin-7-yl)-N-(2-furylmethyl)carbamate (40 mg, 0.10 mmol, 1.0 eq.) prepared according to the procedure in Example 20 in DCM, a solution of methylamine (2.0 M in THF, 0.2 mL, 4 eq.) and sodium triacetoxyborohydride (64 mg, 0.30 mmol) was added. The reaction mixture was stirred overnight at room temperature and then quenched by the addition of NaHCO3 (sat. aq.). The crude product was extracted with DCM and the combined organic phase was dried and concentrated. This crude material was mixed with 4-DMAP (5 mg) and di-tert-butyl dicarbonate (50 mg) in DCM (1 mL). After stirring at room temperature for 1-2 h, the reaction was concentrated and directly purified by flash column chromatography on silica gel eluting with 0-100% EtOAc in hexanes to give tert-butyl ((7-((tert-butoxycarbonyl)(furan-2-ylmethyl)amino)-5-chlorothieno[3,2-b]pyridin-2-yl)methyl)(methyl)carbamate, MS m / z 508.1, 510.1, [M+H] + To give tert-butyl (2-(((tert-butoxycarbonyl)oxy)methyl)-5-chlorothieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate.

[0222] Step 2: 5-Chloro-N-(furan-2-ylmethyl)-2-((methylamino)methyl)thieno[3,2-b]pyridin-7-amine and (5-chloro-7-((furan-2-ylmethyl)amino)thieno[3,2-b]pyridin-2-yl)methanol The intermediate tert-butyl ((7-((tert-butoxycarbonyl)(furan-2-ylmethyl)amino)-5-chlorothieno[3,2-b]pyridin-2-yl)methyl)(methyl)carbamate was stirred in a solution of HCl (4M in dioxane, 0.5 mL) at room temperature for 1 h, then the organic volatiles were removed. The crude solid was triturated with diethyl ether and filtered to give 5-chloro-N-(furan-2-ylmethyl)-2-((methylamino)methyl)thieno[3,2-b]pyridin-7-amine (1.8 mg, 5.8% yield over 3 steps) as the hydrochloride salt. MS m / z 308.1, 310.1 [M+H] + ; 1 H NMR (methanol-d4) δ: 7.61 (s, 1H), 7.51 (s, 1H), 7.06 (s, 1H), 6.42-6.46 (m, 2H), 4.73 (s, 2H), 4.63 (s, 2H), 2.83 (s, 3H).

[0223] (5-Chloro-7-((furan-2-ylmethyl)amino)thieno[3,2-b]pyridin-2-yl)methanol The intermediate tert-butyl (2-(((tert-butoxycarbonyl)oxy)methyl)-5-chlorothieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate was stirred in a solution of HCl (4M in dioxane, 0.5 mL) at room temperature for 1 h, then the organic volatiles were removed. The crude solid was triturated with diethyl ether and filtered to give (5-chloro-7-((furan-2-ylmethyl)amino)thieno[3,2-b]pyridin-2-yl)methanol (9 mg, 31% yield over 3 steps). MS m / z 295.0, 297.0 [M+H] + ; 1 H NMR (methanol-d4) δ: 7.35 (s, 1H), 7.29 (s, 1H), 6.66 (s, 1H), 6.26-6.27 (m, 2H), 4.49 (s, 2H), 4.29 (br s, 2H).

[0224] The following compounds were prepared following the reductive amination procedure of Example 23 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 20]

[0225] Example 24 (Compound 163) N 2 -[(2S)-2-aminopropyl]-5-chloro-3-methyl-N 7 -[(Thiophen-2-yl)methyl]thieno[3,2-b]pyridine-2,7-diamine [ka] Step 1: tert-Butyl (S)-(2-((2-((tert-butoxycarbonyl)amino)propyl)amino)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(thiophen-2-ylmethyl)carbamate A mixture of tert-butyl (5-chloro-2-iodo-3-methylthieno[3,2-b]pyridin-7-yl)(thiophen-2-ylmethyl)carbamate (100 mg, 0.19 mmol, 1.0 eq), tert-butyl (S)-(1-aminopropan-2-yl)carbamate (50 mg, 0.29 mmol, 1.5 eq), Cs2CO3 (200 mg, 0.61 mmol, 3.0 eq), Pd2(dba)3 (9 mg, 0.01 mmol, 0.1 eq), Xantphos (12 mg, 0.02 mmol, 0.2 eq) and toluene (1 mL) was heated at 100 °C under an argon atmosphere for 3 h. The crude reaction mixture was cooled to rt and diluted with EtOAc (20 mL). The organic phase was washed with HO (20 mL) followed by brine (20 mL). The organic phase was dried over MgSO, filtered and concentrated in vacuo. The crude residue was purified by silica gel column chromatography eluting with 0-30% EtOAc in hexanes to give tert-butyl (S)-(2-((2-((tert-butoxycarbonyl)amino)propyl)amino)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(thiophen-2-ylmethyl)carbamate (80 mg, 74%) as a yellow foam. MS m / z 567.2, 569.2 [M+H] + ; 1 H NMR (DMSO-d6) δ: 7.39-7.43 (m, 1H), 6.71-6.95 (m, 5H), 5.00 (s, 2H), 3.67-3.80 (m, 1H), 3.14-3.23 (m, 1H), 3.03-3.13 (m, 1H), 2.05 (s, 3H), 1.39 (s, 18H), 1.03-1.10 (d, J= 6.4 Hz, 3H).

[0226] Step 2:N 2 -[(2S)-2-aminopropyl]-5-chloro-3-methyl-N 7 -[(Thiophen-2-yl)methyl]thieno[3,2-b]pyridine-2,7-diamine A mixture of tert-butyl (S)-(2-((2-((tert-butoxycarbonyl)amino)propyl)amino)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(thiophen-2-ylmethyl)carbamate (80 mg, 0.14 mmol) in a solution of HCl (4 M in dioxane, 1 mL) at room temperature for 1 h. The organic volatiles were removed. The residue was triturated with diethyl ether, filtered, and purified to give (S)-N 2 -(2-aminopropyl)-5-chloro-3-methyl-N 7 -(Thiophen-2-ylmethyl)thieno[3,2-b]pyridine-2,7-diamine (52 mg, 62% yield) was obtained as the hydrochloride salt. MS m / z 367.2, 369.2 [M+H] + ; 1 H NMR (DMSO-d6) δ: 8.34 (br s, 4H), 8.11 (br s, 1H), 7.39-7.46 (m, 1H), 7.08-7.14 (m, 1H), 6.97-7.02 (m, 1H), 6.58 (s, 1H), 4.71-4.80 (m, 2H), 3.47-3.55 (m, 1H), 3.41-3.45 (m, 1H), 3.31-3.36 (m, 1H), 2.15 (s, 3H), 1.29 (d, J=6.4 Hz, 3H).

[0227] The following compounds were prepared according to the procedure of Example 24 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 21]

[0228] Example 25 (Compound 131) Methyl 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-D-alaninate [ka] Step 1: Methyl (R)-3-(7-((tert-butoxycarbonyl)(furan-2-ylmethyl)amino)-5-chloro-3-methylthieno[3,2-b]pyridin-2-yl)-2-((tert-butoxycarbonyl)amino)propanoate To a solution of (R)-3-(7-((tert-butoxycarbonyl)(furan-2-ylmethyl)amino)-5-chloro-3-methylthieno[3,2-b]pyridin-2-yl)-2-((tert-butoxycarbonyl)amino)propanoic acid (45 mg, 0.08 mmol, 1.0 eq.) prepared according to Example 12, step 2 and K2CO3 (35 mg, 0.25 mmol, 3.0 eq.) in DMF (1 mL) was added MeI (25 μL, 0.4 mmol, 5 eq.) and then stirred at 50 °C for 12 h. The reaction mixture was cooled to room temperature and diluted with H2O (10 mL). The aqueous phase was extracted with EtOAc (2 × 30 mL). The combined organic phase was washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The crude residue was purified by silica gel column chromatography eluting with 0-30% EtOAc in hexanes to give methyl (R)-3-(7-((tert-butoxycarbonyl)(furan-2-ylmethyl)amino)-5-chloro-3-methylthieno[3,2-b]pyridin-2-yl)-2-((tert-butoxycarbonyl)amino)propanoate (28 mg, 60%) as a clear oil. MS m / z 580.2 [M+H] + ; 1 H NMR (methanol-d4) δ: 7.36-7.48 (m, 1H), 7.12-7.20 (m, 1H), 6.27-6.35 (m, 1H), 6.16-6.26 (m, 1H), 4.88-4.95 (m, 2H), 4.46-4.55 (m, 1H), 4.06-4.18 (m, 1H), 3.75 (s, 3H), 3.45-3.57 (m, 1H), 2.38 (s, 3H), 1.44 (s, 9H), 1.42 (s, 9H), no 1NH observed.

[0229] Step 2: Methyl 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-D-alaninate A mixture of (R)-3-(7-((tert-butoxycarbonyl)(furan-2-ylmethyl)amino)-5-chloro-3-methylthieno[3,2-b]pyridin-2-yl)-2-((tert-butoxycarbonyl)amino)propanoate (28 mg, 0.05 mmol) in a solution of HCl (4M in dioxane) (1 mL, 4 mmol) was stirred at room temperature for 1 h. The mixture was concentrated under reduced pressure. The solid was triturated with diethyl ether and filtered to give methyl (R)-2-amino-3-(5-chloro-7-((furan-2-ylmethyl)amino)-3-methylthieno[3,2-b]pyridin-2-yl)propanoate dihydrochloride (12 mg, 65% yield). MS m / z 380.1, 382.1 [M+H] + ; 1 H NMR (methanol-d4) δ: 7.49-7.56 (m, 1H), 7.12-7.18 (m, 1H), 6.45-6.51 (m, 1H), 6.40-6.44 (m, 1H), 4.75 (s, 2H), 4.46-4.53 (m, 1H), 3.90 (s, 3H), 3.67-3.74 (m, 1H), 3.58-3.66 (m, 1H), 2.46 (s, 3H), no 3NH observed.

[0230] Example 26 (Compound 127, Compound 130, and Compound 132) (2S)-2-Amino-1-[3,5-dichloro-7-(2-thienylmethylamino)thieno[3,2-b]pyridin-2-yl]propan-1-ol dihydrochloride and 2-[(2S)-2-Amino-1-fluoro-propyl]-3,5-dichloro-N-(2-thienylmethyl)thieno[3,2-b]pyridin-7-amine formate and 2-[(2S)-2-Amino-1,1-difluoro-propyl]-3,5-dichloro-N-(2-thienylmethyl)thieno[3,2-b]pyridin-7-amine [ka] Step 1: N-[2-[(2S)-2-(tert-butoxycarbonylamino)-1-hydroxy-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-thienylmethyl)carbamate To a solution of tert-butyl N-(3,5-dichlorothieno[3,2-b]pyridin-7-yl)-N-(2-thienylmethyl)-carbamate (110 mg, 0.27 mmol, 2.0 eq.) in THF (1.0 mL) cooled at -78°C, LDA (2.0 M, 0.15 mL, 0.30 mmol, 2.2 eq.) was added. After 15 min, a solution of Boc-L-alaninal (25 mg, 0.14 mmol, 1.0 eq.) in THF (0.5 mL) was added dropwise and the temperature was allowed to warm to 0°C over 30 min. The reaction was quenched with saturated NH4Cl, then diluted with ethyl acetate, washed with brine, dried and concentrated. The residue was purified on silica gel using ethyl acetate in hexanes (10-50% gradient) to give tert-butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)-1-hydroxy-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-thienylmethyl)carbamate (28 mg, 35% yield). MS m / z 588.2, 590.2, 592.5 [M+H] + .

[0231] Step 2: (2S)-2-Amino-1-[3,5-dichloro-7-(2-thienylmethylamino)thieno[3,2-b]pyridin-2-yl]propan-1-ol dihydrochloride A general deprotection procedure using HCl in dioxane was then performed to give (2S)-2-amino-1-[3,5-dichloro-7-(2-thienylmethylamino)thieno[3,2-b]pyridin-2-yl]propan-1-ol dihydrochloride (20 mg). MS m / z 388.2, 390.2, 392.2 [M+H]. + ; 1 H NMR (methanol-d4) δ: 7.34 (d, J=5.2 Hz, 1H), 7.07-7.20 (m, 1H), 7.00 (t, J=4.0 Hz, 1H), 6.89 (s, 1H), 5.25 (d, J=7.6 Hz, 1H), 4.87 (s, 2H), 3.59-3.70 (m, 1H), 1.33 (d, J=6.7 Hz, 3H), no 3NH or 1OH.

[0232] Step 3: tert-Butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)-1-fluoro-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-thienylmethyl)carbamate To a solution of tert-butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)-1-hydroxy-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-thienylmethyl)carbamate (30.0 mg, 0.0510 mmol, 1.00 eq.) and DIPEA (26.9 mg, 0.036 mL, 0.20 mmol, 4.00 eq.) in DCM (0.5 mL) at -78°C, DAST (1.0 M in DCM, 0.20 mL, 0.20 mmol, 4.00 eq.) was added. The temperature was then slowly raised to room temperature and stirred at room temperature overnight. The reaction intermediates were observed by LC / MS. The reaction was quenched with saturated sodium bicarbonate, then diluted with ethyl acetate, washed with brine, dried and then evaporated. The residue was purified on silica with ethyl acetate and hexanes (10-50% gradient) to give tert-butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)-1-fluoro-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-thienylmethyl)carbamate (17 mg, 56% yield). MS m / z 590.3, 592.2, 594.2 [M+H] + .

[0233] Step 4: 2-[(2S)-2-amino-1-fluoro-propyl]-3,5-dichloro-N-(2-thienylmethyl)thieno[3,2-b]pyridin-7-amine formate A general deprotection procedure using HCl in dioxane followed by reversed-phase HPLC purification with formic acid used as mobile phase modifier gave 2-[(2S)-2-amino-1-fluoro-propyl]-3,5-dichloro-N-(2-thienylmethyl)thieno[3,2-b]pyridin-7-amine formate (8.0 mg, 64% yield). MS m / z 390.2, 392.2, 394.2 [M+H]. + ; 1H NMR (methanol-d4) δ: 8.23-8.56 (br s, 1H), 7.33 (d, J=4.3 Hz, 1H), 7.06-7.17 (m, 1H), 7.00 (t, J=4.3 Hz, 1H), 6.68 (s, 1H), 6.34 (d, J=45.3 Hz, 1H), 4.79 (s, 2H), 3.89-4.07 (m, 1H), 1.39 (d, J=6.4 Hz, 3H), no 3NH observed.

[0234] Step 5: tert-Butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)propanoyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-thienylmethyl)carbamate A mixture of tert-butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)-1-hydroxy-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-thienylmethyl)carbamate (28 mg, 0.048 mmol, 1.0 eq.) and Dess-Martin periodinane (31 mg, 0.071 mmol, 1.5 eq.) in DCM (0.5 mL) was stirred at room temperature for 1 h. The DCM was removed and the residue was diluted with ether to which was added 1.0 M Na2S2O3 and saturated sodium bicarbonate. The mixture was separated. The organic layer was washed with 2.0 M K2CO3 and brine, dried over sodium sulfate, and evaporated to give tert-butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)propanoyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-thienylmethyl)carbamate (32 mg), which was used in the next step without further purification. MS m / z 586.2, 588.3, ​​590.3 [M+H] + .

[0235] Step 6: tert-Butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)-1,1-difluoro-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-thienylmethyl)carbamate A mixture of tert-butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)propanoyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-thienylmethyl)carbamate (32 mg, 0.055 mmol, 1.1 eq.) and DAST (1.0 M in DCM) (1.0 mL, 1.0 mmol, 21 eq.) was stirred at room temperature overnight. LC / MS showed about 13% of the desired product. The mixture was transferred to an Eppendorf vial to which Deoxo-Fluor (55 mg, 0.046 mL, 0.24 mmol, 5.0 eq.) was added and the mixture was stirred at room temperature for 6 h, then quenched with saturated sodium bicarbonate. The mixture was extracted with ethyl acetate, washed with water and brine, dried over sodium sulfate, and evaporated. The residue was purified on silica gel using ethyl acetate in hexanes (5-50% gradient) to give tert-butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)-1,1-difluoro-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-thienylmethyl)carbamate (3.5 mg, 12% yield). MS m / z 608.2, 610.2, 612.2 [M+H] + .

[0236] Step 7: 2-[(2S)-2-amino-1,1-difluoro-propyl]-3,5-dichloro-N-(2-thienylmethyl)thieno[3,2-b]pyridin-7-amine A general deprotection procedure using HCl in dioxane followed by reversed-phase HPLC purification with formic acid used as mobile phase modifier afforded 2-[(2S)-2-amino-1,1-difluoro-propyl]-3,5-dichloro-N-(2-thienylmethyl)thieno[3,2-b]pyridin-7-amine (2.3 mg, 98% yield) as the free base. MS m / z 408.3, 410.3, 412.2 [M+H] + ; 1H NMR (methanol-d4) δ: 7.28-7.38 (m, 1H), 7.07-7.17 (m, 1H), 6.95-7.05 (m, 1H), 6.73 (s, 1H), 4.79 (s, 2H), 4.47-4.58 (br s, 1H), 1.40 (br d, J=7.0 Hz, 3H), no 3NH observed.

[0237] The following compounds were prepared according to the procedure of Example 26 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 22]

[0238] Example 27 (Compound 149) 5-Chloro-3-(difluoromethoxy)-N-(2-thienylmethyl)thieno[3,2-b]pyridin-7-amine [ka] Step 1: tert-Butyl N-(5-chloro-3-hydroxy-thieno[3,2-b]pyridin-7-yl)-N-(2-thienylmethyl)carbamate To a mixture of tert-butyl N-(3-bromo-5-chloro-thieno[3,2-b]pyridin-7-yl)-N-(2-thienylmethyl)carbamate (460 mg, 1.0 mmol, 1.0 eq.) and 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (220 mg, 0.24 mL, 1.2 mmol, 1.2 eq.) in THF (1.0 mL) and toluene (4.0 mL) cooled to −78° C., n-BuLi (2.5 M in hexanes, 0.48 mL, 1.2 mmol, 1.2 eq.) was added dropwise. The mixture was stirred at −78° C. for 1 h, then quenched with saturated ammonium chloride, diluted with ethyl acetate, washed with brine, then dried and concentrated. To the residue was added Et2O (10 mL) followed by hydrogen peroxide (30% by weight in water, 0.41 mL, 4.0 mmol, 4.0 eq.). The mixture was stirred at room temperature for 16 h, then diluted with ether, treated with saturated sodium thiosulfate and separated. The organic layer was washed with water and brine, dried over sodium sulfate and concentrated. The residue was purified on silica using ethyl acetate in hexanes (5-40% gradient) to give tert-butyl N-(5-chloro-3-hydroxy-thieno[3,2-b]pyridin-7-yl)-N-(2-thienylmethyl)carbamate (294 mg, 74% yield). MS m / z 397.3, 399.3 [M+H] + .

[0239] Step 2: tert-Butyl N-[5-chloro-3-(difluoromethoxy)thieno[3,2-b]pyridin-7-yl]-N-(2-thienylmethyl)carbamate A mixture of tert-butyl N-(5-chloro-3-hydroxy-thieno[3,2-b]pyridin-7-yl)-N-(2-thienylmethyl)carbamate (100 mg, 0.252 mmol, 1.00 eq.), sodium chlorodifluoroacetate (91.1 mg, 0.579 mmol, 2.30 eq.) and Cs2CO3 (115 mg, 0.353 mmol, 1.40 eq.) in DMF (240 mg) and water (0.025 mL) was stirred at 100° C. for 16 h, then cooled, diluted with ethyl acetate, then washed with brine, dried and evaporated. The residue was purified on silica gel using ethyl acetate in hexanes (5-25% gradient) to give tert-butyl N-[5-chloro-3-(difluoromethoxy)thieno[3,2-b]pyridin-7-yl]-N-(2-thienylmethyl)carbamate (29 mg, 26% yield). MS m / z 447.1, 449.1 [M+H] + .

[0240] Step 3: 5-Chloro-3-(difluoromethoxy)-N-(2-thienylmethyl)thieno[3,2-b]pyridin-7-amine A general deprotection procedure using HCl in dioxane was then performed and after purification using a C18 EZ-Prep with formic acid as a modifier, 5-chloro-3-(difluoromethoxy)-N-(2-thienylmethyl)thieno[3,2-b]pyridin-7-amine was obtained. MS m / z 347.0, 349.0 [M+H] + ; 1 H NMR (CDCl3) δ: 7.31-7.36 (m, 1H), 7.22-7.26 (m, 1H), 7.10-7.15 (m, 1H), 7.03-7.07 (m, 1H), 6.95-6.98 (t, J=77 Hz, 1H), 6.62 (s, 1H), 4.87-5.01 (m, 1H), 4.75 (br s, 2H).

[0241] The following compounds were prepared according to the procedure of Example 27 by substituting the appropriate starting materials, reagents and reaction conditions. [Table 23]

[0242] Example 28 (Compound 167) 2-[(2R)-2-Amino-3-methylsulfinyl-propyl]-3,5-dichloro-N-(2-furylmethyl)thieno[3,2-b]pyridin-7-amine [ka] Step 1: tert-Butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-methylsulfinyl-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate To a stirred solution of tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-methylsulfanyl-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (119.6 mg, 0.19 mmol, 1.0 eq.) in a mixture of THF (2.0 mL) and water (1.0 mL), sodium periodate (60 mg, 0.28 mmol, 1.4 eq.) was added at 0° C. The reaction was stirred at 0° C. for 1 h, then warmed to room temperature and stirred for 48 h. The reaction was quenched with water and then extracted with EtOAc (2×30 mL). The combined organic phase was washed with brine, dried over sodium sulfate, and then concentrated to give the crude product, which was purified by flash column chromatography (0-80% EtOAc in DCM) to give tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-methylsulfinyl-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (103.3 mg, 84% yield) as a pale yellow foam. MS m / z 640.1, 642.1, [M+Na] + ; 1H NMR (acetone-d6) δ ppm: 7.46 (br d, J=4.4 Hz, 1H), 7.39 (s, 1H), 6.44 (br d, J=8.1 Hz, 1H), 6.30-6.32 (m, 1H), 6.27 (t, J=2.7 Hz, 1H), 4.98 (s, 2H), 4.33-4.46 (m, 1H), 3.49-3.56 (m, 1H), 3.42 (br dd, J=14.0, 7.9 Hz, 1H), 2.91-3.18 (m, 2H), 2.63 (s, 2H), 2.58 (s, 1H), 1.43 (s, 9H), 1.37 (s, 9H).

[0243] Step 2: tert-2-[(2R)-2-amino-3-methylsulfinyl-propyl]-3,5-dichloro-N-(2-furylmethyl)thieno[3,2-b]pyridin-7-amine To a solution of tert-butyl N-[2-[(2R)-2-(tert-butoxycarbonylamino)-3-methylsulfinyl-propyl]-3,5-dichloro-thieno[3,2-b]pyridin-7-yl]-N-(2-furylmethyl)carbamate (103.3 mg, 0.167 mmol, 1.0 eq.) in acetonitrile (3.0 mL) and THF (1.0 mL), p-toluenesulfonic acid monohydrate (135 mg, 0.672 mmol, 4.0 eq.) was added and heated to 60° C., then stirred at 60° C. for 1 h. LC-MS analysis indicated complete consumption of starting material. The reaction mixture was quenched with sodium carbonate (aq. 0.3 M, 5 mL) and then extracted with EtOAc (2×30 mL). The combined organic phases were dried over sodium sulfate and then concentrated to give the crude product, which was dried under high vacuum overnight to give 2-[(2R)-2-amino-3-methylsulfinyl-propyl]-3,5-dichloro-N-(2-furylmethyl)thieno[3,2-b]pyridin-7-amine (55.8 mg, 80% yield) as an off-white solid. MS m / z 418.4, 420.4, [M+H] + ; 1H NMR (DMSO-d6) δ ppm: 7.83-7.91 (m, 1H), 7.60 (s, 1H), 6.65 (d, J=4.0 Hz, 1H), 6.37-6.43 (m, 2H), 4.50-4.55 (m, 2H), 3.39-3.57 (m, 1H), 3.31 (s, 3H), 3.19 (td, J=14.6, 5.5 Hz, 1H), 3.05 (ddd, J=14.5, 12.4, 7.3 Hz, 1H), 2.72-2.84 (m, 2H), no 2NH observed.

[0244] Example 29 (Compound 129) 2-[(2S)-2-Aminopropyl]-5-chloro-N-[(5-fluorothiazol-2-yl)methyl]-3-methyl-thieno[3,2-b]pyridin-7-amine [ka] Step 1: tert-Butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-(2-trimethylsilylethoxymethyl)carbamate To a two-necked round bottom flask was added tert-butyl N-(5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl)-N-(2-trimethylsilylethoxymethyl)carbamate (1.95 g, 4.55 mmol, 1.0 eq.) dissolved in THF (0.25 M), followed by tert-butyl (4S)-4-methyl-2,2-dioxo-oxathiazolidine-3-carboxylate (1.40 g, 5.91 mmol, 1.3 eq.). The mixture was cooled to -78°C. To the cooled reaction mixture was added dropwise lithium diisopropylamide (2.0 M, 2.7 mL, 5.45 mmol, 1.2 eq.) in THF / heptane / ethylbenzene and the reaction was stirred until completion as monitored by UPLC. Upon reaction completion (approximately 1.5 hours), the reaction was removed from the bath, quenched with 1.0 M citric acid, and extracted with ethyl acetate. The combined extracts were washed with water and brine, dried over Na2SO4, and concentrated. The crude mixture was subjected to column chromatography (EtOAc / DCM, 0-15%) to give tert-butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-(2-trimethylsilylethoxymethyl)carbamate (1.91 g, 72% yield). MS m / z 586.4, 588.4, [M+H] + ; 1 H NMR (CDCl3) δ ppm: 7.25 (s, 1H), 5.07 (s, 2H), 4.47 (br d, J=1.7 Hz, 1H), 4.02 (br s, 1H), 3.13-3.19 (m, 1H), 3.05 (br s, 1H), 2.43 (s, 3H), 1.65 (br s, 1H), 1.44 (s, 18H), 1.17 (d, J=6.7 Hz, 3H), 0.98 (s, 1H), 0.95 (s, 1H), 0.03 (s, 9H), no 1NH observed.

[0245] Step 2: tert-Butyl N-[(1S)-2-[7-(tert-butoxycarbonylamino)-5-chloro-3-methyl-thieno[3,2-b]pyridin-2-yl]-1-methyl-ethyl]carbamate To a reaction tube with tert-butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-(2-trimethylsilylethoxymethyl)carbamate (0.41 g, 0.70 mmol, 1.0 eq.) was added THF (7.0 mL) and tetrabutylammonium fluoride (1 mol / L) in THF (7 mL, 7.0 mmol, 10 eq.) under nitrogen atmosphere. The reaction was stirred at 40° C. for 12 hours. Upon completion, the reaction was cooled to room temperature, diluted with ethyl acetate, washed with water, dried and concentrated. The crude material was subjected to column chromatography (EtOAc / DCM, 0-15%) to give tert-butyl N-[(1S)-2-[7-(tert-butoxycarbonylamino)-5-chloro-3-methyl-thieno[3,2-b]pyridin-2-yl]-1-methyl-ethyl]carbamate (19 mg, 6.0% yield). MS m / z 456.4, 458.4, [M+H] + , 1 H NMR (CDCl3) δ ppm: 6.61 (s, 1H), 4.47 (br s, 1H), 4.02 (br s, 1H), 3.32-3.32 (m, 1H), 3.09-3.16 (m, 1H), 3.01-3.06 (m, 1H), 2.41 (s, 3H), 1.57 (s, 9H), 1.43 (s, 9H), 1.18 (d, J=6.7 Hz, 3H).

[0246] Step 3: tert-Butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-[(5-fluorothiazol-2-yl)methyl]carbamate A solution of tert-butyl N-[(1S)-2-[7-(tert-butoxycarbonylamino)-5-chloro-3-methyl-thieno[3,2-b]pyridin-2-yl]-1-methyl-ethyl]carbamate (19 mg, 0.041 mmol, 1.0 eq.) and (5-fluorothiazol-2-yl)methanol (17 mg, 0.125 mmol, 3.0 eq.) in toluene (0.1 M) was sparged with N2 for 30 min. To this mixture was added 1,1'-(azodicarbonyl)dipiperidine (33 mg, 0.129 mmol, 3.1 eq.) and the mixture was sparged again with N2 and stirred for an additional 10 min. Tri-n-butylphosphine (28 mg, 0.138 mmol, 3.3 eq.) was added and the reaction mixture was stirred at 30° C. for about 17 h. The mixture was cooled to room temperature and concentrated in vacuo. The crude material was purified by silica gel flash chromatography to give tert-butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-[(5-fluorothiazol-2-yl)methyl]carbamate (13 mg, 55% yield). MS m / z 571.3, 573.3 [M+H] + , 1 H NMR (CDCl3) δ ppm: 7.20 (d, J=2.4 Hz, 1H), 7.14 (s, 1H), 4.99 (s, 2H), 4.47 (br d, J=1.1 Hz, 1H), 4.01 (br s, 1H), 3.12-3.17 (m, 1H), 3.05 (br s, 1H), 2.41 (s, 3H), 1.44 (s, 18H), 1.16 (d, J=6.7 Hz, 3H).

[0247] Step 4: 2-[(2S)-2-aminopropyl]-5-chloro-N-[(5-fluorothiazol-2-yl)methyl]-3-methyl-thieno[3,2-b]pyridin-7-amine To a reaction tube containing tert-butyl N-[2-[(2S)-2-(tert-butoxycarbonylamino)propyl]-5-chloro-3-methyl-thieno[3,2-b]pyridin-7-yl]-N-[(5-fluorothiazol-2-yl)methyl]carbamate (13 mg, 0.022 mmol, 1.0 eq.), hydrochloric acid in dioxane (4.0 M, 1.0 mL, 4.0 mmol) was added and stirred at room temperature for 1 hour. Upon completion, the reaction was diluted with diethyl ether and filtered to give 2-[(2S)-2-aminopropyl]-5-chloro-N-[(5-fluorothiazol-2-yl)methyl]-3-methyl-thieno[3,2-b]pyridin-7-amine (5.6 mg, 66% yield). MS m / z 371.2, 373.2, [M+H] + , 1 H NMR (methanol-d4) δ ppm: 7.41 (d, J=2.0 Hz, 1H), 7.04 (s, 1H), 4.92 (s, 2H), 3.63-3.71 (m, 1H), 3.35-3.42 (m, 1H), 3.23-3.29 (m, 1H), 2.45 (s, 3H), 1.38 (d, J=6.4 Hz, 3H), no 3NH observed.

[0248] Example 30 (Compound 148) 2-(1-aminopropan-2-yl)-5-chloro-N-(furan-2-ylmethyl)-3-methylthieno[3,2-b]pyridin-7-amine [ka] Step 1: Ethyl 2-(7-((tert-butoxycarbonyl)(furan-2-ylmethyl)amino)-5-chloro-3-methylthieno[3,2-b]pyridin-2-yl)-2-cyanoacetate A solution of tert-butyl (5-chloro-2-iodo-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (202 mg, 0.40 mmol, 1.0 eq.) and ethyl 2-cyanoacetate (50 mg, 1.1 eq.) prepared according to the procedure in Intermediate 6 in dioxane (1.6 mL) was added under argon to a suspension of KOtBu (116 mg, 2.5 eq.) in dioxane (0.5 mL), followed by the addition of Pd(OAc)2 (4.5 mg, 0.05 eq.) and dppf (23 mg, 0.100 eq.). After bubbling argon for 2 min, the reaction was sealed and heated to 70° C. for 2 h. After cooling, the reaction was quenched with citric acid (1.0 M) and EtOAc, then extracted with EtOAc. The crude material was purified by flash column chromatography on silica gel eluting with 0-60% EtOAc in hexanes to give ethyl 2-(7-((tert-butoxycarbonyl)(furan-2-ylmethyl)amino)-5-chloro-3-methylthieno[3,2-b]pyridin-2-yl)-2-cyanoacetate (145 mg, 74% yield) as an orange oil. MS m / z 490.1, 492.1 [M+H] + .

[0249] Step 2: Ethyl 2-(7-((tert-butoxycarbonyl)(furan-2-ylmethyl)amino)-5-chloro-3-methylthieno[3,2-b]pyridin-2-yl)-2-cyanopropanoate To a cold mixture of ethyl 2-(7-((tert-butoxycarbonyl)(furan-2-ylmethyl)amino)-5-chloro-3-methylthieno[3,2-b]pyridin-2-yl)-2-cyanoacetate (145 mg, 0.30 mmol, 1.0 eq.) and K2CO3 (62 mg, 1.5 eq.) in acetone (0.6 mL) was added MeI (127 mg, 3.0 eq.) under argon. The mixture was stirred at room temperature for 3 h and UPLC analysis indicated completion of the reaction. After cooling to 0° C., the reaction was quenched with citric acid (1.0 M) and EtOAc. The crude product was directly applied to the next step without further purification. MS m / z 504.1, 506.1 [M+H]+ .

[0250] Step 3: tert-Butyl (5-chloro-2-(1-cyanoethyl)-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate A mixture of ethyl 2-(7-((tert-butoxycarbonyl)(furan-2-ylmethyl)amino)-5-chloro-3-methylthieno[3,2-b]pyridin-2-yl)-2-cyanopropanoate (149 mg, 0.30 mmol, 1.0 eq.) and K2CO3 (62 mg, 1.5 eq.) was stirred in MeOH (0.60 mL) at room temperature for 3 h, then quenched with EtOAc and citric acid (1.0 M, aq.). The crude material was purified by flash column chromatography on silica gel eluting with 0-50% EtOAc in hexanes to give tert-butyl (5-chloro-2-(1-cyanoethyl)-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (81 mg, 63% yield). MS m / z 432.1, 434.2 [M+H] + .

[0251] Step 4: tert-Butyl (2-(1-aminopropan-2-yl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate To a cold solution of tert-butyl (5-chloro-2-(1-cyanoethyl)-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (81 mg, 0.19 mmol, 1.0 eq.) in THF (2.0 mL) was added dropwise LAH (1.0 M in THF, 0.28 mL, 1.5 eq.) at 0° C. After stirring for 15 min, the mixture was allowed to reach room temperature and continued to stir at room temperature for 3 h. The reaction was quenched by the addition of Na2SO4.×H2O (solid) at 0° C. The mixture was stirred at room temperature for 1 h, filtered and the solid was washed with MeOH. The combined filtrate was concentrated and purified by preparative HPLC eluting with 5-100% ACN in water with 0.1% formic acid to give tert-butyl (2-(1-aminopropan-2-yl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (10 mg, 12% yield). MS m / z 436.2, 438.2 [M+H] + .

[0252] Step 5: 2-(1-aminopropan-2-yl)-5-chloro-N-(furan-2-ylmethyl)-3-methylthieno[3,2-b]pyridin-7-amine General Boc-deprotection procedure: A mixture of tert-butyl (2-(1-aminopropan-2-yl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (10 mg, 0.022 mmol) was stirred in a solution of HCl (4 M in dioxane, 1 mL) at room temperature for 1 h, then the organic volatiles were removed. The crude solid was purified by preparative HPLC eluting with 5-40% ACN in water with 0.1% formic acid to give 2-(1-aminopropan-2-yl)-5-chloro-N-(furan-2-ylmethyl)-3-methylthieno[3,2-b]pyridin-7-amine as the formate salt (5.0 mg, 65% yield). MS m / z 335.8, 338.0 [M+H] + ; 1H NMR (methanol-d4) δ: 8.44 (s, 1 H), 7.46 (t, J= 1.2 Hz, 1 H), 6.62 (s, 1 H), 6.38 (d, J= 1.3 Hz, 1H), 4.55 (s, 2 H), 3.69 - 3.74 (m, 1 H), 3.23 - 3.25 (m, 1 H), 3.18 - 3.20 (m, 1 H), 2.39 (s, 3 H), 1.48 (d, J= 6.6 Hz, 3 H), 3NH not observed, formate.

[0253] Example 31 (Compound 146) 2-(5-chloro-7-((furan-2-ylmethyl)amino)-3-methylthieno[3,2-b]pyridin-2-yl)propan-1-ol [ka] Step 1: tert-Butyl (5-chloro-3-methyl-2-(prop-1-en-2-yl)thieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate A mixture of tert-butyl (5-chloro-2-iodo-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (101 mg, 0.20 mmol, 1.0 eq.), prepared according to the procedure in Intermediate 6, and 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (46.0 mg, 1.3 eq.), and Pd(dppf)Cl2 (8.3 mg, 0.05 eq.) in dioxane (1 mL) and K2CO3 (2M in H2O, 0.30 mL, 3.0 eq.) was stirred at 75° C. for 3 h. The reaction was quenched with EtOAc and water. The crude material was purified by flash column chromatography on silica gel eluting with 0-5% EtOAc in hexanes to give tert-butyl (5-chloro-3-methyl-2-(prop-1-en-2-yl)thieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (75 mg, 90% yield) as a colorless oil which was used directly in the next step. MS m / z 419.2, 421.2 [M+H] + .

[0254] Step 2: tert-Butyl (5-chloro-2-(1-hydroxypropan-2-yl)-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate To a cold solution of tert-butyl (5-chloro-3-methyl-2-(prop-1-en-2-yl)thieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (75 mg, 1.0 eq.) in THF (1 mL) was added dropwise at 0° C. 9-BBN (0.5 M in THF, 1 mL, 4.0 eq.). After stirring at 0° C. for 1 h, the mixture was allowed to reach room temperature and continued to stir overnight. The mixture was then cooled to 0° C. EtOH (0.2 mL) was added, followed by NaOAc (sat., 0.5 mL) and hydrogen peroxide (30% by weight in water, 0.2 mL). The mixture was continued to stir at 0° C. for 1 h and at room temperature for 5 h, then quenched with EtOAc and water. The organic phase was washed with water and brine. The crude material was purified by flash column chromatography on silica gel eluting with 0-60% EtOAc in hexanes to give tert-butyl (5-chloro-2-(1-hydroxypropan-2-yl)-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (62 mg, 79% yield) as a pale yellow oil. MS m / z 437.2, 439.2 [M+H] + .

[0255] Step 3: 2-(5-chloro-7-((furan-2-ylmethyl)amino)-3-methylthieno[3,2-b]pyridin-2-yl)propan-1-ol A mixture of tert-butyl (5-chloro-2-(1-hydroxypropan-2-yl)-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (16 mg, 0.037 mmol) and HCl (4 M) in dioxane (1.0 mL) was stirred at room temperature for 1 h. The mixture was diluted with diethyl ether (2×) and filtered. The filter cake was washed with ether, collected and dried to give 2-(5-chloro-7-((furan-2-ylmethyl)amino)-3-methylthieno[3,2-b]pyridin-2-yl)propan-1-ol (6 mg, 48% yield). MS m / z 337.1, 339.1 [M+H] + ; 1H NMR (DMSO-d6) δ: 7.59 (s, 1H), 7.50 (br s, 1 H), 6.52 (s, 1 H), 6.39 (d, J= 1.3 Hz, 1 H), 6.34 (d, J= 1.3 Hz, 1 H), 4.90 (br s, 1 H), 4.49 (s, 2 H), 3.51-3.55 (m, 2 H), 3.43-3.48 (m, 1 H), 2.24 (s, 3 H), 1.27 (d, J= 6.1 Hz, 3 H).

[0256] Example 32 (Compound 150 and Compound 151) 2-[(2R,3S)-3-aminobutan-2-yl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine and 2-[(2S,3S)-3-aminobutan-2-yl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine [ka] Step 1: tert-Butyl (5-chloro-3-methyl-2-(1-oxopropan-2-yl)thieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate To a solution of tert-butyl (5-chloro-2-(1-hydroxypropan-2-yl)-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (141 mg, 0.32 mmol, 1.0 eq.), prepared according to the procedure in Example 31, in DCM (1.0 mL) was added Martin's reagent (171 mg, 1.2 eq.) at 0° C. The light pink solution was stirred at room temperature for 1 h and UPLC analysis indicated the reaction was complete. The mixture was filtered and the solid was washed with DCM. The filtrates were combined, washed with NaHCO3 (sat. aq.) and concentrated. The resulting crude product was applied to the next step without purification. MS m / z 433.3, 435.3 [MH] + .

[0257] Step 2: tert-Butyl (2-((E)-1-(((R)-tert-butylsulfinyl)imino)propan-2-yl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate A mixture of tert-butyl (5-chloro-3-methyl-2-(1-oxopropan-2-yl)thieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (115 mg, 0.26 mmol, 1.0 eq.), R-(+)-2-methylpropane-2-sulfinamide (48 mg, 1.5 eq.) and CuSO4 (215 mg, 5.0 eq.) in DCE (0.5 mL) was stirred at room temperature for 18 h. After cooling, the mixture was purified by flash column chromatography on silica gel eluting with 0-30% EtOAc in hexanes to give tert-butyl (2-((E)-1-(((R)-tert-butylsulfinyl)imino)propan-2-yl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (79 mg, 49% yield). MS m / z 560.2, 562.2 [M+Na] + .

[0258] Step 3: (R)-N-((2S,3R / S)-3-(5-chloro-7-((furan-2-ylmethyl)amino)-3-methylthieno[3,2-b]pyridin-2-yl)butan-2-yl)-2-methylpropane-2-sulfinamide and (R)-N-((2S,3S / R)-3-(5-chloro-7-((furan-2-ylmethyl)amino)-3-methylthieno[3,2-b]pyridin-2-yl)butan-2-yl)-2-methylpropane-2-sulfinamide To a solution of tert-butyl (2-((E)-1-(((R)-tert-butylsulfinyl)imino)propan-2-yl)-5-chloro-3-methylthieno[3,2-b]pyridin-7-yl)(furan-2-ylmethyl)carbamate (70 mg, 0.13 mmol, 1.0 eq.) in DCM (0.9 mL) was added MeMgBr (3.0 M in Et2O, 0.11 mL, 2.5 eq.) at -78°C. The mixture was warmed to -50°C and maintained at -50°C for 4 h, then warmed to room temperature and continued stirring overnight. The reaction was quenched with a saturated solution of NH4Cl. The mixture was diluted with EtOAc and then washed with water followed by brine, the organic layer was dried over sodium sulfate and evaporated. The residue was purified by flash column chromatography on silica gel eluting with 0-100% EtOAc in hexanes to give a mixture of two diastereoisomers, which was further purified by preparative HPLC eluting with 10-80% CH3CN in water with 0.1% formic acid to give (R)-N-((2S,3R / S)-3-(5-chloro-7-((furan-2-ylmethyl)amino)-3-methylthieno[3,2-b]pyridin-2-yl)butan-2-yl)-2-methylpropane-2-sulfinamide (18 mg, 45% yield), MS m / z 454.3, 456.3 [M+H]. + To obtain (R)-N-((2S,3S / R)-3-(5-chloro-7-((furan-2-ylmethyl)amino)-3-methylthieno[3,2-b]pyridin-2-yl)butan-2-yl)-2-methylpropane-2-sulfinamide (20 mg, 42% yield), MS m / z 454.3, 456.3 [M+H] + .

[0259] Step 4: 2-[(2R,3S)-3-aminobutan-2-yl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine A mixture of (R)-N-((2S,3R / S)-3-(5-chloro-7-((furan-2-ylmethyl)amino)-3-methylthieno[3,2-b]pyridin-2-yl)butan-2-yl)-2-methylpropane-2-sulfinamide (18 mg, 0.04 mmol) and HCl (4 M) in dioxane (1.0 mL) was stirred at room temperature for 1 h. The mixture was diluted with diethyl ether (2×) and filtered. The filter cake was washed with ether, collected, and dried to give 2-((2R / S,3S)-3-aminobutan-2-yl)-5-chloro-N-(furan-2-ylmethyl)-3-methylthieno[3,2-b]pyridin-7-amine (5.4 mg, 41% yield) as the HCl salt. MS m / z 350.2, 352.2 [M+H] + ; 1 H NMR (methanol-d4) δ: 7.50 (d, J= 1.1 Hz, 1 H), 7.16 (s, 1 H), 6.48 (d, J= 3.0 Hz, 1 H), 6.42 (dd, J= 3.0, 1.1 Hz, 1 H), 4.77 (s, 2 H), 3.69 - 3.71 (m, 1 H), 3.58 - 3.61 (m, 1 H), 2.50 (s, 3 H), 1.50 (d, J= 7.0 Hz, 3 H), 1.44 (d, J= 6.56 Hz, 3 H), no 3NH observed.

[0260] 2-[(2S,3S)-3-aminobutan-2-yl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine A mixture of (R)-N-((2S,3S / R)-3-(5-chloro-7-((furan-2-ylmethyl)amino)-3-methylthieno[3,2-b]pyridin-2-yl)butan-2-yl)-2-methylpropane-2-sulfinamide (20 mg, 0.04 mmol) and HCl (4 M) in dioxane (1.0 mL) was stirred at room temperature for 1 h. The mixture was diluted with diethyl ether (2×) and filtered. The filter cake was washed with ether, collected and dried to give 2-((2R / S,3S)-3-aminobutan-2-yl)-5-chloro-N-(furan-2-ylmethyl)-3-methylthieno[3,2-b]pyridin-7-amine (7.4 mg, 53% yield) as the HCl salt. MS m / z 350.2, 352.2 [M+H] + ; 1 H NMR (methanol-d4) δ: 7.50 (d, J= 1.1 Hz, 1 H), 7.10 (s, 1 H), 6.46 (d, J= 3.2 Hz, 1 H), 6.42 (dd, J= 3.0, 1.1 Hz, 1 H), 4.74 (s, 2 H), 3.64 - 3.67 (m, 1 H), 3.55 - 3.58 (m, 1 H), 2.47 (s, 3 H), 1.54 (d, J= 7.0 Hz, 3 H), 1.27 (d, J= 6.56 Hz, 3 H), no 3NH observed.

[0261] Biological Examples The following in vitro biological examples demonstrate the utility of the compounds herein for the treatment of familial dysautonomia.

[0262] To more particularly describe and aid in the understanding of the present specification, the following non-limiting biological examples are provided to more particularly illustrate the scope of the description and should not be construed as specifically limiting the scope thereof. Such variations of the present specification that may be within the scope of ascertainment by one of ordinary skill in the art and that may be currently known or that may later be developed are considered to be within the scope of the present specification and as claimed below.

[0263] Example 1 IKBKAP-HTRF assay The assay is used to quantitatively determine the concentration of Elongator complex protein 1 (ELP1, also called IKBKAP) in cell lysates using HTRF® (homogeneous time-resolved fluorescence) technology. IKBKAP is detected in a sandwich HTRF assay by using a donor-labeled anti-IKAP antibody and an acceptor-labeled anti-IKAP antibody. [Table 24]

[0264] Protocol Cells were thawed and incubated in DMEM-10% FBS for 72 hours. Cells were trypsinized, counted, and resuspended in DMEM-10% FBS to a concentration of 50,000 cells / mL. 199 μL of cell suspension was seeded at 10,000 cells per well in a 96-well microtiter plate and incubated for 3-5 hours. To obtain a control signal, 3 wells were left without cells as blank control wells. Test compounds were serially diluted 3.16-fold in 100% DMSO to generate a 7-point concentration curve. 1 μL of 200× compound solution was transferred to cell-containing wells and cells were incubated in a cell culture incubator (37°C, 5% CO2, 100% relative humidity) for 48 hours. Triplicate samples were set up for each compound concentration. After 48 hours, the supernatant was removed from the cells, and 50 μL of 1×LB4 lysis buffer containing protease inhibitors was added to the cells and incubated with shaking at room temperature for 1 hour. 36 μL of this lysate was then transferred to a 384-well plate containing 4 μL of antibody solution (anti-IKAP d2 and anti-IKAP K(9+8) diluted 1:50 in detection buffer). The 384-well plate was then centrifuged for 1 minute to allow the solution to settle to the bottom of the plate and incubated overnight at 4° C. The fluorescence of each well of the plate at 665 nm and 620 nm was measured with an EnVision plate reader (Perkin Elmer). ΔF for each sample was calculated as follows:

[0265]

number

[0266] MFI ≦1.9 is indicated by one star (*), >1.9 to ≦2.9 is indicated by two stars (**), >2.9 to ≦3.9 is indicated by three stars (***), >3.9 to ≦4.9 is indicated by four stars (****), and >4.9 is indicated by five stars (*****).

[0267] EC50 values ​​for IKBKAP protein expression obtained from 7-point concentration curves generated for each test compound according to the protocol in Biological Example 1. 2× The EC50-dependent IKBKAP protein expression is also shown in Table 1. 2× The term "effective" is defined as the concentration of test compound effective to produce twice the amount of IKBKAP protein in FD patient cells than was produced from the DMSO vehicle control.

[0268] EC 2× >1 μM is indicated by one star (*), >0.5 μM to ≦1 μM is indicated by two stars (**), >0.02 μM to ≦0.5 μM is indicated by three stars (***), >0.005 μM to ≦0.02 μM is indicated by four stars (****), and ≦0.005 μM is indicated by five stars (*****). [Table 25] TIFF0007587511000103.tif246141

[0269] Regardless of whether the documents cited in this specification are specifically and individually indicated to be incorporated by reference, all documents mentioned in this specification are incorporated by reference into this application for all purposes to the same extent as if each individual reference was fully set forth herein.

[0270] Claimed subject matter is described in detail herein, and those skilled in the art will recognize that it may be practiced under a broad range of equivalents without affecting the scope of the subject matter or specific embodiments described herein, and it is intended that the appended claims be construed to include all such equivalents.

Claims

1. A compound of formula (I), or a form thereof, wherein the compound is a compound selected from the group consisting of a salt, a hydrate, a solvate, and a tautomeric form of the compound. 【Chemical 1】 (I) (In the formula, R 1 is one, two, three or four independently selected R 1a selected from the group consisting of optionally substituted phenyl and heteroaryl; heteroaryl is a radical of a 5-8 membered monocyclic aromatic carbon atom ring system containing 1-3 heteroatoms selected from N, O and S; R 1a is a halo, R 3 is hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 alkyl-amino; C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each occurrence of alkynyl is selected from 1, 2, 3, or 4 independently selected R 3a may be substituted with a substituent; C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each occurrence of alkynyl may contain a chiral carbon having either the (R) or the (S) configuration; R 3a cyano, halo, hydroxy, oxo, C 1-6 Alkyl, C 1-6 Alkoxy, halo-C 1-6 Alkoxy, carboxyl, amino, C 1-6 Alkoxy-carbonyl, C 1-6 Alkyl-amino, halo-C 1-6 Alkyl-amino, (C 1-6 alkyl) 2 -amino, phenyl-amino, heteroaryl-amino, phenyl-(C 1-6 alkyl)-amino, C 1-6 Alkyl-thio, C 1-6 Alkyl-sulfoxyl and C 1-6 selected from the group consisting of alkyl-sulfonyl; heteroaryl is a radical of a 5-8 membered monocyclic or bicyclic aromatic carbon atom ring system containing 1-3 heteroatoms selected from N, O and S; Each occurrence of phenyl and heteroaryl is selected from 1, 2, 3, or 4 independently selected R 3a’ may be substituted with a substituent; R3a' is cyano, halo, C 1-6 Alkyl and C 1-6 alkoxy; R 4 is hydrogen, cyano, halo, hydroxy, C 1-6 Alkyl, C 1-6 Alkoxy, halo-C 1-6 Alkoxy and C 3-10 cycloalkyl; R 5 is cyano, halo and C 1-6 is selected from the group consisting of alkyl, R 6 is hydrogen)

2. R 1 is selected from the group consisting of phenyl, furanyl, thiophenyl, 1H-pyrazolyl, 1H-imidazolyl, isoxazolyl, 1,3-thiazolyl, 1,3-oxazolyl, tetrazolyl, 1,2,3-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl.

3. R 1 The compound of claim 2, wherein is selected from the group consisting of phenyl, furanyl, thiophenyl, 1,3-thiazolyl, and pyridinyl.

4. The compound of claim 1, wherein R 1 is selected from the group consisting of furanyl, thiophenyl, 1,3-thiazolyl, and pyridinyl.

5. R 3 C containing a chiral carbon having the (S) configuration 1-6 The compound of claim 1 , wherein the compound is alkyl.

6. R 3 C containing a chiral carbon having the (R) configuration 1-6 The compound of claim 1 , wherein the compound is alkyl.

7. 5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 1-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)ethan-1-ol; 1-(5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)ethan-1-ol; (5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)methanol; 3,5-Dichloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 3-Bromo-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 3,5-Dichloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 3-Bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 3-chloro-5-methyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 3-Bromo-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridine-5-carbonitrile; 7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridine-3,5-dicarbonitrile; 5-chloro-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridine-3-carbonitrile; 5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridine-3-carbonitrile; 7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridine-3,5-dicarbonitrile; 2-[(2S)-2-aminopropyl]-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; (2R)-2-amino-3-(5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol; 2-[(2S)-2-aminopropyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminobutyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminopropyl]-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridine-5-carbonitrile; 2-[(1S)-1-aminoethyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 2-[(1R)-1-aminoethyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 2-[(1R)-1-aminoethyl]-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(1S)-1-aminoethyl]-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 5-chloro-N-[(furan-2-yl)methyl]-2-[(methylamino)methyl]thieno[3,2-b]pyridin-7-amine; 5-chloro-N-[(furan-2-yl)methyl]-3-methyl-2-[(1S)-1-(methylamino)ethyl]thieno[3,2-b]pyridin-7-amine; 5-chloro-N-[(furan-2-yl)methyl]-3-methyl-2-[(methylamino)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminopropyl]-5-chloro-3-methyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminopropyl]-5-chloro-N-[(2-fluorophenyl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 2-[(1S)-1-amino-2-methylpropyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 2-[(1R)-1-amino-2-methylpropyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 5-chloro-N-[(furan-2-yl)methyl]-3-methyl-2-[(1S)-2-methyl-1-(methylamino)propyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminobutyl]-5-chloro-3-methyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminopropyl]-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminopropyl]-5-chloro-N-[(3-fluoropyridin-4-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminopropyl]-3,5-dichloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminopropyl]-3-bromo-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminopropyl]-3,5-dichloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; (2R)-2-amino-3-(3,5-dichloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol; 2-[(2R)-2-amino-3-methoxypropyl]-3,5-dichloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; (2R)-2-amino-3-(3-bromo-5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol; 5-chloro-N-[(furan-2-yl)methyl]-3-methyl-2-[(2S)-2-(methylamino)propyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminopropyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R)-2-amino-3-methoxypropyl]-3-bromo-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R)-2-amino-3-methoxypropyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 2-[(2R)-2-amino-3-fluoropropyl]-3-bromo-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-amino-4-fluorobutyl]-3,5-dichloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; (3S)-3-amino-4-(3,5-dichloro-7-{[(1,3-thiazol-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)butan-1-ol; 2-[(2S)-2-aminopropyl]-3-bromo-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridine-5-carbonitrile; 2-[(2S)-2-aminopropyl]-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridine-3,5-dicarbonitrile; 2-[(2S)-2-aminopropyl]-5-chloro-3-cyclopropyl-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminopropyl]-3,5-dichloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminopropyl]-3-bromo-5-chloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminopropyl]-3-methyl-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridine-5-carbonitrile; 2-[(1S)-1-aminoethyl]-5-chloro-3-methyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(1R)-1-aminoethyl]-5-chloro-3-methyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminopropyl]-5-chloro-3-methyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; (2R)-2-amino-3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)propan-1-ol; 2-[(2S)-2-amino-3-fluoropropyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminopropyl]-3-chloro-5-methyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-amino-4-methylpentyl]-5-chloro-3-methyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-amino-4-methylpentyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-amino-3-fluoropropyl]-3-bromo-5-chloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R)-2-amino-3-(trifluoromethoxy)propyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; (2R)-3-(3-bromo-5-chloro-7-{[(1,3-thiazol-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)-2-[(trifluoromethyl)amino]propan-1-ol; 2-[(2S)-2-amino-3-fluoropropyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-amino-3-fluoropropyl]-3,5-dichloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-amino-4-methylpentyl]-5-chloro-3-methyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R)-2-amino-3-fluoropropyl]-5-chloro-3-methyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R)-2-amino-3-fluoropropyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; (2R)-2-amino-3-(3-bromo-5-chloro-7-{[(1,3-thiazol-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol; 2-[(2R)-2-aminobut-3-en-1-yl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminobutyl]-3-bromo-5-chloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-amino-4-fluorobutyl]-3-bromo-5-chloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminobutyl]-5-chloro-3-cyclopropyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R)-2-amino-3-fluoropropyl]-3-bromo-5-chloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R)-2-amino-3-fluoropropyl]-5-chloro-3-cyclopropyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminobutyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-amino-4-methylpentyl]-3,5-dichloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-amino-4-methylpentyl]-5-chloro-3-cyclopropyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R)-2-amino-3-fluoropropyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminobutyl]-3,5-dichloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminobutyl]-3,5-dichloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R)-2-amino-3-fluoropropyl]-3,5-dichloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminobutyl]-5-chloro-3-methyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminobutyl]-5-chloro-3-cyclopropyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R)-2-amino-3-fluoropropyl]-5-chloro-3-cyclopropyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-amino-4-fluorobutyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; (3S)-3-amino-4-(3-bromo-5-chloro-7-{[(1,3-thiazol-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)butan-1-ol; 2-[(2R)-2-amino-3-fluoropropyl]-3,5-dichloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R)-2-amino-3-fluoropropyl]-5-chloro-3-methyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-amino-4-fluorobutyl]-5-chloro-3-methyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-amino-4-fluorobutyl]-3,5-dichloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R)-2-amino-3-fluoropropyl]-3,5-dichloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-amino-4-fluorobutyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminopropyl]-5-chloro-3-cyclopropyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-amino-4-fluorobutyl]-3-bromo-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-amino-4-fluorobutyl]-3,5-dichloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-amino-4-fluorobutyl]-5-chloro-3-methyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; (3S)-3-amino-4-(3-bromo-5-chloro-7-{[(2-fluorophenyl)methyl]amino}thieno[3,2-b]pyridin-2-yl)butan-1-ol; 2-[(2S)-2-aminopropyl]-3-bromo-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridine-5-carbonitrile; 2-[(2S)-2-aminopropyl]-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridine-3,5-dicarbonitrile; (3S)-3-amino-4-(3-bromo-5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)butanenitrile; 2-[(2R)-2-amino-3-(methylsulfanyl)propyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; (3S)-3-amino-4-(5-chloro-3-methyl-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)butanenitrile; (3S)-3-amino-4-(3,5-dichloro-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)butanenitrile; 2-[(2S)-2-amino-4,4-difluorobutyl]-3-bromo-5-chloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R)-2-amino-3-(methanesulfonyl)propyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminopropyl]-5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridine-3-carbonitrile; 2-[(2S)-2-aminopropyl]-5-chloro-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridine-3-carbonitrile; (3S)-3-amino-4-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)butanenitrile; 2-[(2S)-2-aminopropyl]-3-chloro-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridine-5-carbonitrile; 2-[(2R)-2-amino-3-(methanesulfonyl)propyl]-3,5-dichloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R)-2-amino-3-(methylsulfanyl)propyl]-3,5-dichloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-D-alanine; 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N,N-dimethyl-D-alaninamide; 2-[(2R)-2-amino-3-(methanesulfonyl)propyl]-3-bromo-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R)-2-amino-3-(methylsulfanyl)propyl]-3-bromo-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R)-2-aminobut-3-en-1-yl]-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 3-(3,5-dichloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)-N-(2-fluorophenyl)-D-alaninamide; 3-(3,5-dichloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)-D-alanine; 3-(3,5-dichloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)-N-phenyl-D-alaninamide; 2-[(2R)-2-aminobut-3-yn-1-yl]-3-methyl-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R,3S)-2-amino-3-fluorobutyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R,3S)-2-amino-3-fluorobutyl]-5-chloro-3-methyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; (2S)-2-amino-1-(3,5-dichloro-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol; 2-[(2R,3S)-2-amino-3-fluorobutyl]-5-chloro-3-methyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-aminopropyl]-5-chloro-N-[(5-fluoro-1,3-thiazol-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 2-[(2S)-2-amino-1-fluoropropyl]-3,5-dichloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; Methyl 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-D-alaninate; 2-[(2S)-2-amino-1,1-difluoropropyl]-3,5-dichloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-(4-cyanophenyl)-D-alaninamide; 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-pyridin-2-yl-D-alaninamide; 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-pyrazin-2-yl-D-alaninamide; 2-[(2S)-2-aminopropyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methoxythieno[3,2-b]pyridin-7-amine; 5-chloro-N-[(furan-2-yl)methyl]-3-methoxythieno[3,2-b]pyridin-7-amine; 5-chloro-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridin-3-ol; 2-[(2S)-2-aminopropyl]-5-chloro-3-(difluoromethoxy)-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-pyridin-4-yl-D-alaninamide; 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-methyl-N-phenyl-D-alaninamide; 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-(4-methylphenyl)-D-alaninamide; 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-(3-chlorophenyl)-D-alaninamide; 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-(3-methoxyphenyl)-D-alaninamide; 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-(1-methyl-1H-pyrazol-5-yl)-D-alaninamide; 2-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)propan-1-ol; 2-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)propane-1,2-diol; 2-(1-aminopropan-2-yl)-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 5-chloro-3-(difluoromethoxy)-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; 2-[(2R,3S)-3-aminobutan-2-yl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 2-[(2S,3S)-3-aminobutan-2-yl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; 2-(2-aminoethyl)-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine; (2S)-2-amino-1-(3-bromo-5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol; 2-[(2S)-2-amino-1-fluoropropyl]-3-bromo-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; (2S)-2-amino-1-(3-bromo-5-chloro-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol; (2S)-2-amino-1-(3-bromo-5-chloro-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-one; (2S)-2-amino-1-(3-bromo-5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-one; 2-[(2S)-2-amino-1-fluoropropyl]-3-bromo-5-chloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; (2S)-2-amino-1-(3-bromo-5-chloro-7-{[(1,3-thiazol-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol; (2S)-2-amino-1-(3-bromo-5-chloro-7-{[(1,3-thiazol-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-one; 2-[(2S)-2-amino-1-fluoropropyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; (2R)-2-amino-3-(5-chloro-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol; N 2 -[(2S)-2-aminopropyl]-5-chloro-3-methyl-N 7 -[(thiophen-2-yl)methyl]thieno[3,2-b]pyridine-2,7-diamine; N 2 -[(2R)-2-aminopropyl]-5-chloro-3-methyl-N 7 -[(thiophen-2-yl)methyl]thieno[3,2-b]pyridine-2,7-diamine; (2R,3R)-3-amino-4-(3-bromo-5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)butan-2-ol; 2-[(2R)-2-aminobut-3-yn-1-yl]-3,5-dichloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine; and [(2R)-2-amino-3-(3,5-dichloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propyl](methyl)sulfaniumorate; wherein the form of the compound is selected from the group consisting of a salt, a hydrate, a solvate, and a tautomeric form thereof.

8. 3,5-dichloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 3-bromo-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 3-chloro-5-methyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2S)-2-aminopropyl]-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, (2R)-2-amino-3-(5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol dihydrochloride, 2-[(2S)-2-aminopropyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-aminobutyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-aminopropyl]-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridine-5-carbonitrile trifluoroacetate, 2-[(1S)-1-aminoethyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(1R)-1-aminoethyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(1R)-1-aminoethyl]-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(1S)-1-aminoethyl]-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 5-chloro-N-[(furan-2-yl)methyl]-2-[(methylamino)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 5-chloro-N-[(furan-2-yl)methyl]-3-methyl-2-[(1S)-1-(methylamino)ethyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 5-chloro-N-[(furan-2-yl)methyl]-3-methyl-2-[(methylamino)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2S)-2-aminopropyl]-5-chloro-3-methyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-aminopropyl]-5-chloro-N-[(2-fluorophenyl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(1S)-1-amino-2-methylpropyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(1R)-1-amino-2-methylpropyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine hydrochloride, 5-chloro-N-[(furan-2-yl)methyl]-3-methyl-2-[(1S)-2-methyl-1-(methylamino)propyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2S)-2-aminobutyl]-5-chloro-3-methyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-aminopropyl]-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-aminopropyl]-5-chloro-N-[(3-fluoropyridin-4-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-aminopropyl]-3,5-dichloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-aminopropyl]-3-bromo-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-aminopropyl]-3,5-dichloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, (2R)-2-amino-3-(3,5-dichloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol dihydrochloride, 2-[(2R)-2-amino-3-methoxypropyl]-3,5-dichloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, (2R)-2-amino-3-(3-bromo-5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol dihydrochloride, 5-chloro-N-[(furan-2-yl)methyl]-3-methyl-2-[(2S)-2-(methylamino)propyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2S)-2-aminopropyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2R)-2-amino-3-methoxypropyl]-3-bromo-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2R)-2-amino-3-methoxypropyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2R)-2-amino-3-fluoropropyl]-3-bromo-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine formate, 2-[(2S)-2-amino-4-fluorobutyl]-3,5-dichloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, (3S)-3-amino-4-(3,5-dichloro-7-{[(1,3-thiazol-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)butan-1-ol dihydrochloride, 2-[(2S)-2-aminopropyl]-3-bromo-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridine-5-carbonitrile hydrochloride, 2-[(2S)-2-aminopropyl]-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridine-3,5-dicarbonitrile hydrochloride, 2-[(2S)-2-aminopropyl]-5-chloro-3-cyclopropyl-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2S)-2-aminopropyl]-3,5-dichloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-aminopropyl]-3-bromo-5-chloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-aminopropyl]-3-methyl-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridine-5-carbonitrile formate, 2-[(1S)-1-aminoethyl]-5-chloro-3-methyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(1R)-1-aminoethyl]-5-chloro-3-methyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2S)-2-aminopropyl]-5-chloro-3-methyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, (2R)-2-amino-3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)propan-1-ol dihydrochloride, 2-[(2S)-2-amino-3-fluoropropyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-aminopropyl]-3-chloro-5-methyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-amino-4-methylpentyl]-5-chloro-3-methyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2S)-2-amino-4-methylpentyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2S)-2-amino-3-fluoropropyl]-3-bromo-5-chloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2R)-2-amino-3-(trifluoromethoxy)propyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine formate, (2R)-3-(3-bromo-5-chloro-7-{[(1,3-thiazol-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)-2-[(trifluoromethyl)amino]propan-1-ol formate, 2-[(2S)-2-amino-3-fluoropropyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-amino-3-fluoropropyl]-3,5-dichloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-amino-4-methylpentyl]-5-chloro-3-methyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2R)-2-amino-3-fluoropropyl]-5-chloro-3-methyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2R)-2-amino-3-fluoropropyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, (2R)-2-amino-3-(3-bromo-5-chloro-7-{[(1,3-thiazol-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol dihydrochloride, 2-[(2R)-2-aminobut-3-en-1-yl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-aminobutyl]-3-bromo-5-chloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-amino-4-fluorobutyl]-3-bromo-5-chloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2S)-2-aminobutyl]-5-chloro-3-cyclopropyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2R)-2-amino-3-fluoropropyl]-3-bromo-5-chloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2R)-2-amino-3-fluoropropyl]-5-chloro-3-cyclopropyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2S)-2-aminobutyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2S)-2-amino-4-methylpentyl]-3,5-dichloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2S)-2-amino-4-methylpentyl]-5-chloro-3-cyclopropyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2R)-2-amino-3-fluoropropyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-aminobutyl]-3,5-dichloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2S)-2-aminobutyl]-3,5-dichloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-aminobutyl]-5-chloro-3-methyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine formate, 2-[(2S)-2-aminobutyl]-5-chloro-3-cyclopropyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2R)-2-amino-3-fluoropropyl]-5-chloro-3-cyclopropyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-amino-4-fluorobutyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, (3S)-3-amino-4-(3-bromo-5-chloro-7-{[(1,3-thiazol-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)butan-1-ol dihydrochloride, 2-[(2R)-2-amino-3-fluoropropyl]-3,5-dichloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2R)-2-amino-3-fluoropropyl]-5-chloro-3-methyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-amino-4-fluorobutyl]-5-chloro-3-methyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-amino-4-fluorobutyl]-3,5-dichloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2R)-2-amino-3-fluoropropyl]-3,5-dichloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-amino-4-fluorobutyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2S)-2-aminopropyl]-5-chloro-3-cyclopropyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 2-[(2S)-2-amino-4-fluorobutyl]-3-bromo-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-amino-4-fluorobutyl]-3,5-dichloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-amino-4-fluorobutyl]-5-chloro-3-methyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine formate, (3S)-3-amino-4-(3-bromo-5-chloro-7-{[(2-fluorophenyl)methyl]amino}thieno[3,2-b]pyridin-2-yl)butan-1-ol dihydrochloride, 2-[(2S)-2-aminopropyl]-3-bromo-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridine-5-carbonitrile formate, 2-[(2S)-2-aminopropyl]-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridine-3,5-dicarbonitrile formate, (3S)-3-amino-4-(3-bromo-5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)butanenitrile formate, 2-[(2R)-2-amino-3-(methylsulfanyl)propyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine dihydrochloride, (3S)-3-amino-4-(5-chloro-3-methyl-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)butanenitrile dihydrochloride, (3S)-3-amino-4-(3,5-dichloro-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)butanenitrile dihydrochloride, 2-[(2S)-2-amino-4,4-difluorobutyl]-3-bromo-5-chloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2R)-2-amino-3-(methanesulfonyl)propyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-aminopropyl]-5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridine-3-carbonitrile formate, 2-[(2S)-2-aminopropyl]-5-chloro-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridine-3-carbonitrile formate, (3S)-3-amino-4-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)butanenitrile dihydrochloride, 2-[(2S)-2-aminopropyl]-3-chloro-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridine-5-carbonitrile formate, 2-[(2R)-2-amino-3-(methanesulfonyl)propyl]-3,5-dichloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2R)-2-amino-3-(methylsulfanyl)propyl]-3,5-dichloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine hydrochloride, 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-D-alanine dihydrochloride, 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N,N-dimethyl-D-alaninamide dihydrochloride, 2-[(2R)-2-amino-3-(methanesulfonyl)propyl]-3-bromo-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2R)-2-amino-3-(methylsulfanyl)propyl]-3-bromo-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2R)-2-aminobut-3-en-1-yl]-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine formate, 3-(3,5-dichloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)-N-(2-fluorophenyl)-D-alaninamide dihydrochloride, 3-(3,5-dichloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)-D-alanine dihydrochloride, 3-(3,5-dichloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)-N-phenyl-D-alaninamide hydrochloride, 2-[(2R)-2-aminobut-3-yn-1-yl]-3-methyl-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2R,3S)-2-amino-3-fluorobutyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2R,3S)-2-amino-3-fluorobutyl]-5-chloro-3-methyl-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, (2S)-2-amino-1-(3,5-dichloro-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol dihydrochloride, 2-[(2R,3S)-2-amino-3-fluorobutyl]-5-chloro-3-methyl-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-aminopropyl]-5-chloro-N-[(5-fluoro-1,3-thiazol-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S)-2-amino-1-fluoropropyl]-3,5-dichloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine formate, methyl 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-D-alaninate dihydrochloride, 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-(4-cyanophenyl)-D-alaninamide hydrochloride, 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-pyridin-2-yl-D-alaninamide hydrochloride, 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-pyrazin-2-yl-D-alaninamide hydrochloride, 2-[(2S)-2-aminopropyl]-5-chloro-N-[(furan-2-yl)methyl]-3-methoxythieno[3,2-b]pyridin-7-amine dihydrochloride, 5-chloro-N-[(furan-2-yl)methyl]-3-methoxythieno[3,2-b]pyridin-7-amine hydrochloride, 5-chloro-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridin-3-ol hydrochloride, 2-[(2S)-2-aminopropyl]-5-chloro-3-(difluoromethoxy)-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine formate, 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-pyridin-4-yl-D-alaninamide hydrochloride, 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-methyl-N-phenyl-D-alaninamide hydrochloride, 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-(4-methylphenyl)-D-alaninamide hydrochloride, 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-(3-chlorophenyl)-D-alaninamide hydrochloride, 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-(3-methoxyphenyl)-D-alaninamide hydrochloride, 3-(5-chloro-7-{[(furan-2-yl)methyl]amino}-3-methylthieno[3,2-b]pyridin-2-yl)-N-(1-methyl-1H-pyrazol-5-yl)-D-alaninamide hydrochloride, 2-(1-aminopropan-2-yl)-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine formate, 2-[(2R,3S)-3-aminobutan-2-yl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine dihydrochloride, 2-[(2S,3S)-3-aminobutan-2-yl]-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine dihydrochloride, 2-(2-aminoethyl)-5-chloro-N-[(furan-2-yl)methyl]-3-methylthieno[3,2-b]pyridin-7-amine formate, (2S)-2-amino-1-(3-bromo-5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol dihydrochloride, 2-[(2S)-2-amino-1-fluoropropyl]-3-bromo-5-chloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, (2S)-2-amino-1-(3-bromo-5-chloro-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol dihydrochloride, (2S)-2-amino-1-(3-bromo-5-chloro-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-one dihydrochloride, (2S)-2-amino-1-(3-bromo-5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-one dihydrochloride, 2-[(2S)-2-amino-1-fluoropropyl]-3-bromo-5-chloro-N-[(thiophen-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, (2S)-2-amino-1-(3-bromo-5-chloro-7-{[(1,3-thiazol-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol dihydrochloride, (2S)-2-amino-1-(3-bromo-5-chloro-7-{[(1,3-thiazol-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-one dihydrochloride, 2-[(2S)-2-amino-1-fluoropropyl]-3-bromo-5-chloro-N-[(1,3-thiazol-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, (2R)-2-amino-3-(5-chloro-7-{[(thiophen-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)propan-1-ol formate, N 2 -[(2S)-2-aminopropyl]-5-chloro-3-methyl-N 7 -[(thiophen-2-yl)methyl]thieno[3,2-b]pyridine-2,7-diamine hydrochloride, N 2 -[(2R)-2-aminopropyl]-5-chloro-3-methyl-N 7 -[(thiophen-2-yl)methyl]thieno[3,2-b]pyridine-2,7-diamine hydrochloride, (2R,3R)-3-amino-4-(3-bromo-5-chloro-7-{[(furan-2-yl)methyl]amino}thieno[3,2-b]pyridin-2-yl)butan-2-ol hydrochloride, and 2-[(2R)-2-aminobut-3-yn-1-yl]-3,5-dichloro-N-[(furan-2-yl)methyl]thieno[3,2-b]pyridin-7-amine dihydrochloride, wherein the compound salt form is selected from the group consisting of salts, hydrates, solvates and tautomeric forms thereof.

9. A pharmaceutical composition for treating familial dysautonomia, comprising a compound according to claim 1.

10. A pharmaceutical composition for treating familial dysautonomia, comprising a compound according to claim 7.

11. A pharmaceutical composition for treating familial dysautonomia, comprising a compound according to claim 8.

12. 10. A pharmaceutical composition comprising an effective amount of a compound of claim 1 in admixture with a pharmaceutically acceptable excipient.

13. 10. A pharmaceutical composition comprising an effective amount of a compound of claim 7 in admixture with a pharmaceutically acceptable excipient.

14. 10. A pharmaceutical composition comprising an effective amount of a compound of claim 8 in admixture with a pharmaceutically acceptable excipient.

Citation Information

Patent Citations

  • Compounds for improving mRNA splicing

    WO2016115434A1

  • Geographical location-based intelligent domain name resolution method and device

    WO2020155491A1